,Article,Date,Symbol,Time,Title,Url
0,"  Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders in a deal for up to $320 million.Sangamo shares jumped as much as 30 percent to a six-year high of $17.73 on the Nasdaq on Thursday morning.Biogen will use Sangamo's genome-editing technology to develop drugs targeting sickle cell disease and beta-thalassemia.It will provide Sangamo $20 million upfront and reimburse costs related to research and development.Sangamo will also be eligible for milestone payments of about $300 million, as well as double digit royalties on product sales. The upfront payment and the terms of the milestone payments and the double digit royalties were pretty high, Wedbush analyst Liana Moussatos said.""The deal terms are very lucrative for a pre-clinical platform. So I think Biogen must have been impressed with the pre-clinical data that Sangamo presented last month.""Sangamo presented the data last month at the annual meeting of the American Society of Hematology. The company will be responsible for research and development for the first proof-of-concept study for beta-thalassemia, according to Thursday's deal.Beta-thalassemia impairs the body's ability to produce hemoglobin, the protein in red blood cells (RBC). Sickle cell disease changes the shape RBCs, tending to block blood flow.Moussatos said Sangamo also had a promising HIV program, with a patient to stay with undetectable viral load for six months.""That's another viable treatment and I won't be surprised if they announce another partnership for that,"" Moussatos said.(Reporting by Shailesh Kuber; Editing by Joyjeet Das)",2014-01-09,BIIB,"Thu Jan 9, 2014 | 11:47am EST",Sangamo to develop blood disorder drugs with Biogen,http://www.reuters.com//article/us-sangamo-biogen-blooddisorderdrugs-idUSBREA080LC20140109?type=companyNews
1,"  (Adds deal details, analyst comments; updates share movement)Jan 9 Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders in a deal for up to $320 million.Sangamo shares jumped as much as 30 percent to a six-year high of $17.73 on the Nasdaq on Thursday morning.Biogen will use Sangamo's genome-editing technology to develop drugs targeting sickle cell disease and beta-thalassemia.It will provide Sangamo $20 million upfront and reimburse costs related to research and development. Sangamo will also be eligible for milestone payments of about $300 million, as well as double digit royalties on product sales.The upfront payment and the terms of the milestone payments and the double digit royalties were pretty high, Wedbush analyst Liana Moussatos said.""The deal terms are very lucrative for a pre-clinical platform. So I think Biogen must have been impressed with the pre-clinical data that Sangamo presented last month."" Sangamo presented the data last month at the annual meeting of the American Society of Hematology.The company will be responsible for research and development for the first proof-of-concept study for beta-thalassemia, according to Thursday's deal. Beta-thalassemia impairs the body's ability to produce hemoglobin, the protein in red blood cells (RBC).Sickle cell disease changes the shape RBCs, tending to block blood flow.Moussatos said Sangamo also had a promising HIV program, with a patient to stay with undetectable viral load for six months.""That's another viable treatment and I won't be surprised if they announce another partnership for that,"" Moussatos said.   (Reporting by Shailesh Kuber; Editing by Joyjeet Das)",2014-01-09,BIIB,"Thu Jan 9, 2014 | 11:43am EST",UPDATE 1-Sangamo to develop blood disorder drugs with Biogen,http://www.reuters.com//article/sangamo-biogen-blooddisorderdrugs-idUSL3N0KJ4IS20140109?type=companyNews
2,"  Jan 9 Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders.Sangamo shares rose about 8 percent to $14.74 in premarket trading.Biogen will pay Sangamo $20 million upfront, and use Sangamo's gene-based technology to develop drugs targeting sickle cell disease and beta-thalassemia. Sangamo will also be eligible for additional payments of about $300 million in milestones, as well as double digit royalties on product sales. The company will be responsible for research and development activities for the first proof-of-concept study for beta-thalassemia. Biogen will pay for research costs incurred by Sangamo and market drugs developed during the collaboration.    (Reporting By Vrinda Manocha in Bangalore; Editing by Joyjeet Das)",2014-01-09,BIIB,"Thu Jan 9, 2014 | 7:28am EST",Sangamo Biosciences to develop blood disorder drugs with Biogen,http://www.reuters.com//article/sangamo-biogen-blooddisorderdrugs-idUSL3N0KJ3RK20140109?type=companyNews
3,"   By Bill Berkrot  Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market.Some of those sales were due to U.S. inventory stocking ahead of a 10 percent Tecfidera price increase in December. Biogen said underlying patient demand for the drug represented about $348 million of the U.S. sales, still ahead of analysts' consensus expectations of about $335 million.Biogen provided forecasts for 2014 that were likely to be viewed as a mixed bag, with revenue growth projections ahead of Wall Street expectations but an earnings outlook that fell short of the current analysts' view.The company forecast revenue growth of about 22 percent to 25 percent and earnings of $11 to $11.20 per share, excluding items. Analysts, on average, were looking for revenue growth of about 20 percent and earnings of $11.63 per share, according to Thomson Reuters I/B/E/S.""The guidance was very robust on the top line,"" said Cowen and Co analyst Eric Schmidt. ""A conservative management team like Biogen starting the year off with guidance that's significantly above consensus, that's a strong signal.""The earnings forecast shortfall was likely due to $200 million in the research and development budget that the company has earmarked for future business development, Schmidt said. ""The EPS guidance appears conservative in light of revenue growth expectations,"" Sanford Bernstein analyst Geoffrey Porges said in a note. ""Historically, Biogen has been able to beat initial guidance by 7 percent in the top line and 12 percent in the bottom line.""Investors gave Biogen management the benefit of the doubt, sending shares up nearly 2 percent on a down day for the broader markets. Biogen was one of the best performers of 2013, with the stock soaring more than 90 percent.Investor focus has been squarely on the performance of Tecfidera, which has become the top-selling oral MS treatment in the United States despite being third to market. The company expects European approval in the coming days or weeks, which would be another major catalyst for sales.Biogen said it was set to begin selling the drug in Germany as soon as European Union approval comes through with subsequent launches on a country-by-country basis as reimbursement is secured. The drug is already approved in Australia and Canada. Biogen said more than 6,000 doctors have prescribed Tecfidera so far, and that more than 30 percent of new patients in the fourth quarter had not been on prior therapies, such as Biogen's injectable MS drugs Avonex and Tysabri.Biogen said its fourth-quarter profit jumped 57 percent, fueled by Tecfidera. The net profit rose to $457.3 million, or $1.92 per share, from $292.1 million, or $1.23 per share, a year earlier. Excluding special items, Biogen earned $2.34 per share, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S.Total revenue rose 39 percent to $1.97 billion, edging past the average analyst estimate of $1.93 billion. Avonex sales were flat at $751 million, but were about 3 percent ahead of analysts' expectations.Tysabri sales of $427 million fell well short of Wall Street estimates of about $470 million, in part due to an Italian reimbursement dispute that was expected to be settled in the quarter but carried over to 2014.Biogen said Tysabri discontinuation rates improved in the quarter, but that it remained under pressure in Europe due to competition from oral medicines sold by Novartis and Sanofi.The company said it continued to expect approvals this year for hemophilia drugs Eloctate and Alprolix, putting Biogen into that market for the first time. It sees a mid-year launch of Plegridy, a new interferon drug for relapsing MS.Biogen Idec shares rose $5.79 to $311.44 in afternoon trading on Nasdaq.(Reporting by Bill Berkrot in New York and Esha Dey in Bangalore; Editing by Savio D'Souza and Jeffrey Benkoe)",2014-01-29,BIIB,"Wed Jan 29, 2014 | 1:05pm EST",Biogen profit rises as new multiple sclerosis drug shines,http://www.reuters.com//article/us-biogen-results-idUSBREA0S0UE20140129?type=companyNews
4,"  By Bill BerkrotJan 29 Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market.Some of those sales were due to U.S. inventory stocking ahead of a 10 percent Tecfidera price increase in December. Biogen said underlying patient demand for the drug represented about $348 million of the U.S. sales, still ahead of analysts' consensus expectations of about $335 million.Biogen provided forecasts for 2014 that were likely to be viewed as a mixed bag, with revenue growth projections ahead of Wall Street expectations but an earnings outlook that fell short of the current analysts' view.The company forecast revenue growth of about 22 percent to 25 percent and earnings of $11 to $11.20 per share, excluding items. Analysts, on average, were looking for revenue growth of about 20 percent and earnings of $11.63 per share, according to Thomson Reuters I/B/E/S.""The guidance was very robust on the top line,"" said Cowen and Co analyst Eric Schmidt. ""A conservative management team like Biogen starting the year off with guidance that's significantly above consensus, that's a strong signal."" The earnings forecast shortfall was likely due to $200 million in the research and development budget that the company has earmarked for future business development, Schmidt said.""The EPS guidance appears conservative in light of revenue growth expectations,"" Sanford Bernstein analyst Geoffrey Porges said in a note. ""Historically, Biogen has been able to beat initial guidance by 7 percent in the top line and 12 percent in the bottom line.""Investors gave Biogen management the benefit of the doubt, sending shares up nearly 2 percent on a down day for the broader markets. Biogen was one of the best performers of 2013, with the stock soaring more than 90 percent.Investor focus has been squarely on the performance of Tecfidera, which has become the top-selling oral MS treatment in the United States despite being third to market. The company expects European approval in the coming days or weeks, which would be another major catalyst for sales. Biogen said it was set to begin selling the drug in Germany as soon as European Union approval comes through with subsequent launches on a country-by-country basis as reimbursement is secured. The drug is already approved in Australia and Canada.Biogen said more than 6,000 doctors have prescribed Tecfidera so far, and that more than 30 percent of new patients in the fourth quarter had not been on prior therapies, such as Biogen's injectable MS drugs Avonex and Tysabri.Biogen said its fourth-quarter profit jumped 57 percent, fueled by Tecfidera. The net profit rose to $457.3 million, or $1.92 per share, from $292.1 million, or $1.23 per share, a year earlier. Excluding special items, Biogen earned $2.34 per share, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S. Total revenue rose 39 percent to $1.97 billion, edging past the average analyst estimate of $1.93 billion.Avonex sales were flat at $751 million, but were about 3 percent ahead of analysts' expectations.Tysabri sales of $427 million fell well short of Wall Street estimates of about $470 million, in part due to an Italian reimbursement dispute that was expected to be settled in the quarter but carried over to 2014.Biogen said Tysabri discontinuation rates improved in the quarter, but that it remained under pressure in Europe due to competition from oral medicines sold by Novartis and Sanofi.The company said it continued to expect approvals this year for hemophilia drugs Eloctate and Alprolix, putting Biogen into that market for the first time. It sees a mid-year launch of Plegridy, a new interferon drug for relapsing MS.Biogen Idec shares rose $5.79 to $311.44 in afternoon trading on Nasdaq.",2014-01-29,BIIB,"Wed Jan 29, 2014 | 1:04pm EST",UPDATE 3-Biogen profit rises as new multiple sclerosis drug shines,http://www.reuters.com//article/biogen-results-idUSL2N0L31KX20140129?type=companyNews
5,"  (Corrects to shares fell, rather than rose, in last paragraph)By Bill BerkrotJan 29 Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market.Some of those sales were due to U.S. inventory stocking ahead of a 10 percent Tecfidera price increase in December. Biogen said underlying patient demand for the drug represented about $348 million of the U.S. sales, still ahead of analysts' consensus expectations of about $335 million.Biogen provided forecasts for 2014 that were likely to be viewed as a mixed bag, with revenue growth projections ahead of Wall Street expectations but an earnings outlook that fell short of the current analysts' view.The company forecast revenue growth of about 22 percent to 25 percent and earnings of $11 to $11.20 per share, excluding items. Analysts, on average, were looking for revenue growth of about 20 percent and earnings of $11.63 per share, according to Thomson Reuters I/B/E/S.""The guidance was very robust on the top line,"" said Cowen and Co analyst Eric Schmidt. ""A conservative management team like Biogen starting the year off with guidance that's significantly above consensus, that's a strong signal."" The earnings forecast shortfall was likely due to $200 million in the research and development budget that the company has earmarked for future business development, Schmidt said.""The EPS guidance appears conservative in light of revenue growth expectations,"" Sanford Bernstein analyst Geoffrey Porges said in a note. ""Historically, Biogen has been able to beat initial guidance by 7 percent in the top line and 12 percent in the bottom line.""Investor focus has been squarely on the performance of Tecfidera, which has become the top-selling oral MS treatment in the United States despite being third to market. The company expects European approval in the coming days or weeks, which would be another major catalyst for sales. Biogen said more than 6,000 doctors have prescribed Tecfidera so far, and that more than 30 percent of new patients in the fourth quarter had not been on prior therapies, such as Biogen's injectable MS drugs Avonex and Tysabri.Biogen said its fourth-quarter profit jumped 57 percent, fueled by Tecfidera. The net profit rose to $457.3 million, or $1.92 per share, from $292.1 million, or $1.23 per share, a year earlier.Excluding special items, Biogen earned $2.34 per share, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S. Total revenue rose 39 percent to $1.97 billion, edging past the average analyst estimate of $1.93 billion.Avonex sales were flat at $751 million, but were about 3 percent ahead of analysts' expectations.Tysabri sales of $427 million fell well short of Wall Street estimates of about $470 million, in part due to an Italian reimbursement dispute that was expected to be settled in the quarter but carried over to 2014.Biogen said Tysabri discontinuation rates improved in the quarter, but that the drug remained under pressure in Europe due to competition from oral medicines.The company said it continued to expect approvals this year for hemophilia drugs Eloctate and Alprolix, putting Biogen into that market for the first time. It sees a mid-year launch of Plegridy, a new interferon drug for relapsing MS.Biogen Idec shares fell to $298.71 in premarket trading from Tuesday's Nasdaq close at $305.65.   (Reporting by Bill Berkrot in New York and Esha Dey in Bangalore; Editing by Savio D'Souza and Jeffrey Benkoe)",2014-01-29,BIIB,"Wed Jan 29, 2014 | 9:13am EST",CORRECTED-UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines,http://www.reuters.com//article/biogen-results-idUSL3N0L33NR20140129?type=companyNews
6,"  (For more market insights, including options activity, click on  ; for the Day Ahead newsletter link.reuters.com/mex49s)** BOEING CO, Tuesday close $137.09The planemaker's reported strong fourth-quarter results.** DOW CHEMICAL CO, Tuesday close $43.06, +7.76 pct premarketThe largest U.S. chemical maker by sales raised its dividend 15 percent and expanded its share buyback program to $4.5 billion from $1.5 billion after posting a fourth-quarter profit.** TUPPERWARE BRANDS CORP, Tuesday close $83.77The kitchen storage container maker reported lower-than-expected quarterly results hurt by weak sales in established markets such as Germany, United States and Canada.** ROCKWELL AUTOMATION INC, Tuesday close $115.01The company, which makes systems that help factories run smoothly, posted a 23 percent rise in quarterly profit, partly due to sales increases in the United States and Asia Pacific.** EMC CORP, Tuesday close $25.38, -2.13 pct premarketProfit rose 17 percent in the fourth quarter due to higher sales of the company's data storage equipment.** BIOGEN IDEC INC, Tuesday close $305.65, -0.21 pct premarketThe company said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera.** PRAXAIR INC, Tuesday close $125.7, +0.37 pct premarketThe largest industrial gas supplier in the Americas raised its dividend by 8 percent and said it would buy back stock worth $1.5 billion, after reporting a 15 percent rise in quarterly profit.** SOUTHERN CO, Tuesday close $83.77The power company reported a 6 percent rise in fourth-quarter revenue.** AT&T INC, Tuesday close $33.7, -2.94 pct premarketThe telecom company's fourth-quarter wireless subscriber growth and its free cash flow target lagged well behind analyst estimates. Chief Executive Randall Stephenson said a U.S. spying scandal was hurting the company's business.At least one brokerage cut its rating on the stock.** FORD MOTOR CO, Tuesday close $15.72, -0.57 pct premarket The company reported higher-than-expected quarterly results on Tuesday as earnings in its core North American market fell less steeply than Wall Street expected, but declining vehicle prices there raised concerns about 2014.Ford joined a growing number of multinational companies expressing concern that economic turmoil in Venezuela and Argentina could spell trouble for 2014 profits. High inflation in the two countries, along with concern about how their governments will try to steady their economies has Ford rethinking its annual forecasts for South America.** PFIZER INC, Tuesday close $30.42The company reported better-than-expected fourth-quarter results on Tuesday, helped by higher sales of drugs for cancer, nerve pain and arthritis, and forecast 2014 earnings in line with Wall Street estimates.** VERIZON COMMUNICATIONS INC, Tuesday close $47.36** VODAFONE GROUP PLC, Tuesday close $37.17, +0.35 pct premarketShareholders of both Vodafone and Verizon approved Verizon's $130 billion takeover of their Verizon Wireless venture on Tuesday, paving the way for the third-biggest deal in corporate history.** WAL-MART STORES INC, Tuesday close $74.67, +1.25 pct premarketThe U.S. retailer said it will upgrade its vendor compliance process in China, requiring more documentation and making use of a computer-based system to help suppliers manage associated paperwork.** APPLE INC, Tuesday close $506.5, +0.15 pct premarketThe company may have to wait a little longer for its watershed moment in China. A disappointing March-quarter revenue forecast, coupled with surprisingly weak holiday iPhone sales, suggest pundits may have over-estimated initial demand from China Mobile's 700 million-plus subscribers, a key factor that has pushed its shares 18 percent higher in the fourth quarter. ** CIRRUS LOGIC INC, Tuesday close $18.74, -5 pct after marketThe company, whose audio chips are used in Apple's iPhones and iPads, forecast current-quarter revenue that missed analysts' average estimate.** VMWARE INC, Tuesday close $94.94, +0.06 pct premarketThe virtualization software maker reported a slightly better-than-expected quarterly profit helped by higher revenue from license sales.At least four brokerages raised their price targets on the stock.** ELECTRONIC ARTS INC, Tuesday close $24.87, +4.54 pct premarketThe videogame publisher lowered its 2015 revenue forecast on Tuesday as the arrival of new Xbox One and PlayStation 4 consoles has hurt sales of games for older consoles sooner than the industry had anticipated.At least two brokerages raised their price targets on the stock.** CHECK POINT SOFTWARE TECHNOLOGIES LTD, Tuesday close $65.93, +3.14 pct premarketThe computer security specialist topped fourth-quarter profit and revenue forecasts and said it sees growth continuing into 2014 on strong demand for high-end products that protect data centers.** AMGEN INC, Tuesday close $120.7, +2.4 pct after market The world's biggest biotechnology company on Tuesday reported a quarterly profit that beat Wall Street forecasts as it gained full control of its blockbuster rheumatoid arthritis drug Enbrel and recorded solid growth in sales of newer products. The company also announced another positive result from a late-stage study of its high-profile experimental cholesterol drug, evolocumab.At least four brokerages raised their price targets on the stock.** ABERCROMBIE & FITCH CO, Tuesday close $36.27The teen apparel retailer stripped Chief Executive Mike Jeffries of his chairman duties, bowing to investor pressure to reduce his control over the struggling company.** YAHOO INC, Tuesday close $38.22, -4.50 pct premarketThe company's online ad prices slid again in the fourth quarter and Alibaba, the Chinese e-commerce giant in which it owns a big stake, saw revenue growth decelerate from its recent rip-roaring pace. Overall revenue fell 6 percent in the last three months of the year, the company said.At least two brokerages cut their price targets on the stock.** QUALCOMM INC, Tuesday close $71.99, -1.93 pct premarketThe world's biggest cellphone chip maker may be hit with a record fine exceeding $1 billion in a Chinese antitrust probe, raising the specter of harsh penalties for foreign firms facing an increasingly aggressive regulator.** NOVARTIS AG, Tuesday close $79.56, -100.00 pct premarketThe Basel-based company is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said, in a review due to be completed by the end of summer.** TEVA PHARMACEUTICAL INDUSTRIES, Tuesday close $44.1, +3.40 pct premarketTeva's shares open higher after the company said  U.S. regulators approved its three-times-a-week multiple sclerosis drug Copaxone. The world's largest generics drugmaker has been banking on a three-times-a-week version of Copaxone ahead of possible competition from generic rivals of the drug this year.** MEDIVATION INC, Tuesday close $75.78, +13.49 pct premarketThe company's drug for advanced prostate cancer significantly delayed progression of the disease and extended survival in a large, late stage study of patients who had not yet received chemotherapy, likely paving the way for an expanded approval of the medicine.** FACEBOOK INC, Tuesday close $55.14, +0.11 pct premarketThe company's executive in charge of revolutionizing data centers on Tuesday lauded low-energy server technology that is expected to compete against heavyweight Intel Corp.** COMMVAULT SYSTEMS, Tuesday close $76.1The company, which makes software applications to manage data and information, is scheduled to report third-quarter results before the bell.** MEREDITH CORP, Tuesday close $44.49The media and marketing company is expected to report second-quarter results before the bell.   (Compiled by Natalie Grover in Bangalore; Editing by Joyjeet Das)",2014-01-29,BIIB,"Wed Jan 29, 2014 | 7:43am EST","MARKET PULSE-Boeing, Dow, Tupperware, EMC, Biogen, Praxair, Rockwell",http://www.reuters.com//article/markets-usa-stocks-pulse-idUSL3N0L24SU20140129?type=companyNews
7,"  Jan 29 Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera.The U.S. biotechnology company's net profit rose to $457.3 million, or $1.92 per share, in the quarter ended Dec. 31, from $292.1 million, or $1.23 per share, a year earlier. Excluding special items, Biogen earned $2.34 per share. Analysts on average expected $2.28 per share, according to Thomson Reuters I/B/E/S.  The high-profile multiple sclerosis drug had sales of $398 million for the period. Total sales rose 39 percent to $1.97 billion, beating the analysts' average estimate of $1.93 billion.",2014-01-29,BIIB,"Wed Jan 29, 2014 | 6:50am EST",Biogen Idec profit rises as new multiple sclerosis drug shines,http://www.reuters.com//article/biogen-results-idUSL3N0L33GR20140129?type=companyNews
8,"   By Bill Berkrot  Biogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval, the company said on Monday, opening the door for its launch in one of the world's largest markets for MS treatments.The approval was widely expected after the European Medicines Agency endorsed the drug in November. European health regulators typically follow EMA recommendations within a couple of months.Tecfidera will be the third oral MS drug available in Europe. However, if its impressive early performance in the United States is any indication, the Biogen drug is likely to surpass sales of Novartis' Gilenya and Aubagio from Sanofi.Tecfidera has consistently shattered Wall Street sales forecasts and is well on the way to racking up more than $1 billion in sales in its first year on the market.Biogen reported Tecfidera sales of $398 million for the fourth quarter of 2013, only the medicine's third full quarter since winning U.S. approval. It is also approved for sale in Canada and Australia. The introduction in Europe will start in the coming weeks, although its full roll-out will take place over the course of this year and next as Biogen must negotiate reimbursement for the treatment on a country by country basis.First up will be Germany, ""where you can get pricing reimbursement rather quickly,"" Tony Kingsley, Biogen's head of global commercial operations, said in a telephone interview. ""We're ready to go,"" said Kingsley, adding that Biogen's Germany sales force for the new drug has been in place for months.Tecfidera's prospects in Europe had been in doubt at one stage because of uncertainty about protection against generic copies. This issue was resolved in November when Biogen won 10 years of regulatory exclusivity.There are an estimated 400,000 people in Europe with multiple sclerosis. Biogen declined to comment on what type of market share Tecfidera was likely to seize in Europe. ""We're very encouraged by our U.S. experience,"" Kingsley said.Robert W Baird analyst Christopher Raymond forecast 2014 Tecfidera sales outside the United States of $291 million.Looking further ahead, analysts on average forecast annual worldwide sales of the drug reaching some $6 billion by 2019, with more than a third of that coming from Europe and other non-U.S. markets, according to consensus forecasts compiled by Thomson Reuters Pharma.(Additional reporting by Ben Hirschler)",2014-02-03,BIIB,"Mon Feb 3, 2014 | 9:29am EST",Biogen multiple sclerosis drug Tecfidera wins European approval,http://www.reuters.com//article/us-biogen-europe-idUSBREA120V920140203?type=companyNews
9,"   By Bill Berkrot  Feb 3 Biogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval, the company said on Monday, opening the door for its launch in one of the world's largest markets for MS treatments.The approval was widely expected after the European Medicines Agency endorsed the drug in November. European health regulators typically follow EMA recommendations within a couple of months.Tecfidera will be the third oral MS drug available in Europe. However, if its impressive early performance in the United States is any indication, the Biogen drug is likely to surpass sales of Novartis' Gilenya and Aubagio from Sanofi.Tecfidera has consistently shattered Wall Street sales forecasts and is well on the way to racking up more than $1 billion in sales in its first year on the market. Biogen reported Tecfidera sales of $398 million for the fourth quarter of 2013, only the medicine's third full quarter since winning U.S. approval. It is also approved for sale in Canada and Australia.The introduction in Europe will start in the coming weeks, although its full roll-out will take place over the course of this year and next as Biogen must negotiate reimbursement for the treatment on a country by country basis.First up will be Germany, ""where you can get pricing reimbursement rather quickly,"" Tony Kingsley, Biogen's head of global commercial operations, said in a telephone interview. ""We're ready to go,"" said Kingsley, adding that Biogen's Germany sales force for the new drug has been in place for months.Tecfidera's prospects in Europe had been in doubt at one stage because of uncertainty about protection against generic copies. This issue was resolved in November when Biogen won 10 years of regulatory exclusivity. There are an estimated 400,000 people in Europe with multiple sclerosis. Biogen declined to comment on what type of market share Tecfidera was likely to seize in Europe.""We're very encouraged by our U.S. experience,"" Kingsley said.Robert W Baird analyst Christopher Raymond forecast 2014 Tecfidera sales outside the United States of $291 million.Looking further ahead, analysts on average forecast annual worldwide sales of the drug reaching some $6 billion by 2019, with more than a third of that coming from Europe and other non-U.S. markets, according to consensus forecasts compiled by Thomson Reuters Pharma.",2014-02-03,BIIB,"Mon Feb 3, 2014 | 9:27am EST",Biogen multiple sclerosis drug Tecfidera wins European approval,http://www.reuters.com//article/biogen-europe-idUSL5N0L82ID20140203?type=companyNews
10,"  * Isis shares jump on drug results; Biogen up* G Asset Management offers to buy stake in Barnes & Noble or Nook* Groupon shares drop after company forecasts loss* U.S. home resales fall to 18-month low in January* Dow off 0.2 pct; S&P 500 down 0.2 pct; Nasdaq off 0.1 pctBy Rodrigo CamposNEW YORK, Feb 21 U.S. stocks slipped on Friday on options-related trading, with the S&P 500 facing resistance as it flirts with its record high even as economic data continues to underwhelm.Shares declined late in the session due in part to trades related to options expiration, according to market participants.U.S. home resales, also known as existing home sales, fell more than expected in January and hit an 18 month-low as the combination of cold weather and a lack of housing stock sidelined potential buyers.Traders have selectively dismissed weak economic data, which is being blamed on the extreme weather that has affected large swaths of the United States. An index of homebuilder stocks rose 0.8 percent to hit a nine-month closing high.""The bigger picture theme is we continue to see economic reports that have been pretty underwhelming, but any disappointing data has been shrugged off and attributed to weather,"" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.""You would have expected that the markets would be a fair amount lower than where they are.""The S&P 500 ended 0.66 percent below its record close of 1,848.38 set on Jan. 15. ""The late-day selling was somewhat induced by the futures and options expirations on the close; it's hard to put too much credence in the market's action in the last couple hours because there's so much positioning that has to do with where things close,"" James said.February individual equity options and some options  on stock indexes stopped trading at Friday's close and will settle on Saturday. Typically, options expiration is orderly, but some volatility may occur as players unwind those positions against stock and index products. Volume, however, was below the recent average.The Dow Jones industrial average fell 29.93 points or 0.19 percent, to end at 16,103.30. The S&P 500 lost 3.53 points or 0.19 percent, to finish at 1,836.25. The Nasdaq Composite dropped 4.135 points or 0.10 percent, to close at 4,263.41.For the week, the Dow fell 0.3 percent and the S&P 500 dipped 0.1 percent. The Nasdaq, up 0.5 percent, scored its third consecutive week of gains.Giving support to equities, data showed that fund investors worldwide poured a net $8.3 billion into funds that specialize in U.S. equities in the week ending Feb. 19. Inflows into global stock funds were $13.4 billion, the biggest in 12 weeks. Shares of Isis Pharmaceuticals surged 15.5 percent to $59 after the company said a mid-stage trial of its experimental treatment for a rare spinal disorder showed that it increased muscle function in children. Shares of Biogen , Isis' partner in the drug's development, hit a record high of $349.77 on the news before closing up 3.6 percent at $347.11.Priceline.com stock rose 2.5 percent and ranked as one of the S&P 500's biggest gainers, rising to close at a record $1,315.65 a day after the online travel company reported results that beat expectations.Hewlett-Packard Co also reported results that topped expectations, and the computer maker raised its 2014 profit view, though its stock fell 1.3 percent to end at $29.79.Investment firm G Asset Management said it had offered to take a 51 percent stake in either Barnes & Noble Inc or in the bookseller's Nook digital books and device business. Barnes and Noble shares rose 5.4 percent to $17.69.Shares of Safeway Inc rose 4.3 percent to $36.84 on news that the U.S. grocery store operator is in advanced talks with private equity firm Cerberus Capital over a leveraged buyout deal that may come within the next few weeks, according to people familiar with the matter.Groupon shares tumbled 21.9 percent to $8.03 a day after the daily deals website unexpectedly forecast a quarterly loss, even as it reported revenue that was ahead of expectations.About 6.55 billion shares traded on U.S. exchanges, according to the latest available data from BATS Global Markets, below the 7.0 billion average so far in February.Despite the slight drop in the major indexes, advancing issues outnumbered declining ones on the New York Stock Exchange by a ratio of about 4 to 3. On the Nasdaq, about 13 issues rose for every 12 that fell.",2014-02-21,BIIB,"Fri Feb 21, 2014 | 5:30pm EST",US STOCKS-Wall St dips with S&P 500's record high in sight,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LQ2ET20140221?type=companyNews
11,"  * Isis shares jump on drug results, Biogen up* G Asset Management offers to buy Barnes & Noble or Nook stake* Groupon shares tumble after forecasting loss* Home resales fall to 18-month low in January* Major indexes nearly unchangedBy Rodrigo CamposNEW YORK, Feb 21 U.S. stocks were little changed on Friday, with the S&P 500 facing resistance as it flirts with its record high, as company news dominated trading amid another soft reading on the economy.Home resales in the United States fell more than expected in January and hit an 18 month-low as the combination of cold weather and a lack of housing stock sidelined potential buyers. Traders continue to selectively dismiss weak economic data which is being blamed on the extreme weather that has affected large swaths of the U.S. territory.An index of homebuilder stocks rose 1 percent and could close at its highest since mid 2007.Giving support to equities, data showed fund investors worldwide poured a net $8.3 billion into funds that specialize in U.S. equities in the week ending Feb. 19. Inflows into global stock funds were $13.4 billion, the biggest in 12 weeks. ""You have very strong momentum and there's cash on the sidelines,"" said Kevin Caron, market strategist at Stifel, Nicolaus & Co in Florham Park, New Jersey.He said softer data is being dismissed because of the weather and, with the U.S. 10-year note yielding less than 3 percent, ""equities are one of the few games in town.""The Dow Jones industrial average fell 10.62 points or 0.07 percent, to 16,122.61, the S&P 500 gained 0.23 points or 0.01 percent, to 1,840.01 and the Nasdaq Composite  added 1.756 points or 0.04 percent, to 4,269.301.All three indexes are gunning for a third week of advances, and the S&P is within striking distance of its record close of 1,848.38 reached Jan. 15. Shares of Isis Pharmaceuticals rose 13.6 percent to $58 after the company said a mid-stage trial of its experimental treatment for a rare spinal disorder showed that it increased muscle function in children. Shares of Biogen, Isis' partner in the drug's development, hit a record high on the news.Priceline.com rose 3 percent as one of the S&P 500's biggest gainers, rising to $1,321.79 a day after reporting results that beat expectations.Hewlett Packard Co also reported results that topped expectations, and the computer maker also raised its 2014 profit view, though shares dipped 1.7 percent to $29.67.Investment firm G Asset Management said it had offered to take a 51 percent stake in either Barnes & Noble Inc or in the bookseller's Nook digital books and device business. Barnes and Noble shares rose 5.8 percent to $17.76.Groupon shares tumbled 20.1 percent to $8.13 a day after unexpectedly forecasting a quarterly loss, even as it reported revenue that was ahead of expectations.Pharmacy benefit manager Express Scripts Holding Co  late Thursday forecast 2014 earnings in line with Wall Street expectations and said it expects long-term earnings growth of up to 20 percent per year. Shares fell 4.3 percent to $73.82.",2014-02-21,BIIB,"Fri Feb 21, 2014 | 2:34pm EST",US STOCKS-Wall St little changed with record high in sight,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LQ1Z720140221?type=companyNews
12,"  Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application.Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies.Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week.Interferon is hard to tolerate as it leads to flu-like symptoms, prompting patients to delay or discontinue treatment. Analysts say the market for such interferon-based treatments will shrink over the next decade as newer generation products enter the fray. Multiple sclerosis is a chronic condition that occurs when the body's immune system mistakenly attacks and destroys the protective sheath surrounding nerve cells in the brain, optic nerve or spinal cord.Symptoms may include loss of balance, difficulty moving arms and legs, weakness, numbness and blindness. Biogen shares closed at $345.60 on Monday on the Nasdaq.(Reporting by Esha Dey in Bangalore)",2014-03-18,BIIB,"Tue Mar 18, 2014 | 8:49am EDT",FDA delays decision on Biogen's multiple sclerosis drug,http://www.reuters.com//article/us-biogen-fda-multiplesclerosis-idUSBREA2H0ZU20140318?type=companyNews
13,"  March 18 Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application.Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies.Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week. Interferon is hard to tolerate as it leads to flu-like symptoms, prompting patients to delay or discontinue treatment.Analysts say the market for such interferon-based treatments will shrink over the next decade as newer generation products enter the fray. Multiple sclerosis is a chronic condition that occurs when the body's immune system mistakenly attacks and destroys the protective sheath surrounding nerve cells in the brain, optic nerve or spinal cord. Symptoms may include loss of balance, difficulty moving arms and legs, weakness, numbness and blindness.Biogen shares closed at $345.60 on Monday on the Nasdaq.",2014-03-18,BIIB,"Tue Mar 18, 2014 | 8:33am EDT",FDA delays decision on Biogen's multiple sclerosis drug,http://www.reuters.com//article/biogen-fda-multiplesclerosis-idUSL3N0MF32I20140318?type=companyNews
14,"  Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide.Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It is expected to be approved in the United States later this year.Traditional hemophilia treatments must be infused two to three times a week, while Biogen's drug needs to be administered only once a week or once every 10 to 14 days to protect against bleeding episodes. Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. A single injection of the drug controlled bleeding in more than 90 percent of cases in a late-stage clinical trial.Biogen is also developing a drug, Elocate, to treat hemophilia A, a more common form of the disease that affects an estimated 20,000 people in the United States. Patients with hemophilia A lack or have reduced levels of coagulation factor VIII. Current treatments for hemophilia B generate about $1 billion a year, according to Biogen, while the market for hemophilia A therapies is about $6 billion. If approved in the United States, Alprolix is expected to generate sales of $286 million by 2019, according to Thomson Reuters data. Elocate is expected to generate sales of $1.1 billion.Biogen shares closed at $347.04 on the Nasdaq on Thursday.(Reporting by Toni Clarke in Washington, Additional reporting by Esha Dey in Bangalore; Editing by Simon Jennings)",2014-03-21,BIIB,"Fri Mar 21, 2014 | 8:34am EDT",Biogen Idec wins Canadian approval for hemophilia drug Alprolix,http://www.reuters.com//article/us-biogen-idec-approval-idUSBREA2K0T020140321?type=companyNews
15,"  (Adds details and background)March 21 Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide.Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It is expected to be approved in the United States later this year. Traditional hemophilia treatments must be infused two to three times a week, while Biogen's drug needs to be administered only once a week or once every 10 to 14 days to protect against bleeding episodes.Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. A single injection of the drug controlled bleeding in more than 90 percent of cases in a late-stage clinical trial. Biogen is also developing a drug, Elocate, to treat hemophilia A, a more common form of the disease that affects an estimated 20,000 people in the United States. Patients with hemophilia A lack or have reduced levels of coagulation factor VIII. Current treatments for hemophilia B generate about $1 billion a year, according to Biogen, while the market for hemophilia A therapies is about $6 billion.If approved in the United States, Alprolix is expected to generate sales of $286 million by 2019, according to Thomson Reuters data. Elocate is expected to generate sales of $1.1 billion.Biogen shares closed at $347.04 on the Nasdaq on Thursday.   (Reporting by Toni Clarke in Washington, Additional reporting by Esha Dey in Bangalore; Editing by Simon Jennings)",2014-03-21,BIIB,"Fri Mar 21, 2014 | 8:26am EDT",UPDATE 1-Biogen Idec wins Canadian approval for hemophilia drug Alprolix,http://www.reuters.com//article/biogen-idec-approval-idUSL3N0MI2R920140321?type=companyNews
16,"  March 21 Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide.  Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It is expected to be approved in the United States later this year.   (Reporting by Toni Clarke in Washington, Additional reporting by Esha Dey in Bangalore; Editing by Simon Jennings) ",2014-03-21,BIIB,"Fri Mar 21, 2014 | 8:07am EDT",Biogen Idec wins Canadian approval for hemophilia drug Alprolix,http://www.reuters.com//article/biogen-idec-approval-idUSL3N0MI2PR20140321?type=companyNews
17,"   By Toni Clarke  Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.Hemophilia B is a rare, inherited disorder in which a person's blood does not clot properly, which can lead to prolonged bleeding and bruising. It affects about 4,000 people in the United States and 25,000 worldwide.Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It received approval in Canada a week ago. Hemophilia drugs in general must be infused two to three times a week to prevent bleeding episodes. Biogen's drug needs to be administered once a week or once every 10 to 14 days.The company is also developing a long-lasting drug, Eloctate, for Hemophilia A, a more common form of the disease, that affects about 20,000 people in the United States. Patients with hemophilia A lack or have reduced levels of coagulation factor VIII. Current treatments for hemophilia B generate about $1 billion a year, according to Biogen. The market for hemophilia A therapies is worth about $6 billion. Eloctate would compete with Baxter International Inc's drug Advate. Baxter is seeking to develop its own long-acting version but Biogen is expected to be first to the market.Alprolix is expected to generate sales of $286 million by 2019, according to Thomson Reuters data. Eloctate is expected to generate sales of $1.1 billion.(Reporting by Toni Clarke in Washington; Editing by David Gregorio)",2014-03-28,BIIB,"Fri Mar 28, 2014 | 5:11pm EDT",U.S. FDA approves Biogen's hemophilia B drug Alprolix,http://www.reuters.com//article/us-biogen-idec-hemophilia-idUSBREA2R1W120140328?type=companyNews
18,"  (Updates with background, sales forecast)By Toni ClarkeMarch 28 Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.Hemophilia B is a rare, inherited disorder in which a person's blood does not clot properly, which can lead to prolonged bleeding and bruising. It affects about 4,000 people in the United States and 25,000 worldwide. Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It received approval in Canada a week ago.Hemophilia drugs in general must be infused two to three times a week to prevent bleeding episodes. Biogen's drug needs to be administered once a week or once every 10 to 14 days. The company is also developing a long-lasting drug, Eloctate, for Hemophilia A, a more common form of the disease, that affects about 20,000 people in the United States. Patients with hemophilia A lack or have reduced levels of coagulation factor VIII. Current treatments for hemophilia B generate about $1 billion a year, according to Biogen. The market for hemophilia A therapies is worth about $6 billion.Eloctate would compete with Baxter International Inc's drug Advate. Baxter is seeking to develop its own long-acting version but Biogen is expected to be first to the market.Alprolix is expected to generate sales of $286 million by 2019, according to Thomson Reuters data. Eloctate is expected to generate sales of $1.1 billion.   (Reporting by Toni Clarke in Washington; Editing by David Gregorio)",2014-03-28,BIIB,"Fri Mar 28, 2014 | 5:09pm EDT",UPDATE 1-U.S. FDA approves Biogen's hemophilia B drug Alprolix,http://www.reuters.com//article/biogen-idec-hemophilia-idUSL1N0MP1YH20140328?type=companyNews
19,"  March 28 Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.Hemophilia B is a rare, inherited disorder in which a person's blood does not clot properly, potentially leading to prolonged bleeding and bruising. It affects about 4,000 people in the United States and 25,000 worldwide.  Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It received approval in Canada a week ago.   (Reporting by Toni Clarke in Washington; Editing by David Gregorio) ",2014-03-28,BIIB,"Fri Mar 28, 2014 | 4:56pm EDT",U.S. FDA approves Biogen's hemophilia B drug Alprolix,http://www.reuters.com//article/biogen-idec-hemophilia-idUSWNBB040OI20140328?type=companyNews
20,"  Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.The drug, Eloctate, was able to maintain low bleeding rates in children with hemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a protein called factor VIII.The late-stage trial tested Eloctate in previously treated children under 12 years with severe hemophilia A.The main goal of the study was to evaluate the frequency of antibody development that can interfere with the therapy and none were detected. Eloctate is a long-acting hemophilia treatment that was given to patients as twice-weekly preventive injections. Hemophilia drugs generally need to be infused every two or three days to prevent bleeding episodes.Biogen and Swedish Orphan Biovitrum have also developed another hemophilia drug, Alprolix, that was approved by the U.S. Food and Drug Administration last month for treating hemophilia B. Hemophilia B is caused by the absence of the factor IX protein. Biogen shares were up slightly at $300.92 in premarket trading. They closed at $300.68 on Wednesday on the Nasdaq.(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-04-10,BIIB,"Thu Apr 10, 2014 | 9:05am EDT",Biogen's blood disorder drug succeeds in late-stage trial,http://www.reuters.com//article/us-biogen-idec-study-blooddisorder-idUSBREA390RI20140410?type=companyNews
21,"  (Adds details, background, stock movement)April 10 Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.The drug, Eloctate, was able to maintain low bleeding rates in children with hemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a protein called factor VIII.The late-stage trial tested Eloctate in previously treated children under 12 years with severe hemophilia A. The main goal of the study was to evaluate the frequency of antibody development that can interfere with the therapy and none were detected. Eloctate is a long-acting hemophilia treatment that was given to patients as twice-weekly preventive injections.Hemophilia drugs generally need to be infused every two or three days to prevent bleeding episodes. Biogen and Swedish Orphan Biovitrum have also developed another hemophilia drug, Alprolix, that was approved by the U.S. Food and Drug Administration last month for treating hemophilia B. Hemophilia B is caused by the absence of the factor IX protein.Biogen shares were up slightly at $300.92 in premarket trading. They closed at $300.68 on Wednesday on the Nasdaq.   (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-04-10,BIIB,"Thu Apr 10, 2014 | 8:42am EDT",UPDATE 1-Biogen's blood disorder drug succeeds in late-stage trial,http://www.reuters.com//article/biogen-idec-study-blooddisorder-idUSL3N0N23FZ20140410?type=companyNews
22,"  April 10 Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial. The drug, Eloctate, was being developed as a treatment for  haemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a particular protein.    (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)  ",2014-04-10,BIIB,"Thu Apr 10, 2014 | 7:23am EDT",Biogen's blood disorder drug succeeds in late-stage trial,http://www.reuters.com//article/biogen-idec-study-blooddisorder-idUSL3N0N23EF20140410?type=companyNews
23,"   By Bill Berkrot  Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts.Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide.""We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis,"" Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview.Drug pricing in the U.S. market has come under new scrutiny as state governments and health insurers balk over the $84,000 cost of Sovaldi, a new hepatitis C drug from Gilead Sciences Inc. It is the first of several new drugs expected on the market over the next two years that are seen as a major breakthrough in treatment of the liver-destroying disease.Treating two-thirds of the estimated 3.2 million U.S. hepatitis C patients with the drug could top $200 billion, according to some analysts.The Biogen hemophilia drug targets a relatively minuscule patient population. But the U.S. biotechnology company, and its peers including Gilead, have seen their shares drop sharply in recent weeks as investors question how much they will be able to charge for novel medicines in the future. Unlike in Europe and elsewhere, where price controls help keep healthcare costs down and drugs may be rejected outright if they are viewed as too expensive for the benefit they provide, the U.S. Food and Drug Administration is not allowed to take cost into consideration in approving new medicines, and no such price controls on what drugmakers may charge for their products exist.Extremely high prices for lifesaving drugs for rare diseases and genetic disorders have come under less payer pressure because they treat so few patients, even though they must be taken for a lifetime. In addition, the premium pricing had long been perceived as necessary to encourage pharmaceutical companies to develop treatments for extremely rare diseases in order to make the payoff worth their while.The recent pricing pressure has evolved as insurance companies and government health plans, such as Medicare and Medicaid, grapple with the skyrocketing expense of innovative new medicines that could be used by tens of thousands, or millions, of patients. They include therapies combining new cancer drugs that could cost $90,000 or more each for a course of treatment, and the hepatitis C drugs that promise a cure with few side effects.FACTORS IN PRICING BIOGEN  Kingsley said Biogen had been discussing the pricing for its new hemophilia drug prior to the furor over Sovaldi. But it would appear that the company has taken public perception of the new medicine's cost into consideration. Biogen Chief Executive George Scangos had signaled earlier this year that if he believed Alprolix was likely to be perceived as more of an advance in convenience than efficacy, it would probably be priced on a par with existing treatments.Biogen, which in the next few months expects a U.S. approval decision for another drug to treat the more common hemophilia A, set a price for Alprolix of $2.85 per international unit. That is more than double the price of about $1.19 per unit for Pfizer's Benefix, one of the most widely used treatments for the disorder. Other approved, older hemophilia B products include Rixubis from Baxter International Inc and Mononine from CSL Behring.But while current drugs are typically needed about two to three times a week, Alprolix is taken once a week or every 10 days, Biogen said. The total annual cost can vary widely based on a patient's weight, the severity of their clotting deficiency and other factors. Deutsche Bank estimates that Biogen's hemophilia products can reach annual sales of $1.2 billion by 2017.""We think it's a meaningful advance in a market that hasn't seen a significant advance in a decade and a half,"" said Kingsley, adding that Alprolix should be available to patients early next month.Hemophilia is a hereditary disorder that prevents blood from clotting properly due to lack of a clotting factor protein in the blood. Patients with more severe hemophilia require larger and more frequent doses of blood clotting factors. Worldwide, about one in 5,000 men are born with hemophilia A and one in 25,000 men are born with hemophilia B each year.Denmark's Novo Nordisk is also developing a long-acting treatment for hemophilia B, and expects to file next year for regulatory approval.Alprolix is a bioengineered version of the blood coagulation protein known as factor IX, which is needed for normal blood clotting. If not properly treated, hemophilia can lead to bleeding into joints and muscles that can cause stiffness, pain, severe joint damage, disability, and death.Biogen developed the drug in partnership with Swedish Orphan Biovitrum ABN.(Reporting by Bill Berkrot; Editing by Michele Gershberg, Bernard Orr)",2014-04-18,BIIB,"Fri Apr 18, 2014 | 3:05pm EDT",Exclusive: Biogen prices hemophilia drug on par with older therapies,http://www.reuters.com//article/us-biogen-hemophilia-idUSBREA3H0KL20140418?type=companyNews
24,"   By Bill Berkrot  Biogen Idec Inc (BIIB.O) on Wednesday raised its full-year earnings and revenue forecasts as first-quarter sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations.Tecfidera racked up sales of $506 million for the quarter, easily topping analysts' expectations of about $440 million and the previous quarter's sales of $398 million.The oral medicine, which was approved in the United States in March 2013, had been on track to become the drug to reach $1 billion in sales in the shortest time. But that pharmaceutical industry record was shattered on Tuesday, when Gildead Sciences Inc (GILD.O) said its Sovaldi hepatitis C treatment logged more than $2 billion in sales in its first full quarter on the market.Based on the strong performance of its MS drugs, Biogen raised its full-year forecast and now expects revenue growth of 26 percent to 28 percent, up from a prior range of 22 percent to 25 percent.The U.S. biotechnology company said it expected 2014 earnings, excluding items, of $11.35 to $11.45 per share, compared with a prior outlook of $11.00 to $11.20. Analysts on average are looking for a profit of $11.32 per share, according to Thomson Reuters I/B/E/S.Shares of Biogen were down 0.6 percent at $304.41 in late afternoon trading.""The raised guidance is a testament to the U.S. beat on Tecfidera sales and signals confidence in both the hemophilia launch as well as the Tecfidera launch in Europe,"" RBC Capital Markets analyst Michael Yee said. Biogen plans to begin selling Alprolix, its recently approved long-acting treatment for hemophilia B, in the United States in early May. The company said last week it would price Alprolix on a par with older, less convenient treatments, which should help it get off to a strong start.The company reported net income of $479.9 million, or $2.02 per share for the quarter, compared with $426.7 million, or $1.79 per share, a year earlier.Excluding special items, Biogen said it earned $2.47 per share, missing the analysts' average estimate of $2.55. But the company said its earnings were reduced by about 35 cents a share due to a $118 million expense from a collaboration with Japan's Eisai Co (4523.T) on development of Alzheimer's disease treatments.Without that expense, ""the (earnings) number could have been as high as $2.82, which would have crushed expectations,"" Yee said. Revenue jumped 51 percent to $2.1 billion, edging past Wall Street estimates of $1.99 billion.Biogen said $46 million of the Tecfidera sales came from outside the United States. The drug began selling in Germany in February, and the company said it planned to introduce the medicine in additional European countries in the coming months, with reimbursement agreements already secured in Norway and Scotland.""We're encouraged by the signs from Germany,"" Tony Kingsley, Biogen's head of global commercial operations, told analysts and investors on a conference call. Biogen's older MS drugs also performed well in the quarter.Sales of Avonex rose 2 percent to $761 million, topping Wall Street estimates of about $735 million.Tysabri sales were $441 million, an increase of 41 percent, due in part to Biogen's regaining full rights to the drug in the second quarter of last year.Biogen said some patients were still discontinuing use of Tysabri, but the company had retained 70 percent of that business, primarily due to switchovers to Tecfidera.The company also said in a regulatory filing that it was subpoenaed by state and federal authorities investigating its sales and promotional practices, and by the federal government for documents related to Biogen's relationship with certain pharmacy benefit managers.The company, which had previously said it was being investigated by governmental authorities, said it was cooperating in the investigations.(Additional reporting by Deena Beasley; Editing by Lisa Von Ahn and Jonathan Oatis)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 3:41pm EDT",Biogen raises outlook as new MS drug again tops forecasts,http://www.reuters.com//article/us-biogen-idec-results-idUSBREA3M1SZ20140423?type=companyNews
25,"  (Adds investigation into sales and promotional practices; updates stock price, 6th paragraph)By Bill BerkrotApril 23 Biogen Idec Inc on Wednesday raised its full-year earnings and revenue forecasts as first-quarter sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations.Tecfidera racked up sales of $506 million for the quarter, easily topping analysts' expectations of about $440 million and the previous quarter's sales of $398 million.The oral medicine, which was approved in the United States in March 2013, had been on track to become the drug to reach $1 billion in sales in the shortest time. But that pharmaceutical industry record was shattered on Tuesday, when Gildead Sciences Inc said its Sovaldi hepatitis C treatment logged more than $2 billion in sales in its first full quarter on the market.Based on the strong performance of its MS drugs, Biogen raised its full-year forecast and now expects revenue growth of 26 percent to 28 percent, up from a prior range of 22 percent to 25 percent.The U.S. biotechnology company said it expected 2014 earnings, excluding items, of $11.35 to $11.45 per share, compared with a prior outlook of $11.00 to $11.20. Analysts on average are looking for a profit of $11.32 per share, according to Thomson Reuters I/B/E/S.Shares of Biogen were down 0.6 percent at $304.41 in late afternoon trading. ""The raised guidance is a testament to the U.S. beat on Tecfidera sales and signals confidence in both the hemophilia launch as well as the Tecfidera launch in Europe,"" RBC Capital Markets analyst Michael Yee said.Biogen plans to begin selling Alprolix, its recently approved long-acting treatment for hemophilia B, in the United States in early May. The company said last week it would price Alprolix on a par with older, less convenient treatments, which should help it get off to a strong start.The company reported net income of $479.9 million, or $2.02 per share for the quarter, compared with $426.7 million, or $1.79 per share, a year earlier.Excluding special items, Biogen said it earned $2.47 per share, missing the analysts' average estimate of $2.55. But the company said its earnings were reduced by about 35 cents a share due to a $118 million expense from a collaboration with Japan's Eisai Co on development of Alzheimer's disease treatments. Without that expense, ""the (earnings) number could have been as high as $2.82, which would have crushed expectations,"" Yee said.Revenue jumped 51 percent to $2.1 billion, edging past Wall Street estimates of $1.99 billion.Biogen said $46 million of the Tecfidera sales came from outside the United States. The drug began selling in Germany in February, and the company said it planned to introduce the medicine in additional European countries in the coming months, with reimbursement agreements already secured in Norway and Scotland. ""We're encouraged by the signs from Germany,"" Tony Kingsley, Biogen's head of global commercial operations, told analysts and investors on a conference call.Biogen's older MS drugs also performed well in the quarter.Sales of Avonex rose 2 percent to $761 million, topping Wall Street estimates of about $735 million.Tysabri sales were $441 million, an increase of 41 percent, due in part to Biogen's regaining full rights to the drug in the second quarter of last year.Biogen said some patients were still discontinuing use of Tysabri, but the company had retained 70 percent of that business, primarily due to switchovers to Tecfidera.The company also said in a regulatory filing that it was subpoenaed by state and federal authorities investigating its sales and promotional practices, and by the federal government for documents related to Biogen's relationship with certain pharmacy benefit managers.The company, which had previously said it was being investigated by governmental authorities, said it was cooperating in the investigations.   (Additional reporting by Deena Beasley; Editing by Lisa Von Ahn and Jonathan Oatis)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 3:38pm EDT",UPDATE 3-Biogen raises outlook as new MS drug again tops forecasts,http://www.reuters.com//article/biogen-idec-results-idUSL2N0NF0HM20140423?type=companyNews
26,"   By Bill Berkrot  Biogen Idec Inc (BIIB.O) on Wednesday raised its full-year earnings and revenue forecasts as first-quarter sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations.Tecfidera racked up sales of $506 million for the quarter, easily topping analysts' expectations of about $440 million and the previous quarter's sales of $398 million.The oral medicine, which was approved in the United States in March 2013, had been on track to become the drug to reach $1 billion in sales in the shortest time. But that pharmaceutical industry record was shattered on Tuesday, when Gildead Sciences Inc (GILD.O) said its Sovaldi hepatitis C treatment logged more than $2 billion in sales in its first full quarter on the market.Based on the strong performance of its MS drugs, Biogen raised its full-year forecast and now expects revenue growth of 26 percent to 28 percent, up from a prior range of 22 percent to 25 percent.The U.S. biotechnology company said it expected 2014 earnings, excluding items, of $11.35 to $11.45 per share, compared with a prior outlook of $11.00 to $11.20. Analysts on average are looking for a profit of $11.32 per share, according to Thomson Reuters I/B/E/S.Shares of Biogen were up 1.1 percent at $309.66 in premarket trading. ""The raised guidance is a testament to the U.S. beat on Tecfidera sales and signals confidence in both the hemophilia launch as well as the Tecfidera launch in Europe,"" RBC Capital Markets analyst Michael Yee said.Biogen plans to begin selling Alprolix, its recently approved long-acting treatment for hemophilia B, in the United States in early May. The company said last week it would price Alprolix on a par with older, less-convenient treatments, which should help it get off to a strong start.The company reported net income of $479.9 million, or $2.02 per share for the quarter, compared with $426.7 million, or $1.79 per share, a year earlier.Excluding special items, Biogen said it earned $2.47 per share, missing the analysts' average estimate of $2.55. But the company said its earnings were reduced by about 35 cents a share due to a $118 million expense from a collaboration with Japan's Eisai Co (4523.T) on development of Alzheimer's disease treatments. Without that expense, ""the (earnings) number could have been as high as $2.82, which would have crushed expectations,"" Yee said.Revenue jumped 51 percent to $2.1 billion, edging past Wall Street estimates of $1.99 billion.Biogen said $46 million of the Tecfidera sales came from outside the United States. The drug began selling in Germany in February, and the company said it planned to introduce the medicine in additional European countries in the coming months, with reimbursement agreements already secured in Norway and Scotland. ""We're encouraged by the signs from Germany,"" Tony Kingsley, Biogen's head of global commercial operations, told analysts and investors on a conference call.Biogen's older MS drugs also performed well in the quarter.Sales of Avonex rose 2 percent to $761 million, topping Wall Street estimates of about $735 million.Tysabri sales were $441 million, an increase of 41 percent, due in part to Biogen's regaining full rights to the drug in the second quarter of last year.Biogen said some patients were still discontinuing use of Tysabri, but the company had retained 70 percent of that business, primarily due to switchovers to Tecfidera.(Reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 9:25am EDT",Biogen raises outlook as new MS drug again tops forecasts,http://www.reuters.com//article/us-biogen-idec-results-idUSBREA3M12O20140423?type=companyNews
27,"  Biogen Idec Inc (BIIB.O) on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations, and the U.S. biotechnology company raised its full-year forecasts.Tecfidera racked up sales of $506 million for the quarter, easily topping analysts' expectations of about $440 million and the previous quarter's sales of $398 million.The oral medicine, which was approved in the United States in March 2013, had been on track to become the drug to reach $1 billion in sales in the shortest time. But that pharmaceutical industry record was shattered on Tuesday, when Gildead Sciences Inc (GILD.O) said its Sovaldi hepatitis C treatment had logged more than $2 billion in sales in its first full quarter on the market.Based on the strong performance of its MS drugs, Biogen raised its full-year forecast and now expects revenue growth of 26 percent to 28 percent, up from a prior range of 22 percent to 25 percent. The company said it expected 2014 earnings, excluding items, of $11.35 to $11.45 per share, compared with a prior outlook of $11.00 to $11.20.Analysts on average are looking for a profit of $11.32 per share, according to Thomson Reuters I/B/E/S. The company reported net income of $479.9 million, or $2.02 per share for the quarter, compared with $426.7 million, or $1.79 per share, a year earlier. Excluding special items, Biogen said it earned $2.47 per share, missing the analysts' average estimate of $2.55. But the company said its earnings were reduced by about 35 cents a share due to a $118 million expense from a collaboration with Japan's Eisai Co (4523.T) on development of an Alzheimer's disease treatment.Biogen sales rose 1.4 percent at $310.50 in premarket trading.(Reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 8:03am EDT",Biogen raises outlook as new MS drug again tops forecasts,http://www.reuters.com//article/us-biogen-idec-results-idUSBREA3M0VA20140423?type=companyNews
28,"  Biogen Idec Inc (BIIB.O) on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended its run of eclipsing Wall Street sales forecasts.The oral medicine racked up sales of $506 million for the quarter, easily toping analysts' expectations of about $440 million and the previous quarter's sales of $398 million. The U.S. biotechnology company reported net income of $479.9 million, or $2.02 per share, compared with $426.7 million, or $1.79 per share, a year earlier. Excluding special items, Biogen said it had earned $2.47 per share. (Reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 7:19am EDT",Biogen posts higher profit as new MS drug again tops forecasts,http://www.reuters.com//article/us-biogen-results-idUSBREA3M0RC20140423?type=companyNews
29,"  April 23 Biogen Idec Inc on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended its run of eclipsing Wall Street sales forecasts.The oral medicine racked up sales of $506 million for the quarter, easily toping analysts' expectations of about $440 million and the previous quarter's sales of $398 million. The U.S. biotechnology company reported net income of $479.9 million, or $2.02 per share, compared with $426.7 million, or $1.79 per share, a year earlier.  Excluding special items, Biogen said it had earned $2.47 per share.   (Reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2014-04-23,BIIB,"Wed Apr 23, 2014 | 7:17am EDT",Biogen posts higher profit as new MS drug again tops forecasts,http://www.reuters.com//article/biogen-results-idUSL2N0ND1DL20140423?type=companyNews
30,"   By Bill Berkrot  Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade.The potentially life-saving clotting factor medicines would be intended for use in Africa, Asia and elsewhere, where three quarters of the world's 400,000 hemophilia sufferers have limited or no access to such drugs, and where most fail to live into adulthood as a result.Biogen and Sobi announced their intention to donate one billion international units of clotting factor drugs over 10 years at the World Federation of Hemophilia (WFH) meeting in Melbourne, Australia.""WFH do their work in countries that consume less than 1 iu per capita. That's a level below which people are dying, where they don't even have enough to treat the life-threatening bleeds,"" Paula Cobb, Biogen's head of hematology, said in a telephone interview. Hemophilia, an inherited disorder in which the blood does not clot properly, is a new therapeutic area for Biogen. The companies last month received U.S. approval for Alprolix, which treats the more rare hemophilia B. The success of the humanitarian effort will hinge on Food and Drug Administration approval of Eloctate for hemophilia A, which would account for at least 85 percent of the donated product. That approval is expected later this year.Biogen, based in Weston, Massachusetts and Stockholm-based Sobi initially committed to donate up to 500 million units to WFH over five years. The remaining 500 million units will be made available for future distribution.The drugs would primarily be used for emergency treatments rather than preventive care as is common in the developed world, where a year of treatment can cost upwards of $300,000. The quantity of donated product would enable doctors to treat more than 75,000 joint bleeding episodes, more than 2,000 life-threatening bleeds and to perform thousands of surgical procedures that would not be possible without access to clotting drugs, the companies said.""We wanted to do something significant that would change and really shift the way donation programs in that field will work,"" said John Cox, Biogen's head of manufacturing and supply. He added that he hopes other companies would be prompted follow suit. It was not possible to put a commercial value on the donation as Biogen has yet to set a price for Eloctate. Alprolix was priced at $2.85 per unit. ""It is tens of millions of dollars in terms of internal manufacturing supply and cost,"" Cox said.Drugmakers, under pressure from the international community over the high prices of their medicines, have sought to burnish their images by offering HIV drugs and other medicines at drastically reduced cost in Africa and poor nations in other regions. Biogen officials said they were responding to a plea for help from the WFH.""Trying to price this for the developing world was not part of the conversation. When we sat down with the executive team, it was not a public relations discussion,"" Cox said. (Reporting by Bill Berkrot in New York; Editing by Eric Walsh)",2014-05-12,BIIB,"Mon May 12, 2014 | 2:05am EDT","Biogen, Sobi pledge hemophilia drug donation in developing world",http://www.reuters.com//article/us-biogen-hemophilia-donation-idUSKBN0DS07W20140512?type=companyNews
31,"   By Bill Berkrot  May 12 Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade.The potentially life-saving clotting factor medicines would be intended for use in Africa, Asia and elsewhere, where three quarters of the world's 400,000 hemophilia sufferers have limited or no access to such drugs, and where most fail to live into adulthood as a result.Biogen and Sobi announced their intention to donate one billion international units of clotting factor drugs over 10 years at the World Federation of Hemophilia (WFH) meeting in Melbourne, Australia.""WFH do their work in countries that consume less than 1 iu per capita. That's a level below which people are dying, where they don't even have enough to treat the life-threatening bleeds,"" Paula Cobb, Biogen's head of hematology, said in a telephone interview. Hemophilia, an inherited disorder in which the blood does not clot properly, is a new therapeutic area for Biogen. The companies last month received U.S. approval for Alprolix, which treats the more rare hemophilia B.The success of the humanitarian effort will hinge on Food and Drug Administration approval of Eloctate for hemophilia A, which would account for at least 85 percent of the donated product. That approval is expected later this year.Biogen, based in Weston, Massachusetts and Stockholm-based Sobi initially committed to donate up to 500 million units to WFH over five years. The remaining 500 million units will be made available for future distribution. The drugs would primarily be used for emergency treatments rather than preventive care as is common in the developed world, where a year of treatment can cost upwards of $300,000.The quantity of donated product would enable doctors to treat more than 75,000 joint bleeding episodes, more than 2,000 life-threatening bleeds and to perform thousands of surgical procedures that would not be possible without access to clotting drugs, the companies said. ""We wanted to do something significant that would change and really shift the way donation programs in that field will work,"" said John Cox, Biogen's head of manufacturing and supply. He added that he hopes other companies would be prompted follow suit.It was not possible to put a commercial value on the donation as Biogen has yet to set a price for Eloctate. Alprolix was priced at $2.85 per unit. ""It is tens of millions of dollars in terms of internal manufacturing supply and cost,"" Cox said.Drugmakers, under pressure from the international community over the high prices of their medicines, have sought to burnish their images by offering HIV drugs and other medicines at drastically reduced cost in Africa and poor nations in other regions. Biogen officials said they were responding to a plea for help from the WFH.""Trying to price this for the developing world was not part of the conversation. When we sat down with the executive team, it was not a public relations discussion,"" Cox said.   (Reporting by Bill Berkrot in New York; Editing by Eric Walsh)",2014-05-12,BIIB,"Mon May 12, 2014 | 2:00am EDT","Biogen, Sobi pledge hemophilia drug donation in developing world",http://www.reuters.com//article/biogen-hemophilia-donation-idUSL2N0NV1Y920140512?type=companyNews
32,"  LONDON European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukemia, boosting the Swiss group's line-up of new cancer treatments.The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.The European Medicines Agency also gave a green light to Biogen Idec's Plegridy for multiple sclerosis and a recommendation for conditional approval to PTC Therapeutics' Translarna for Duchenne muscular dystrophy. Shares in PTC soared on the green light. Novartis received a mixed bag of news, with its Alcon eyecare unit winning a recommendation for Simbrinza, a treatment for open-angle glaucoma or ocular hypertension, but heart treatment serelaxin was rebuffed once again following further re-examination by EU experts. Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.  (Reporting by Ben Hirschler; Editing by Paul Sandle, Greg Mahlich)",2014-05-23,BIIB,"Fri May 23, 2014 | 8:51am EDT","EU agency recommends new drugs from Roche, Biogen and PTC",http://www.reuters.com//article/us-pharmaceuticals-medicines-roche-idUSKBN0E317G20140523?type=companyNews
33,"  (Adds details on medicines, link to story on PTC shares)LONDON May 23 European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukaemia, boosting the Swiss group's line-up of new cancer treatments.The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies. The European Medicines Agency also gave a green light to Biogen Idec's Plegridy for multiple sclerosis and a recommendation for conditional approval to PTC Therapeutics'  Translarna for Duchenne muscular dystrophy. Shares in PTC soared on the green light. Novartis received a mixed bag of news, with its Alcon eyecare unit winning a recommendation for Simbrinza, a treatment for open-angle glaucoma or ocular hypertension, but heart treatment serelaxin was rebuffed once again following further re-examination by EU experts.Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.   (Reporting by Ben Hirschler; Editing by Paul Sandle, Greg Mahlich)",2014-05-23,BIIB,"Fri May 23, 2014 | 8:44am EDT","UPDATE 1-EU agency recommends new drugs from Roche, Biogen and PTC",http://www.reuters.com//article/pharmaceuticals-medicines-roche-idUSL6N0O934P20140523?type=companyNews
34,"  LONDON May 23 European regulators said on Friday they had recommended approval of Roche's new drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukaemia.The European Medicines Agency also gave a green light to Biogen Idec's Plegridy for multiple sclerosis, a new eye drug from Novartis' Alcon unit called Simbrinza and PTC Therapeutics' Translarna for Duchenne muscular dystrophy.  Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.   (Reporting by Ben Hirschler, Editing by Paul Sandle) ",2014-05-23,BIIB,"Fri May 23, 2014 | 7:45am EDT","EU agency recommends drugs from Roche, Novartis, Biogen and PTC",http://www.reuters.com//article/pharmaceuticals-medicines-roche-idUSWLB0089O20140523?type=companyNews
35,"   By Toni Clarke | WASHINGTON  WASHINGTON The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders.Hemophilia A is a rare, inherited blood-clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficient levels in the body of factor VIII, a protein needed to clot the blood.The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix. Biogen developed both drugs with Swedish Orphan Biovitrum AB, or Sobi, and expects the products to form the basis of a new non-malignant blood disorder portfolio.""We see Alprolix and Eloctate as the anchor tenants in a growing franchise,"" said Douglas Williams, Biogen's head of research and development. ""We're in this space to stay.""   Biogen's biggest products are currently the multiple sclerosis drugs Avonex, Tecfidera and Tysabri.     Eloctate is expected to generate annual sales of $1.5 billion by 2019, according to the average estimate of six analysts polled by Thomson Reuters. Sales of Alprolix are expected to generate annual sales of $286 million over the same time period.    Current treatments for hemophilia B generate about $1 billion a year, according to Biogen, while the market for hemophilia A therapies is worth about $6 billion.    Hemophilia A is the more common form of the disease, affecting about 16,000 people in the United States, Biogen said. Hemophilia B affected about 4,000 people.     Hemophilia drugs must be infused two to three times a week to prevent bleeding episodes. Eloctate cuts the number of doses needed per week to between three and five days.Biogen has not set a price for the drug, but Tony Kingsley, head of commercial operations, said the cost for patients who switch from a short-acting product to Biogen's longer-acting product should be roughly the same, even though they will be dosing themselves less frequently.     Last month, Weston, Massachusetts-based Biogen and Stockholm-based Sobi said they would donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade.    The drugs will primarily be used in those nations for emergency treatments rather than preventative care. (Reporting by Toni Clarke; Editing by Sandra Maler and Peter Cooney)",2014-06-06,BIIB,"Fri Jun 6, 2014 | 4:50pm EDT",U.S. FDA approves Biogen's hemophilia A drug Eloctate,http://www.reuters.com//article/us-biogen-idec-fda-approval-idUSKBN0EH2AW20140606?type=companyNews
36,"  (Updates with comment from company, FDA, background)By Toni ClarkeWASHINGTON, June 6 The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's  long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders.Hemophilia A is a rare, inherited blood-clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficient levels in the body of factor VIII, a protein needed to clot the blood.The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix. Biogen developed both drugs with Swedish Orphan Biovitrum AB, or Sobi, and expects the products to form the basis of a new non-malignant blood disorder portfolio.""We see Alprolix and Eloctate as the anchor tenants in a growing franchise,"" said Douglas Williams, Biogen's head of research and development. ""We're in this space to stay."" Biogen's biggest products are currently the multiple sclerosis drugs Avonex, Tecfidera and Tysabri.Eloctate is expected to generate annual sales of $1.5 billion by 2019, according to the average estimate of six analysts polled by Thomson Reuters. Sales of Alprolix are expected to generate annual sales of $286 million over the same time period. Current treatments for hemophilia B generate about $1 billion a year, according to Biogen, while the market for hemophilia A therapies is worth about $6 billion.Hemophilia A is the more common form of the disease, affecting about 16,000 people in the United States, Biogen said. Hemophilia B affected about 4,000 people.Hemophilia drugs must be infused two to three times a week to prevent bleeding episodes. Eloctate cuts the number of doses needed per week to between three and five days. Biogen has not set a price for the drug, but Tony Kingsley, head of commercial operations, said the cost for patients who switch from a short-acting product to Biogen's longer-acting product should be roughly the same, even though they will be dosing themselves less frequently.Last month, Weston, Massachusetts-based Biogen and Stockholm-based Sobi said they would donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade.The drugs will primarily be used in those nations for emergency treatments rather than preventative care.(Reporting by Toni Clarke; Editing by Sandra Maler and Peter Cooney)",2014-06-06,BIIB,"Fri Jun 6, 2014 | 4:46pm EDT",UPDATE 1-U.S. FDA approves Biogen's hemophilia A drug Eloctate,http://www.reuters.com//article/biogen-idec-fda-approval-idUSL1N0ON1W820140606?type=companyNews
37,"  WASHINGTON, June 6 The U.S. Food and Drug Administration said on Friday it has approved Biogen Idec Inc's  long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders.Hemophilia A is a rare, inherited blood clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficient levels in the body of factor VIII, a protein needed to clot the blood.  The FDA's ruling follows its approval in March of Biogen's hemophilia B treatment, Alprolix. Biogen developed both drugs with Swedish Orphan Biovitrum AB and expects the products to form the basis of a new non-malignant blood disorder portfolio.   (Reporting by Toni Clarke; Editing by Sandra Maler) ",2014-06-06,BIIB,"Fri Jun 6, 2014 | 4:29pm EDT",U.S. FDA approves Biogen's hemophilia A drug Eloctate,http://www.reuters.com//article/biogen-idec-fda-approval-idUSWNBB04K8S20140606?type=companyNews
38,"   By Ransdell Pierson  A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.The Phase III international study of the medicine, called daclizumab, involved more than 1,800 patients with relapsing-remitting multiple sclerosis, the most common form of MS, which can lead to disability and paralysis. The companies disclosed partial results from the new trial on Monday. The study, called DECIDE, tested monthly injections of daclizumab against weekly injections of Biogen's blockbuster Avonex (interferon beta-1a) treatment for MS. Patients taking daclizumab, which is meant to tame the immune system by blocking a protein called the CD25 receptor, had 45 percent fewer annual relapses than those receiving Avonex. In addition, patients taking daclizumab had 54 percent  fewer new or enlarging brain and spinal lesions at week 96 of the study, compared to those taking Avonex; those results met a secondary goal of the study. The overall incidence of side effects was similar in both patient groups. But there was a two-fold higher incidence of serious infections among those taking daclizumab, at 4 percent, as well as a two-fold higher incidence of elevated liver enzymes - a potential marker for liver toxicity.Daclizumab would be a new approach to treating MS, if it is approved for the condition.Alex Arfaei, an analyst with BMO Capital Markets, said the decline in annual relapses seen with daclizumab was a bit less impressive than the reductions of 52 percent, versus Avonex, achieved in earlier trials by the oral medication Gilenya, which is made by Novartis AG. Gilenya had sales of $1.9 billion last year. ""Our first impression is that these results are good enough for (daclizumab) to be competitive"" with Gilenya and other oral treatments, Arfaei said in a research note.He predicted the Biogen/AbbVie drug could be introduced in 2016 and conservatively generate U.S. sales of $256 million by 2018.Biogen and AbbVie said they would discuss with health regulators the timing for potential marketing applications for daclizumab.  Swiss drugmaker Roche Holding AG introduced daclizumab in 1997 to prevent rejection of transplanted kidneys, under the brand name Zenapax. It stopped selling the drug in 2009 due to poor sales and the availability of newer treatments.Multiple sclerosis is believed to be caused by overactive immune system cells, called t-cells, that attack and destroy the protective covering of nerves.Biogen shares were up 0.8 percent in morning trading on the Nasdaq. AbbVie shares slipped 0.3 percent on the New York Stock Exchange.  (Reporting by Ransdell Pierson; Editing by Nick Zieminski and Leslie Adler)",2014-06-16,BIIB,"Mon Jun 16, 2014 | 11:54am EDT","Biogen, AbbVie drug slows MS episodes, safety issues recur",http://www.reuters.com//article/us-biogen-abbvie-ms-idUSKBN0ER1KR20140616?type=companyNews
39,"  (Adds analyst comment, background on daclizumab, MS drugs, byline)By Ransdell PiersonJune 16 A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec  and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.The Phase III international study of the medicine, called daclizumab, involved more than 1,800 patients with relapsing-remitting multiple sclerosis -- the most common form of MS, which can lead to disability and paralysis.The companies disclosed partial results from the new trial on Monday.The study, called DECIDE, tested monthly injections of daclizumab against weekly injections of Biogen's blockbuster Avonex (interferon beta-1a) treatment for MS. Patients taking daclizumab, which is meant to tame the immune system by blocking a protein called the CD25 receptor, had 45 percent fewer annual relapses than those receiving Avonex. In addition, patients taking daclizumab had 54 percent  fewer new or enlarging brain and spinal lesions at week 96 of the study, compared to those taking Avonex; those results met a secondary goal of the study.The overall incidence of side effects was similar in both patient groups. But there was a two-fold higher incidence of serious infections among those taking daclizumab, at 4 percent, as well as a two-fold higher incidence of elevated liver enzymes - a potential marker for liver toxicity.Daclizumab would be a new approach to treating MS, if it is approved for the condition. Alex Arfaei, an analyst with BMO Capital Markets, said the decline in annual relapses seen with daclizumab was a bit less impressive than the reductions of 52 percent, versus Avonex, achieved in earlier trials by the oral medication Gilenya, which is made by Novartis AG. Gilenya had sales of $1.9 billion last year.""Our first impression is that these results are good enough for (daclizumab) to be competitive"" with Gilenya and other oral treatments, Arfaei said in a research note. He predicted the Biogen/AbbVie drug could be introduced in 2016 and conservatively generate U.S. sales of $256 million by 2018.Biogen and AbbVie said they would discuss with health regulators the timing for potential marketing applications for daclizumab.Swiss drugmaker Roche Holding AG introduced daclizumab in 1997 to prevent rejection of transplanted kidneys, under the brand name Zenapax. It stopped selling the drug in 2009 due to poor sales and the availability of newer treatments.Multiple sclerosis is believed to be caused by overactive immune system cells, called t-cells, that attack and destroy the protective covering of nerves.Biogen shares were up 0.8 percent in morning trading on the Nasdaq. AbbVie shares slipped 0.3 percent on the New York Stock Exchange.    (Reporting by Ransdell Pierson; Editing by Nick Zieminski and Leslie Adler)",2014-06-16,BIIB,"Mon Jun 16, 2014 | 11:50am EDT","UPDATE 1-Biogen, AbbVie drug slows MS episodes, safety issues recur",http://www.reuters.com//article/biogen-abbvie-ms-idUSL2N0OX0PB20140616?type=companyNews
40,"  June 16 A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec  and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.The mixed results were seen in a Phase III international study of the medicine, called daclizumab, that involved more than 1,800 patients with relapsing-remitting multiple sclerosis - the most common form of MS which can lead to disability and paralysis.The companies disclosed partial results from the new trial on Monday. Shares of both Biogen and AbbVie were little changed in morning trading.In the study, called DECIDE, once-monthly injections of daclizumab were tested against once-weekly injections of Biogen's blockbuster Avonex (interferon beta-1a) treatment for MS. Patients taking daclizumab, which is meant to tame the immune system by blocking a protein called the CD25 receptor, had 45 percent fewer annual relapses than those receiving Avonex. Moreover, patients taking daclizumab had 54 percent  fewer new or enlarging brain and spinal lesions at week 96 of the study, compared to those taking Avonex, thereby meeting a secondary goal of the study. The overall incidence of side effects was similar in both patient groups. But there was a two-fold higher incidence of serious infections among those taking daclizumab, at 4 percent, as well as a two-fold higher incidence of elevated liver enzymes - a potential marker for liver toxicity.Daclizumab would be a new approach to treating MS, if it is approved for the condition. Biogen and AbbVie said they would discuss with health regulators timing for potential marketing applications for the drug.MS is believed to be caused by overactive immune system cells, called t-cells, that attack and destroy the protective covering of nerves.   (Reporting by Ransdell Pierson; Editing by Nick Zieminski)",2014-06-16,BIIB,"Mon Jun 16, 2014 | 9:47am EDT","Biogen, AbbVie drug slows MS episodes, safety issues recur",http://www.reuters.com//article/biogen-abbvie-ms-idUSL2N0OX0J820140616?type=companyNews
41,"   By Ransdell Pierson  Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis, boosting shares 11 percent.""These are spectacular results, and this is one of the biggest profit beats for Biogen I've seen in years,"" said RBC Capital Markets analyst Michael Yee.Tecfidera, which was approved in March 2013, posted sales of $700 million in the second quarter, making it one of the fastest-growing prescription medicines in history. U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range.  The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.Gilenya, with annual sales of more than $2 billion, in 2010 became the first pill approved for MS, followed by Aubagio, which has annual sales of about $400 million.But Gilenya has been associated with cardiovascular risks, and reports of sudden death, while Aubagio is deemed to be somewhat lacking in potency and raises the risk of liver problems. ""Tecfidera has the best balance of efficacy and safety"" among the three oral agents, said Robert Baird and Co analyst Chris Raymond.He said Tecfidera, which costs about $48,000 a year in the United States and about $30,000 in Europe, could eventually reap annual sales of up to $6 billion.  ""Clearly, if you have to take a chronic therapy, you'd rather take a pill than an injection,"" he said.  Multiple sclerosis affects an estimated 2.3 million people worldwide. The condition, often leading to paralysis, is caused by damage to the protective myelin sheath of nerves and is believed to be the result of attacks by an overactive immune system.Biogen's revenue jumped 40 percent to $2.42 billion, about $250 million above Wall Street expectations. Earnings of $3.49 per share, excluding special items, blew past the $2.83 average forecast of analysts surveyed by Thomson Reuters I/B/E/S.  The results prompted Biogen to raise its 2014 earnings outlook to between $12.90 and $13.10 per share. In April, it had forecast $11.35 to $11.45.RBC Capital Markets' Yee said he believed Biogen would likely beat analysts' estimates in coming quarters and keep raising its forecasts.Avonex, an injectable interferon treatment for MS that is still Biogen's biggest product, posted slightly lower sales of $774 million.    Sales of Tysabri, a high-potency infused MS treatment, leaped 38 percent to $533 million. That included $54 million of previously deferred revenue from Italy.The company on Wednesday received European approval for a longer-lasting interferon treatment for MS called Plegridy that is awaiting U.S. approval. Cowen and Co analyst Eric Schmidt said he expects Plegridy sales of close to $300 million next year, as some patients switch from Avonex.Leading rival MS brands include Teva Pharmaceutical Industries Ltd's Copaxone and its newer version, which is taken less frequently.Others include Bayer AG's Betaseron and Rebif from Pfizer Inc.Biogen is conducting mid-stage trials of an MS drug meant to restore myelin and thereby improve physical and cognitive function. But data from the trial is not expected until 2016, and Schmidt cautioned that it was a high-risk ""speculative"" effort.Biogen said it earned $723.1 million, or $3.01 per share, in the quarter, versus $491 million, or $2.06 per share, a year earlier.Shares of Biogen closed up $33.93, or 11.2 percent, to $337.60 on the Nasdaq. (Reporting by Ransdell Pierson and Caroline Humer; Editing by Lisa Von Ahn and Jonathan Oatis)",2014-07-23,BIIB,"Wed Jul 23, 2014 | 4:09pm EDT",Biogen revenue trounces forecast as MS drug sales surge,http://www.reuters.com//article/us-biogen-idec-results-idUSKBN0FS12K20140723?type=companyNews
42,"  (Adds analyst comment, closes shares)By Ransdell PiersonJuly 23 Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis, boosting shares 11 percent.""These are spectacular results, and this is one of the biggest profit beats for Biogen I've seen in years,"" said RBC Capital Markets analyst Michael Yee.Tecfidera, which was approved in March 2013, posted sales of $700 million in the second quarter, making it one of the fastest-growing prescription medicines in history. U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range.The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.Gilenya, with annual sales of more than $2 billion, in 2010 became the first pill approved for MS, followed by Aubagio, which has annual sales of about $400 million.But Gilenya has been associated with cardiovascular risks, and reports of sudden death, while Aubagio is deemed to be somewhat lacking in potency and raises the risk of liver problems.""Tecfidera has the best balance of efficacy and safety"" among the three oral agents, said Robert Baird and Co analyst Chris Raymond. He said Tecfidera, which costs about $48,000 a year in the United States and about $30,000 in Europe, could eventually reap annual sales of up to $6 billion.""Clearly, if you have to take a chronic therapy, you'd rather take a pill than an injection,"" he said.Multiple sclerosis affects an estimated 2.3 million people worldwide. The condition, often leading to paralysis, is caused by damage to the protective myelin sheath of nerves and is believed to be the result of attacks by an overactive immune system.Biogen's revenue jumped 40 percent to $2.42 billion, about $250 million above Wall Street expectations. Earnings of $3.49 per share, excluding special items, blew past the $2.83 average forecast of analysts surveyed by Thomson Reuters I/B/E/S.The results prompted Biogen to raise its 2014 earnings outlook to between $12.90 and $13.10 per share. In April, it had forecast $11.35 to $11.45.RBC Capital Markets' Yee said he believed Biogen would likely beat analysts' estimates in coming quarters and keep raising its forecasts.Avonex, an injectable interferon treatment for MS that is still Biogen's biggest product, posted slightly lower sales of $774 million. Sales of Tysabri, a high-potency infused MS treatment, leaped 38 percent to $533 million. That included $54 million of previously deferred revenue from Italy.The company on Wednesday received European approval for a longer-lasting interferon treatment for MS called Plegridy that is awaiting U.S. approval.Cowen and Co analyst Eric Schmidt said he expects Plegridy sales of close to $300 million next year, as some patients switch from Avonex.Leading rival MS brands include Teva Pharmaceutical Industries Ltd's Copaxone and its newer version, which is taken less frequently.Others include Bayer AG's Betaseron and Rebif from Pfizer Inc.Biogen is conducting mid-stage trials of an MS drug meant to restore myelin and thereby improve physical and cognitive function. But data from the trial is not expected until 2016, and Schmidt cautioned that it was a high-risk ""speculative"" effort.Biogen said it earned $723.1 million, or $3.01 per share, in the quarter, versus $491 million, or $2.06 per share, a year earlier.Shares of Biogen closed up $33.93, or 11.2 percent, to $337.60 on the Nasdaq.   (Reporting by Ransdell Pierson and Caroline Humer; Editing by Lisa Von Ahn and Jonathan Oatis)",2014-07-23,BIIB,"Wed Jul 23, 2014 | 4:05pm EDT",UPDATE 4-Biogen revenue trounces forecast as MS drug sales surge,http://www.reuters.com//article/biogen-idec-results-idUSL2N0PY29U20140723?type=companyNews
43,"  (Corrects paragraph 7 to identify Chris Raymond as an analyst at Robert Baird and Co, not Raymond James)By Ransdell PiersonJuly 23 Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis, boosting shares 11 percent.""These are spectacular results, and this is one of the biggest profit beats for Biogen I've seen in years,"" said RBC Capital Markets analyst Michael Yee.Tecfidera, which was approved in March 2013, posted sales of $700 million in the second quarter, making it one of the fastest-growing prescription medicines in history. U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range.The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.Gilenya, with annual sales of more than $2 billion, in 2010 became the first pill approved for MS, followed by Aubagio, which has annual sales of about $400 million.But Gilenya has been associated with cardiovascular risks, and reports of sudden death, while Aubagio is deemed to be somewhat lacking in potency and raises the risk of liver problems.""Tecfidera has the best balance of efficacy and safety"" among the three oral agents, said Robert Baird and Co analyst Chris Raymond. He said Tecfidera, which costs about $48,000 a year in the United States and about $30,000 in Europe, will be the pill of choice and could eventually reap annual sales of up to $6 billion, helped by the dominance of Biogen in the MS field.""Clearly, if you have to take a chronic therapy, you'd rather take a pill than an injection,"" he said.Multiple sclerosis affects an estimated 2.3 million people worldwide. The condition, often leading to paralysis, is caused by damage to the protective myelin sheath of nerves and is believed to be the result of attacks by an overactive immune system.Biogen's revenue jumped 40 percent to $2.42 billion, about $250 million above Wall Street expectations. Earnings of $3.49 per share, excluding special items, blew past the $2.83 average forecast of analysts surveyed by Thomson Reuters I/B/E/S.The results prompted the Cambridge, Massachusetts-based company to raise its full-year earnings outlook, excluding special items, to between $12.90 and $13.10 per share. In April, it had forecast $11.35 to $11.45.RBC Capital Markets' Yee said he believed Biogen would likely beat analysts' estimates in coming quarters and keep raising its forecasts.Avonex, an injectable interferon treatment for MS that is still Biogen's biggest product, posted slightly lower sales of $774 million. Sales of Tysabri, a high-potency infused MS treatment, leaped 38 percent to $533 million. That included $54 million of previously deferred revenue from Italy.The company on Wednesday received European approval for a longer-lasting interferon treatment for MS called Plegridy that is awaiting approval in the United States.Cowen and Co analyst Eric Schmidt said he expects Plegridy sales of close to $300 million next year, as some patients switch from Avonex.Leading rival MS brands include Teva Pharmaceutical Industries Ltd's Copaxone and its newer version, which is taken less frequently.Others include Bayer AG's Betaseron and Rebif from Pfizer Inc.Biogen said it earned $723.1 million, or $3.01 per share, in the quarter, compared with $491 million, or $2.06 per share, a year earlier.The company's recently approved Alprolix treatment for hemophilia posted $10.4 million in sales.Shares of Biogen rose $33.81, or 11 percent, to $337.48 in afternoon trading.     (Reporting by Ransdell Pierson and Caroline Humer; Editing by Lisa Von Ahn and Jonathan Oatis)",2014-07-23,BIIB,"Wed Jul 23, 2014 | 3:14pm EDT",CORRECTED-UPDATE 3-Biogen revenue trounces forecast as MS drug sales surge,http://www.reuters.com//article/biogen-idec-results-idUSL2N0PY0HE20140723?type=companyNews
44,  July 23 Biogen Idec Inc :  * Says EU has approved its Plegridy drug for multiple sclerosis. Medicine is a pegylated form of interferon given by injection once every two weeks.   ,2014-07-23,BIIB,"Wed Jul 23, 2014 | 9:28am EDT",BRIEF-Biogen Idec says EU has approved its Plegridy drug for multiple sclerosis,http://www.reuters.com//article/biogenidec-brief-idUSWEN00DNN20140723?type=companyNews
45,"   By Bill Berkrot | NEW YORK  NEW YORK U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.The company received European approval on July 23 for the drug that is intended to reduce relapses of the debilitating disease and slow its progression.Plegridy, like Avonex, is a type of interferon. It is designed to be injected every two weeks compared with weekly injections for Avonex. It is also injected subcutaneously rather than intramuscularly, meaning it requires a smaller needle.Some other MS treatments from the interferon class of medicines, such as Pfizer Inc's Rebif, are dosed more frequently than Avonex. Biogen said it will continue to support Avonex, which has compiled global sales of more than $1.5 billion in the first half of this year, for patients who are comfortable with the treatment and not looking to switch. Avonex has U.S. patent protection until 2026, Biogen said.The company expects Plegridy to diminish Avonex sales and take market share from other rivals even as overall sales from the class decline with the increasing popularity of oral treatments, such as Biogen's Tecfidera, which was approved in 2013. ""We believe Plegridy has the potential to be the leading interferon on the market,"" Tony Kingsley, Biogen's head of global commercial operations, said in a telephone interview.""As the class shrinks, we will be in a position gain share within that class,"" Kingsley said. ""The most convenient product wins over time."" The company will be ready to launch the new drug quickly, Kingsley said, as it already had the MS sales force in place, given its existing portfolio of three other medicines, including Tysabri.The FDA nod marks the fourth U.S. approval for Biogen in the last 16 months along with Tecfidera and two recently approved long-acting hemophilia drugs, Alprolix and Eloctate, that put the MS focused company into a new therapeutic category. (Reporting by Bill Berkrot; Editing by David Gregorio)",2014-08-15,BIIB,"Fri Aug 15, 2014 | 6:52pm EDT",Biogen wins U.S. approval of long acting multiple sclerosis drug,http://www.reuters.com//article/us-biogen-idec-ms-idUSKBN0GF22W20140815?type=companyNews
46,"   By Bill Berkrot | NEW YORK, AUG 15  NEW YORK, AUG 15 U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment.The company received European approval on July 23 for the drug that is intended to reduce relapses of the debilitating disease and slow its progression.Plegridy, like Avonex, is a type of interferon. It is designed to be injected every two weeks compared with weekly injections for Avonex. It is also injected subcutaneously rather than intramuscularly, meaning it requires a smaller needle. Some other MS treatments from the interferon class of medicines, such as Pfizer Inc's Rebif, are dosed more frequently than Avonex.Biogen said it will continue to support Avonex, which has compiled global sales of more than $1.5 billion in the first half of this year, for patients who are comfortable with the treatment and not looking to switch. Avonex has U.S. patent protection until 2026, Biogen said. The company expects Plegridy to diminish Avonex sales and take market share from other rivals even as overall sales from the class decline with the increasing popularity of oral treatments, such as Biogen's Tecfidera, which was approved in 2013.""We believe Plegridy has the potential to be the leading interferon on the market,"" Tony Kingsley, Biogen's head of global commercial operations, said in a telephone interview. ""As the class shrinks, we will be in a position gain share within that class,"" Kingsley said. ""The most convenient product wins over time.""The company will be ready to launch the new drug quickly, Kingsley said, as it already had the MS sales force in place, given its existing portfolio of three other medicines, including Tysabri.The FDA nod marks the fourth U.S. approval for Biogen in the last 16 months along with Tecfidera and two recently approved long-acting hemophilia drugs, Alprolix and Eloctate, that put the MS focused company into a new therapeutic category.   (Reporting by Bill Berkrot; Editing by David Gregorio)",2014-08-15,BIIB,"Fri Aug 15, 2014 | 6:49pm EDT",UPDATE 1-Biogen wins U.S. approval of long acting multiple sclerosis drug,http://www.reuters.com//article/biogen-ms-idUSL2N0PW25D20140815?type=companyNews
47,"  Aug 15 U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment. The company received European approval on July 23 for the drug that is intended to reduce relapses of the debilitating disease and slow its progression.   (Reporting by Bill Berkrot; Editing by David Gregorio)  ",2014-08-15,BIIB,"Fri Aug 15, 2014 | 6:36pm EDT",FDA approves Biogen Idec's multiple sclerosis drug,http://www.reuters.com//article/biogen-idec-ms-idUSL4N0QL4TT20140815?type=companyNews
48,"  * Indexes turn lower in afternoon trading* Fall in crude oil weighs on energy shares* Investors unnerved by shooting in Ottawa* Indexes down: Dow 0.92 pct, S&P 500 0.73 pct, Nasdaq 0.83 pctBy Yasmeen AbutalebNEW YORK, Oct 22 U.S. stocks erased earlier gains to close lower on Wednesday as a shooting at the Canadian parliament unnerved investors, Boeing and Biogen sold off following results, and energy stocks fell along with oil prices.Indexes had traded in positive territory for much of the session, putting the S&P 500 on track for a fifth straight day of gains. Earnings initially drove the move higher, with technology and material shares up on the back of strong results.Market benchmarks began drifting lower after the government reported a surprise increase in crude oil inventories. Energy shares were off 1.7 percent as crude oil fell, settling near $80 per barrel. Canada's capital was jolted by the fatal shooting of a soldier and an attack on the parliament building in which gunshots were fired outside a room where Prime Minister Stephen Harper was speaking. Toronto stocks fell 1.6 percent, also affected by oil's slide.""The situation out of Ottawa hastened the decline a bit, but I think it started with oil because people are very concerned about global growth,"" said John Canally, chief economic and investment strategist for LPL Financial.If the Ottawa shooting is related to domestic terrorism, Canally added, ""it'll put weight on the markets along with global growth."" The Dow Jones industrial average fell 153.49 points, or 0.92 percent, to 16,461.32, the S&P 500 lost 14.17 points, or 0.73 percent, to 1,927.11 and the Nasdaq Composite  dropped 36.63 points, or 0.83 percent, to 4,382.85.Weaker oil and the Canada violence offset some encouraging economic news. U.S. consumer prices rose 0.1 percent in September as energy costs fell broadly, painting a weak inflation picture that could give the Federal Reserve room to keep interest rates low.Among the day's earnings movers, Biogen Idec fell 5.4 percent to $309.07 after sales of its multiple sclerosis drug, Tecfidera, fell short of lofty expectations.Boeing Co lost 4.5 percent to $121.91, giving back most of the gains from the four prior sessions. Boeing reported higher-than-expected earnings and lifted its outlook, but analysts raised concern about the costs of the 787 Dreamliner. On the upside, Yahoo Inc and Broadcom  rallied a day after both tech companies reported better-than-expected revenue.Broadcom shares climbed 5.5 percent to $39.37 while Yahoo was up 4.5 percent at $41.99. The two made up the S&P 500's top percentage gainers.After the close, revenue at Dow component AT&T fell short of analyst expectations and shares were down more than 2 percent.Declining issues outnumbered advancers on the NYSE by 2,138 to 928, for a 2.30-to-1 ratio on the downside; on the Nasdaq, 1,988 issues fell and 701 advanced.The benchmark S&P 500 index posted 44 new 52-week highs and 1 new low; the Nasdaq Composite recorded 54 new highs and 35 new lows.About 7 billion shares changed hands on U.S. exchanges, below the 8.3 billion October average, according to BATS Global Markets.     (Editing by Nick Zieminski)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 4:59pm EDT",US STOCKS-Wall St ends lower after shooting at Canadian parliament,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0SH2QI20141022?type=companyNews
49,"  * Indexes turn lower in afternoon trading* Fall in crude oil weighs on energy shares* Investors unnerved by Canadian parliament shooting* Indexes down: Dow 0.45 pct, S&P 500 0.23 pct, Nasdaq 0.29 pctBy Yasmeen AbutalebNEW YORK, Oct 22 U.S. stocks were lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as a shooting at the Canadian parliament unnerved investors and Boeing and Biogen sold off following results.Indexes had traded in positive territory for much of the session, putting the S&P 500 on track for a fifth straight day of gains. Earnings initially drove the move higher, with technology and material shares up on the back of strong results. Market benchmarks began drifting lower in late morning after a gunman fatally wounded a soldier in Ottawa, the Canadian capital, and then entered the country's parliament buildings, chased by police. By early afternoon, the market had given up earlier gains.""If markets can connect the dots that this is a wider-ranging concern on domestic terrorism, it'll put weight on the markets along with global growth,"" said John Canally, chief economic and investment strategist for LPL Financial.""If it's unrelated to terrorism, markets can probably move on and focus on fundamentals."" Biogen Idec fell 5 percent to $310.42 after sales of its big-selling new multiple sclerosis drug, Tecfidera, fell short of Wall Street's lofty expectations. It also reported a higher-than-expected quarterly profit and raised its full-year earnings forecast.Boeing Co lost 4.1 percent to $121.91 despite reporting higher-than-expected earnings and lifting its outlook, as analysts raised concern about the costs of the 787 Dreamliner. Its decline comes after a rise of 5.8 percent over the four previous sessions.Along with healthcare and industrial names, energy shares  were among the day's biggest decliners, off 0.9 percent as crude oil lost 2.4 percent. On the upside, Yahoo Inc and Broadcom  rallied a day after both tech companies reported better-than-expected revenue.Broadcom shares climbed 6.7 percent to $39.83 while Yahoo was up 5.7 percent at $42.46; the two made up the S&P 500's top percentage gainers.In the latest economic data, consumer prices rose 0.1 percent in September as energy costs fell broadly, painting a weak inflation picture that could give the Federal Reserve room to keep interest rates low for a while.At 3:01 p.m. the Dow Jones industrial average fell 75.17 points, or 0.45 percent, to 16,539.64, the S&P 500  lost 4.4 points, or 0.23 percent, to 1,936.88 and the Nasdaq Composite dropped 12.80 points, or 0.29 percent, to 4,406.68.Declining issues outnumbered advancing ones on the NYSE by 1,851 to 1,183, for a 1.56-to-1 ratio on the downside; on the Nasdaq, 1,800 issues fell and 863 advanced for a 2.09-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 44 new 52-week highs and 1 new low; the Nasdaq Composite was recording 53 new highs and 30 new lows.     (Editing by Nick Zieminski)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 3:10pm EDT",US STOCKS-Wall St lower after shooting at Canadian parliament,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0SH2FO20141022?type=companyNews
50,"  * Indexes turn lower in afternoon trading* Fall in crude oil weighs on energy shares* Investors unnerved by Canadian parliament shooting* Indexes down: Dow 0.61 pct, S&P 500 0.38 pct, Nasdaq 0.43 pctBy Yasmeen AbutalebNEW YORK, Oct 22 U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as a shooting at the Canadian parliament unnerved investors and Boeing and Biogen sold off following results.Indexes had traded in positive territory for much of the session, putting the S&P 500 on track for a fifth straight day of gains. Earnings initially drove the move higher, with technology and material shares up on the back of strong results. Market benchmarks began drifting lower in late morning after a gunman fatally wounded a soldier in Ottawa, the Canadian capital, and then entered the country's parliament buildings chased by police. By early afternoon, the market had given up earlier gains.The shooting in Ottawa is ""the only news event I'm seeing here that could be spooking this market. There's nothing else other than technical points,"" said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont.Biogen Idec was the biggest drag on the S&P 500, falling 5.1 percent to $310.04 after sales of its big-selling new multiple sclerosis drug, Tecfidera, fell short of Wall Street's lofty expectations. It also reported a higher-than-expected quarterly profit and raised its full-year earnings forecast. Boeing Co lost 4.4 percent to $121.57 despite reporting higher-than-expected earnings and lifting its outlook, as analysts raised concern about the costs of the 787 Dreamliner. Its decline comes after a rise of 5.8 percent over the four previous sessions.Along with healthcare and industrial names, energy shares  were among the day's biggest decliners, off 0.9 percent as crude oil lost 1.7 percent.On the upside, Yahoo Inc and Broadcom  rallied a day after both tech companies reported better-than-expected revenue. Broadcom shares climbed 6.1 percent to $39.62 while Yahoo was up 5.2 percent at $42.25; the two made up the S&P 500's top percentage gainers.In the latest economic data, consumer prices rose 0.1 percent in September as energy costs fell broadly, painting a weak inflation picture that could give the Federal Reserve room to keep interest rates low for a while.At 2:09 p.m. the Dow Jones industrial average fell 100.73 points, or 0.61 percent, to 16,514.08, the S&P 500  lost 7.4 points, or 0.38 percent, to 1,933.88 and the Nasdaq Composite dropped 19.19 points, or 0.43 percent, to 4,400.29.Declining issues outnumbered advancing ones on the NYSE by 1,813 to 1,194, for a 1.52-to-1 ratio on the downside; on the Nasdaq, 1,793 issues fell and 844 advanced for a 2.12-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 44 new 52-week highs and 1 new low; the Nasdaq Composite was recording 53 new highs and 25 new lows.     (Editing by Nick Zieminski)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 2:20pm EDT",US STOCKS-Wall St turns lower after shooting at Canadian parliament,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0SH20K20141022?type=companyNews
51,"   By Bill Berkrot  Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious brain infection in a patient who took the oral medication, sending its shares 7 percent lower.Biogen reported the first case of progressive multifocal leukoencephalopathy (PML) in a Tecfidera patient, who had been part of a clinical trial and was taking the drug for 4-1/2 years.The patient, who died of pneumonia, had been suffering severe lymphopenia, a low white blood cell condition, for more than three years, which Biogen said was a risk factor for developing PML.Biogen, which has notified health regulators of the PML case, said 100,000 patients have taken Tecfidera.The drug, which has far exceeded expectations since its March 2013 U.S. approval, had sales of $787 million in the third quarter. Analysts, who in previous quarters had watched Tecfidera sail past their sales estimates, were looking for about $800 million.""We've always expected that Tecfidera's growth rate would moderate over time,"" Tony Kingsley, Biogen's head of commercial operations, said on a conference call.Shares of the U.S. biotechnology company fell $22.55 to  $304.21 on Nasdaq at mid-afternoon.While Tecfidera has had a clean safety record throughout its  clinical trials and commercial use, PML has long been a concern associated with long-term treatment of MS drugs. Biogen's injectable MS drug Tysabri was pulled from the market in February of 2005 after three cases of the rare brain infection - two of them fatal - were reported among users.U.S. health regulators allowed it back on the market with certain restrictions in June 2006 after campaigning by patients who felt the medicine was so effective they were willing to take on the PML risk.""We think the risk/benefit is clearly still in favor of using Tecfidera for nearly all patients,"" said RBC Capital Markets analyst Michael Yee.   Biogen reported a higher-than-expected quarterly profit and raised its full-year earnings forecast, primarily on lower business development and research and development spending expectations. It now estimates 2014 earnings per share of $13.45 to $13.55, up from its previous forecast of $12.90 to $13.10, excluding items.""For a company that's been beating and crushing numbers, it's hard to see people getting terribly excited about this,"" Sanford Bernstein analyst Geoffrey Porges said. ""You have to wonder if this is the new normal for Biogen or whether they can resume that spectacular growth.""Biogen's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.Excluding items, Biogen earned $3.80 per share, exceeding analysts' average expectations by 34 cents, according to Thomson Reuters I/B/E/S. Revenue rose 37 percent to $2.5 billion, roughly in line with estimates of $2.48 billion.Tysabri had sales of $501 million, beating analyst expectations of about $485 million.The company's interferon-based MS drugs, Avonex and new longer-acting Plegridy, had combined sales of $745 million, missing Wall Street estimates of about $767 million.Avonex has lost market share to Tecfidera. Biogen said 40 percent of patients switching MS treatments have chosen Tecfidera.""With all of their MS products you have to wonder is there enough incremental revenue to support continued growth or are they just cannibalizing the rest of their franchise every time they launch a new product,"" Porges said. (Reporting by Bill Berkrot in New York; Editing by Jeffrey Benkoe, Chizu Nomiyama, Paul Simao and Richard Chang)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 1:55pm EDT",Biogen's Tecfidera sales miss estimates; confirms first PML case,http://www.reuters.com//article/us-biogen-results-idUSKCN0IB19720141022?type=companyNews
52,"  (Adds PML background, updates shares)By Bill BerkrotOct 22 Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious brain infection in a patient who took the oral medication, sending its shares 7 percent lower.Biogen reported the first case of progressive multifocal leukoencephalopathy (PML) in a Tecfidera patient, who had been part of a clinical trial and was taking the drug for 4-1/2 years.The patient, who died of pneumonia, had been suffering severe lymphopenia, a low white blood cell condition, for more than three years, which Biogen said was a risk factor for developing PML.Biogen, which has notified health regulators of the PML case, said 100,000 patients have taken Tecfidera.The drug, which has far exceeded expectations since its March 2013 U.S. approval, had sales of $787 million in the third quarter. Analysts, who in previous quarters had watched Tecfidera sail past their sales estimates, were looking for about $800 million.""We've always expected that Tecfidera's growth rate would moderate over time,"" Tony Kingsley, Biogen's head of commercial operations, said on a conference call. Shares of the U.S. biotechnology company fell $22.55 to  $304.21 on Nasdaq at mid-afternoon.While Tecfidera has had a clean safety record throughout its  clinical trials and commercial use, PML has long been a concern associated with long-term treatment of MS drugs.Biogen's injectable MS drug Tysabri was pulled from the market in February of 2005 after three cases of the rare brain infection - two of them fatal - were reported among users.U.S. health regulators allowed it back on the market with certain restrictions in June 2006 after campaigning by patients who felt the medicine was so effective they were willing to take on the PML risk. ""We think the risk/benefit is clearly still in favor of using Tecfidera for nearly all patients,"" said RBC Capital Markets analyst Michael Yee.Biogen reported a higher-than-expected quarterly profit and raised its full-year earnings forecast, primarily on lower business development and research and development spending expectations.It now estimates 2014 earnings per share of $13.45 to $13.55, up from its previous forecast of $12.90 to $13.10, excluding items.""For a company that's been beating and crushing numbers, it's hard to see people getting terribly excited about this,"" Sanford Bernstein analyst Geoffrey Porges said. ""You have to wonder if this is the new normal for Biogen or whether they can resume that spectacular growth."" Biogen's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.Excluding items, Biogen earned $3.80 per share, exceeding analysts' average expectations by 34 cents, according to Thomson Reuters I/B/E/S.Revenue rose 37 percent to $2.5 billion, roughly in line with estimates of $2.48 billion.Tysabri had sales of $501 million, beating analyst expectations of about $485 million.The company's interferon-based MS drugs, Avonex and new longer-acting Plegridy, had combined sales of $745 million, missing Wall Street estimates of about $767 million.Avonex has lost market share to Tecfidera. Biogen said 40 percent of patients switching MS treatments have chosen Tecfidera.""With all of their MS products you have to wonder is there enough incremental revenue to support continued growth or are they just cannibalizing the rest of their franchise every time they launch a new product,"" Porges said.   (Reporting by Bill Berkrot in New York; Editing by Jeffrey Benkoe, Chizu Nomiyama, Paul Simao and Richard Chang)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 1:52pm EDT",UPDATE 4-Biogen's Tecfidera sales miss estimates; confirms first PML case,http://www.reuters.com//article/biogen-results-idUSL2N0SH0NK20141022?type=companyNews
53,"  * Indexes turn lower in afternoon trading* Broadcom and Yahoo rally after results* Fall in crude oil weighs on energy shares* Indexes down: Dow 0.4 pct, S&P 0.3 pct, Nasdaq 0.5 pctBy Ryan VlastelicaNEW YORK, Oct 22 U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as both Boeing and Biogen sold off following their results.Indexes had traded in positive territory for much of the session, putting the S&P 500 on track for a fifth straight day of gains. Earnings drove the move higher, with technology and material shares up on the back of strong results. Biogen Idec was the biggest drag on the S&P 500, falling 7 percent to $303.88 after the company reported sales of its big-selling new multiple sclerosis drug, Tecfidera, that fell short of Wall Street's lofty expectations. It also reported a higher-than-expected quarterly profit and raised its full-year earnings forecast.Boeing Co lost 3.4 percent to $122.83 despite reporting higher-than-expected earnings and lifting its outlook, as analysts raised concern about the costs of the 787 Dreamliner. Its decline comes after a rise of 5.8 percent over the four previous sessions.Along with healthcare and industrial names, energy shares  were among the day's biggest decliners, off 0.5 percent as crude oil lost 1.1 percent. On the upside, Yahoo Inc and Broadcom  rallied a day after both tech companies reported better-than-expected revenue.Broadcom shares climbed 6 percent to $39.59 while Yahoo was up 4.4 percent at $41.96; the two made up the S&P 500's top percentage gainers.""The season has been mixed, and the global economy is a concern for big multinational companies, but the fact that the market can shake off some bad reports is indicative of what good footing it is on right now,"" said Bruce Bittles, chief investment strategist at Robert W. Baird & Co in Nashville. In the latest economic data, consumer prices rose 0.1 percent in September as energy costs fell broadly, painting a weak inflation picture that should give the Federal Reserve ample room to keep interest rates low for a while.At 12:51 p.m. Eastern time, the Dow Jones industrial average  fell 70.24 points, or 0.42 percent, to 16,544.57, the S&P 500 lost 5.63 points, or 0.29 percent, to 1,935.65 and the Nasdaq Composite dropped 21.67 points, or 0.49 percent, to 4,397.81.Declining issues outnumbered advancing ones on the NYSE by 1,666 to 1,331, for a 1.25-to-1 ratio on the downside; on the Nasdaq, 1,699 issues fell and 904 advanced for a 1.88-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 44 new 52-week highs and 1 new low; the Nasdaq Composite was recording 53 new highs and 20 new lows.The S&P 500 moved 14.07 points from its session high to its session low, a move that is below the 15.6 point average over the past 250 sessions. Wednesday marks the first time the S&P has had a below-average point move since Sept. 23.(Editing by Nick Zieminski and Chris Reese)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 1:06pm EDT","US STOCKS-Wall St turns lower as Boeing, Biogen weigh",http://www.reuters.com//article/markets-stocks-usa-idUSL2N0SH1YS20141022?type=companyNews
54,  Oct 22 Biogen Idec Inc :  * Says confirmed one case of PML in patient taking its multiple sclerosis drugTecfidera who died of pneumonia  * Says FDA been informed of PML case in Tecfidera patient who had taken drug  for 4.5 years ,2014-10-22,BIIB,"Wed Oct 22, 2014 | 9:29am EDT",BRIEF-Biogen confirms one case of PML in patient taking MS drug Tecfidera,http://www.reuters.com//article/biogenidec-brief-idUSWEN00E4Y20141022?type=companyNews
55,"  Oct 22 Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time.Tecfidera, which has enjoyed one of the best new drug launches in pharmaceutical history despite being the third MS pill to market, had sales of $787 million in the quarter. Analysts looked for about $800 million. The U.S. biotechnology company's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.  Revenue rose 37 percent to $2.5 billion, roughly in line with estimates of $2.48 billion, according to Thomson Reuters I/B/E/S.   (Reporting by Bill Berkrot in New York; Editing by Jeffrey Benkoe)",2014-10-22,BIIB,"Wed Oct 22, 2014 | 7:30am EDT","Biogen profit surges, but Tecfidera sales shy of Street view",http://www.reuters.com//article/biogen-results-idUSL2N0SG35X20141022?type=companyNews
56,"  (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.The drug, Obizur, has been approved for use in patients with acquired hemophilia A, which usually affects older adults, Baxter said in a statement. The drug will be launched in the United States in the coming months and is being reviewed by European and Canadian regulators, the company said. Obizur will compete with Biogen Idec Inc's Eloctate, which was approved in June. Both the drugs are long-acting treatments. Hemophilia A is a rare blood-clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficiency of factor VIII, a protein needed to clot the blood. The rarer form of the condition is hemophilia B, caused by deficiency to another protein, factor IX. The FDA had in March approved Biogen's hemophilia B treatment, Alprolix, a bioengineered version of factor IX. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL Behring Ltd's Mononine. Baxter's shares were up about 1 percent at $69.66 in early afternoon trading on the New York Stock Exchange.  (Reporting by Shailesh Kuber in Bangalore; Editing by Kirti Pandey)",2014-10-27,BIIB,"Mon Oct 27, 2014 | 11:34am EDT",Baxter's blood disorder drug gets FDA approval,http://www.reuters.com//article/us-baxter-fda-idUSKBN0IG1OM20141027?type=companyNews
57,"  (Corrects to remove paragraph saying that Obizur will compete with Biogen Idec Inc's Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)Oct 24 Drugmaker Baxter International Inc  said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.The drug, Obizur, has been approved for use in patients with acquired hemophilia A, which usually affects older adults, Baxter said in a statement. The drug will be launched in the United States in the coming months and is being reviewed by European and Canadian regulators, the company said.Hemophilia A is a rare blood-clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficiency of factor VIII, a protein needed to clot the blood. The rarer form of the condition is hemophilia B, caused by deficiency to another protein, factor IX. The FDA had in March approved Biogen's hemophilia B treatment, Alprolix, a bioengineered version of factor IX. Other approved hemophilia B treatments include Baxter's Rixubis, Pfizer Inc's Benefix and CSL Behring Ltd's  Mononine.Baxter's shares were up about 1 percent at $69.66 in early afternoon trading on the New York Stock Exchange.    (Reporting by Shailesh Kuber in Bangalore; Editing by Kirti Pandey)",2014-10-27,BIIB,"Mon Oct 27, 2014 | 11:29am EDT",CORRECTED-UPDATE 1-Baxter's blood disorder drug gets FDA approval (Oct 24),http://www.reuters.com//article/baxter-fda-idUSL3N0SJ5N620141027?type=companyNews
58,"  * More cars and trucks sold in November than analysts expected* Otsuka to buy Avanir; Cypress Semi to buy Spansion* Biogen rallies on expansion of Alzheimer's drug testing* Dow industrials close at record high* Indexes up: Dow 0.58 pct, S&P 0.64 pct, Nasdaq 0.6 pct   (Updates to market close)By Rodrigo CamposNEW YORK, Dec 2 U.S. stocks rose on Tuesday as energy stocks led the S&P 500 and Dow, while Biogen's rally on news about an experimental treatment for Alzheimer's disease topped gains at the Nasdaq. The day's gains were broad, with nine of the 10 S&P 500 industry sectors higher. The only group to fall was telecoms , down 1.8 percent with AT&T down 2.2 percent at $34.29 and Verizon down 1.8 percent at $49.11. Sprint announced it will cut in half the monthly price of service for Verizon and AT&T customers who switch to Sprint.Energy shares on the S&P 500 rose 1.3 percent even as crude oil prices resumed their fall. U.S. crude fell 2.4 percent to near a five-year low while Brent lost 2.3 percent.Exxon Mobil and Chevron were among the largest gainers on both the Dow and the S&P, up about 2 percent each. ""The market is sniffing out a bottom in the underlying commodity and we are seeing a bounce in energy stocks from having been oversold in the last month or so,"" said John Manley, chief equity strategist at Wells Fargo Funds Management in New York.""It's in no one's interest for oil to go any lower; not in ours, or OPEC's,"" he said, adding that it is still a big benefit for consumers but the marginal gain with even lower gas would not be much bigger.The Dow Jones industrial average rose 102.75 points, or 0.58 percent, to 17,879.55, a record high. The S&P 500  gained 13.11 points, or 0.64 percent, to 2,066.55 and the Nasdaq Composite added 28.46 points, or 0.6 percent, to 4,755.81. Carmaker shares advanced as the top six automakers sold more cars and trucks in November than analysts expected. GM  gained 1 percent to $33.26 and Fiat Chrysler gained 3 percent to $13.09.Biogen Idec advanced 6.4 percent to $328.27. The company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug significantly improved cognition in a small early-stage study.Avanir Pharmaceuticals was among the most traded stocks on the Nasdaq, rising 12.8 percent to $16.92. Japanese drugmaker Otsuka Holdings plans to buy it for about $3.5 billion.About two issues advanced for every decliner on both the NYSE and Nasdaq.The S&P 500 posted 89 new 52-week highs and 5 new lows; the Nasdaq Composite set 102 new highs and 95 new lows.About 6.6 billion shares changed hands on U.S. exchanges, according to BATS Global Markets data, above the daily average last month of about 6.17 billion.   (Reporting by Rodrigo Campos; Editing by Nick Zieminski)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 4:46pm EST",US STOCKS-Energy shares lead Wall St higher; telecoms slip,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0TM24A20141202?type=companyNews
59,"  * More cars and trucks sold in November than analysts expected* Otsuka to buy Avanir; Cypress Semi to buy Spansion* Biogen rallies on expansion of Alzheimer's drug testing* Indexes up: Dow 0.4 pct, S&P 0.5 pct, Nasdaq 0.4 pct   (Updates prices, changes byline)By Rodrigo CamposNEW YORK, Dec 2 U.S. stocks rose on Tuesday, led by gains in the energy sector, and as Biogen rallied on news about an experimental treatment for Alzheimer's disease. The day's gains were broad, with nine of the 10 S&P 500 industry sectors higher. The only group to fall was telecoms , down 1.6 percent with AT&T down 2.1 percent and Verizon down 1.5 percent. Sprint announced it will cut in half the monthly price of service for Verizon and AT&T customers who switch to Sprint.Energy shares on the S&P 500 rose 1.6 percent even as crude oil prices resumed their fall. U.S. crude fell 2.6 percent to near a five-year low while Brent lost 2.2 percent.Exxon Mobil and Chevron were among the largest gainers on both the Dow and the S&P. At 2:42 p.m. (1942 GMT) the Dow Jones industrial average  rose 94.27 points, or 0.53 percent, to 17,871.07, the S&P 500 gained 12.43 points, or 0.61 percent, to 2,065.87 and the Nasdaq Composite added 26.75 points, or 0.57 percent, to 4,754.09.Carmaker shares advanced as the top six automakers sold more cars and trucks in November than analysts expected. GM  gained 1.5 percent to $33.42 and Fiat Chrysler gained 2.6 percent to $13.05. Biogen Idec Inc advanced 5.7 percent to $326.07. Its research chief said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug significantly improved cognition in a small early-stage study.Avanir Pharmaceuticals was among the most traded stocks on the Nasdaq, rising 12.8 percent to $16.92 as Japanese drugmaker Otsuka Holdings plans to buy it for about $3.5 billion.Cypress Semiconductor Corp added 12.2 percent to $11.70 after it said it will buy peer Spansion Inc for $1.59 billion in stock. Spansion shares rallied 19.1 percent to $27.21.Advancing issues outnumbered declining ones on the NYSE by 2,023 to 1,034, for a 1.96-to-1 ratio; on the Nasdaq, 1,820 issues rose and 866 fell for a 2.10-to-1 ratio.The S&P 500 was posting 79 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 97 new highs and 81 new lows.     (Reporting by Rodrigo Campos; Editing by Nick Zieminski)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 3:02pm EST",US STOCKS-Energy shares lead Wall St higher in broad advance,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0TM1RL20141202?type=companyNews
60,"  * Energy names rally despite continued drop in oil prices* Otsuka to buy Avanir; Cypress Semi to buy Spansion* Biogen rallies on favorable Alzheimer's drug data* Indexes up: Dow 0.4 pct, S&P 0.5 pct, Nasdaq 0.4 pct   (Updates to midday trading)By Ryan VlastelicaNEW YORK, Dec 2 U.S. stocks rose on Tuesday as a pair of big M&A deals boosted market optimism and helped the market rebound from the broad decline in the previous session, which was the S&P 500's weakest day in a month.The day's gains were broad, with nine of the 10 primary S&P 500 sectors higher. The only group to fall was telecom , off 1 percent. The sector is considered defensive. Energy shares were the strongest sector on the day despite continued weakness in the price of crude oil. While oil  fell 2 percent to $67.66 per barrel - extending a decline that has taken the commodity down more than 30 percent from a recent peak - the S&P energy sector reversed earlier losses and rose 1.5 percent.""Valuations have gotten pummeled under the weight of declining crude prices, and it looks like investors are starting to nibble at the space,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia. ""The group looks extremely oversold, and dividends remain pretty strong.""Among the most active names, Marathon Petroleum rose 4.7 percent to $95.07, while Valero Energy was up 3.8 percent at $50.77. There is currently an inverse correlation of -0.8 between the S&P 500 and crude oil, a dramatic flip from Oct. 20, when the correlation was a positive 0.9, indicating they moved almost perfectly in sync.Cypress Semiconductor Corp agreed to buy Spansion Inc  in an all-stock deal valued at about $4 billion.  Separately, Otsuka Pharmaceutical Co Ltd said it would buy Avanir Pharmaceuticals Inc for about $3.5 billion.Cypress rose 16 percent to $12.08, while Spansion was up 23 percent at $28.09 on heavy volume. Avanir added 13 percent to $16.92. Biogen Idec Inc advanced 5.7 percent to $326.07 as the S&P's biggest advancing stock on favorable data from the Phase III trial of an Alzheimer's drug.Digital Ally jumped 41 percent to $18.16 on heavy volume a day after U.S. President Barack Obama urged lawmakers to spend $263 million over three years on 50,000 body-worn cameras and law enforcement training programs as part of the federal response to civil rights protests in Ferguson, Missouri.At 12:19 p.m. (1719 GMT) the Dow Jones industrial average  rose 63.54 points, or 0.36 percent, to 17,840.34, the S&P 500 gained 9.68 points, or 0.47 percent, to 2,063.12, and the Nasdaq Composite added 20.18 points, or 0.43 percent, to 4,747.52.Advancing issues outnumbered declining ones on the NYSE by 2,057 to 933, for a 2.20-to-1 ratio on the upside; on the Nasdaq, 1,839 issues rose and 765 fell for a 2.40-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 67 new 52-week highs and two new lows; the Nasdaq Composite was recording 79 new highs and 72 new lows.     (Editing by Nick Zieminski; and Peter Galloway)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 12:28pm EST","US STOCKS-Wall St rises, boosted by energy despite oil weakness",http://www.reuters.com//article/markets-stocks-usa-idUSL2N0TM1BO20141202?type=companyNews
61,"   By Ransdell Pierson  Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a smallearly-stage study.Shares of Biogen, whose main drugs treat multiple sclerosis, were up 6 percent in midday trading on the Nasdaq.Douglas Williams, speaking at the Deutsche Bank BioFEST conference, said the encouraging data was seen in a Phase 1b trial of its BIIB037 drug. It was tested in patients with mild symptoms of the progressive neurological disease, or in those who did not yet have apparent symptoms but had other possible signs of Alzheimer's.The medicine, like many other experimental Alzheimer's drugs that have failed in studies or are continuing to be tested, blocks beta amyloid, a protein that plays a key role in the buildup of toxic plaques in the brain that are considered a hallmark of Alzheimer's.     ""We are preparing to implement a Phase III study in early Alzheimer's as soon as we can,"" company spokeswoman Kate Niazi-Sai said after Williams' presentation.The most significant side effects seen with BIIB037 were signs of possible brain swelling and tiny hemorrhages, which the company described as ""largely mild to moderate, and self-resolving."" Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs, including with bapineuzumab from Pfizer Inc and solanezumab from Eli Lilly and Co. It has also been closely associated with an experimental class of drugs called gamma secretase inhibitors that have largely been abandoned.Pfizer and its partner Johnson & Johnson discontinued bapineuzumab after it failed in big late-stage trials to significantly improve cognition in patients with mild to moderate Alzheimer's. But Lilly continues to test solananezumab in patients with mild Alzheimer's.  One of the biggest hopes for patients is another class of Alzheimer's drugs called BACE inhibitors. They block an enzyme called beta secretase which plays a key role in production of beta amyloid. Eli Lilly, Merck & Co are considered furthest along in testing such drugs.As many as 5 million people in the United States and 36 million globally are believed to have Alzheimer's, the most common form of dementia. The U.S. figure for people 65 or older may triple by 2050 as the population ages, according to the Alzheimer's Association. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Marguerita Choy)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 12:00pm EST","Biogen plans late-stage Alzheimer's trial, shares rise",http://www.reuters.com//article/us-biogen-idec-alzheimers-idUSKCN0JG1JX20141202?type=companyNews
62,"  (Adds details on Biogen drug, other treatments)By Ransdell PiersonDec 2 Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study.Shares of Biogen, whose main drugs treat multiple sclerosis, were up 6 percent in midday trading on the Nasdaq.Douglas Williams, speaking at the Deutsche Bank BioFEST conference, said the encouraging data was seen in a Phase 1b trial of its BIIB037 drug. It was tested in patients with mild symptoms of the progressive neurological disease, or in those who did not yet have apparent symptoms but had other possible signs of Alzheimer's. The medicine, like many other experimental Alzheimer's drugs that have failed in studies or are continuing to be tested, blocks beta amyloid, a protein that plays a key role in the buildup of toxic plaques in the brain that are considered a hallmark of Alzheimer's.""We are preparing to implement a Phase III study in early Alzheimer's as soon as we can,"" company spokeswoman Kate Niazi-Sai said after Williams' presentation. The most significant side effects seen with BIIB037 were signs of possible brain swelling and tiny hemorrhages, which the company described as ""largely mild to moderate, and self-resolving.""Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs, including with bapineuzumab from Pfizer Inc and solanezumab from Eli Lilly and Co . It has also been closely associated with an experimental class of drugs called gamma secretase inhibitors that have largely been abandoned. Pfizer and its partner Johnson & Johnson  discontinued bapineuzumab after it failed in big late-stage trials to significantly improve cognition in patients with mild to moderate Alzheimer's. But Lilly continues to test solananezumab in patients with mild Alzheimer's.One of the biggest hopes for patients is another class of Alzheimer's drugs called BACE inhibitors. They block an enzyme called beta secretase which plays a key role in production of beta amyloid. Eli Lilly, Merck & Co are considered furthest along in testing such drugs.As many as 5 million people in the United States and 36 million globally are believed to have Alzheimer's, the most common form of dementia. The U.S. figure for people 65 or older may triple by 2050 as the population ages, according to the Alzheimer's Association.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Marguerita Choy)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 11:58am EST","UPDATE 1-Biogen plans late-stage Alzheimer's trial, shares rise",http://www.reuters.com//article/biogen-idec-alzheimers-idUSL2N0TM0XM20141202?type=companyNews
63,"  * Energy names rally despite continued drop in oil prices* Otsuka to buy Avanir; Cypress Semi to buy Spansion* Biogen rallies on favorable Alzheimer's drug data* Indexes up: Dow 0.4 pct, S&P 0.5 pct, Nasdaq 0.4 pct   (Updates to mid-morning trading)By Ryan VlastelicaNEW YORK, Dec 2 U.S. stocks rose on Tuesday as a pair of big M&A deals boosted market optimism and helped the market rebound from the broad decline in the previous session, which was the S&P 500's weakest day in a month.The day's gains were broad, with nine of the 10 primary S&P 500 sectors higher. The only group to fall was telecom , off 0.6 percent. The sector is considered defensive. Energy shares were the strong sector on the day despite continued weakness in the price of crude oil. While oil  fell 1 percent to $68.35 per barrel - extending a decline that has taken the commodity down more than 30 percent from a recent peak - the S&P energy sector reversed earlier losses and rose 1.8 percent.""Valuations have gotten pummeled under the weight of declining crude prices, and it looks like investors are starting to nibble at the space,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia. ""The group looks extremely oversold, and dividends remain pretty strong.""Among the most active names, Marathon Petroleum rose 4.7 percent to $95.07 while Valero Energy was up 3.8 percent at $50.77. There is currently an inverse correlation of -0.8 between the S&P 500 and crude oil, a dramatic flip from Oct. 20, when the correlation was a positive 0.9, indicating they moved almost perfectly in sync.Cypress Semiconductor Corp agreed to buy Spansion Inc  in an all-stock deal valued at about $4 billion.  Separately, Otsuka Pharmaceutical Co Ltd said it would buy Avanir Pharmaceuticals Inc for about $3.5 billion.Cypress rose 17 percent to $12.20 while Spansion was up 24 percent at $28.38 on heavy volume. Avanir added 13 percent to $16.96. Biogen Idec Inc advanced 5.7 percent to $326.07 as the S&P's biggest advancing stock on favorable data from the Phase III trial of an Alzheimer's drug.Digital Ally jumped 38 percent to $17.75 on heavy volume a day after U.S. President Barack Obama urged lawmakers to spend $263 million over three years on 50,000 body-worn cameras and law enforcement training programs as part of the federal response to civil rights protests in Ferguson, Missouri.At 11:12 a.m. (1612 GMT) the Dow Jones industrial average  rose 69.13 points, or 0.39 percent, to 17,845.93, the S&P 500 gained 9.92 points, or 0.48 percent, to 2,063.36 and the Nasdaq Composite added 20.87 points, or 0.44 percent, to 4,748.21.Advancing issues outnumbered declining ones on the NYSE by 2,136 to 807, for a 2.65-to-1 ratio; on the Nasdaq, 1,908 issues rose and 643 fell for a 2.97-to-1 ratio.The S&P 500 was posting 62 new 52-week highs and 2 new lows; the Nasdaq Composite was recording 70 new highs and 64 new lows.     (Editing by Nick Zieminski)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 11:23am EST",US STOCKS-Wall St rises; energy leads despite oil weakness,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0TM14M20141202?type=companyNews
64,"  Dec 2 Biogen Idec Inc's research chief on Tuesday said the company was planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and improved cognition in a small early-stage study.Shares of Biogen were up 6.8 percent in morning trading on the Nasdaq. Douglas Williams said at the Deutsche Bank BioFEST conference that encouraging data was seen in a Phase 1b trial of its BIIB037 drug. The medicine was tested in patients with mild symptoms of the progressive neurological disease, or in patients who did not yet have apparent symptoms but had other possible signs of Alzheimer's.  ""We are preparing to implement a Phase III study in early Alzheimer's as soon as we can,"" a company spokeswoman said after Williams' presentation.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 10:07am EST",Biogen plans late-stage trial for Alzheimer's treatment,http://www.reuters.com//article/biogen-idec-alzheimers-idUSL2N0TM0WC20141202?type=companyNews
65,"  * Weakness in crude oil again pressures energy names* Otsuka to buy Avanir; Cypress Semi to buy Spansion* Biogen rallies on favorable Alzheimer's drug data* Dow, S&P 500 both up 0.2 pct, Nasdaq up 0.3 pct   (Updates to open)By Ryan VlastelicaNEW YORK, Dec 2 U.S. stocks rose modestly on Tuesday as a pair of big M&A deals boosted market optimism and helped the market rebound from the broad decline in the previous session, which was the S&P 500's weakest day in a month.Energy shares continued to struggle amid ongoing volatility in the price of oil. U.S. crude futures fell 2 percent to $67.58 per barrel, contributing to the 0.5 percent decline in the S&P Energy sector, the worst-performing industry group of 2014. Chesapeake Energy fell 1.3 percent to $19.80 while Devon Energy was off 1.3 percent at $59.14. Crude is down more than 30 percent from a recent peak, and analysts expect the group's weakness to persist.""Fourth-quarter earnings estimates for the energy sector are down about 20 percent, which is significant. There's going to be really broad pain when that materializes,"" said James Liu, global market strategist for JPMorgan Funds in Chicago.""The broader market should be able to weather this storm, but it will still take a hit."" In the latest deal news, Cypress Semiconductor Corp  agreed to buy Spansion Inc in an all-stock deal valued at about $4 billion.Separately, Otsuka Pharmaceutical Co Ltd said it would buy Avanir Pharmaceuticals Inc for about $3.5 billion.Cypress rose 17 percent to $12.20 while Spansion was up 22 percent at $27.97 on heavy volume. Avanir added 13 percent to $16.96. Biogen Idec Inc advanced 6 percent to $327.03 as the S&P's biggest advancing stock on favorable data from the Phase III trial of an Alzheimer's drug.Digital Ally jumped 25 percent to $16.08 on heavy volume a day after U.S. President Barack Obama urged lawmakers to spend $263 million over three years on 50,000 body-worn cameras and law enforcement training programs as part of federal response to civil rights protests in Ferguson, Missouri.At 9:48 a.m. (1448 GMT) the Dow Jones industrial average  rose 34.45 points, or 0.19 percent, to 17,811.25, the S&P 500 gained 4.14 points, or 0.2 percent, to 2,057.58 and the Nasdaq Composite added 14.74 points, or 0.31 percent, to 4,742.08.Advancing issues outnumbered declining ones on the NYSE by 1,561 to 1,159, for a 1.35-to-1 ratio; on the Nasdaq, 1,545 issues rose and 683 fell for a 2.26-to-1 ratio.The S&P 500 was posting 45 new 52-week highs and 1 new lows; the Nasdaq Composite was recording 50 new highs and 39 new lows.     (Editing by Nick Zieminski)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 9:59am EST","US STOCKS-Wall St rises, but oil continues to weigh",http://www.reuters.com//article/markets-stocks-usa-idUSL2N0TM0UT20141202?type=companyNews
66,"  Dec 2 Biogen Idec Inc :  * Research chief says company plans phase III trial of experimental Alzheimer's drug BIIB037, based on promising interim data from early-stage trial  * Says interim analysis indicates drug cut amyloid levels, had statistically significant affect on cognition, in phase 1b study  * Says continuing phase 1b study as company prepares to implement a phase III study in patients with early-stage Alzheimer's disease  * Research chief says most-significant side effects in trial were largely mild to moderate and self-resolving * Company shares rise 5.5 percent in morning trading  ",2014-12-02,BIIB,"Tue Dec 2, 2014 | 9:39am EST","BRIEF-Biogen shares rise on favorable Alzheimer's data, plans for larger trial",http://www.reuters.com//article/biogenidec-brief-idUSWEN00EFD20141202?type=companyNews
67,"  * Bay 81-8973 is based on Bayer's established Kogenate drug* Bayer investing 500 mln eur in haemophilia drug production* Competes with Biogen Idec, Novo Nordisk   (Adds details on haemophilia drug development)FRANKFURT, Dec 2 Drugmaker Bayer AG  said on Tuesday it will this month file for approval of its experimental haemophilia drug Bay 81-8973, based on its established Kogenate brand, as it seeks to build a range of treatments against the hereditary bleeding disorder.The German company in March unveiled plans to spend more than 500 million euros ($622 million) to set up haemophilia drug production sites in Germany, in a sign of confidence in its development pipeline. Patients have seen new treatment options and more are in the offing. U.S. regulators earlier this year approved Biogen Idec's  long-lasting haemophilia A drug Eloctate and hemophilia B treatment Alprolix, both co-developed with Swedish Orphan Biovitrum AB.Novo Nordisk has two long-acting drugs against type A and B in the third and last phase of testing required for regulatory approval. Bayer's established haemophilia A therapy product Kogenate, had 1.2 billion euros ($1.5 billion) in sales last year.Apart from Bay 81-8973, which Bayer aims to bring to U.S. and European markets, the company has another drug candidate against the type A of the bleeding disorder in the third and last phase of testing. Bayer has previously said it expects to seek approval for this drug, known as Damoctocog alfa pegol, in mid-2016.People with haemophilia have a fault in a gene that regulates the body's production of proteins called clotting factors. This can cause spontaneous bleeding as well as severe bleeding following injuries or surgery.($1 = 0.8041 euro)   (Reporting by Ludwig Burger; Editing by Maria Sheahan)",2014-12-02,BIIB,"Tue Dec 2, 2014 | 5:38am EST",UPDATE 1-Bayer to seek approval for haemophilia drug this month,http://www.reuters.com//article/bayer-research-idUSL6N0TM1FP20141202?type=companyNews
68,"  EQUITIESNEW YORK - U.S. stocks rose on Tuesday as energy stocks led the S&P 500 and Dow, while Biogen's rally on news about an experimental treatment for Alzheimer's disease topped gains at the Nasdaq.The Dow Jones industrial average .DJI rose 102.75 points, or 0.58 percent, to 17,879.55, a record high. The S&P 500 .SPX gained 13.11 points, or 0.64 percent, to 2,066.55 and the Nasdaq Composite .IXIC added 28.46 points, or 0.6 percent, to 4,755.81.For a full report, click on- - - - LONDON -  Britain's main equity index rebounded from a two-week low on Tuesday, led by energy shares, as oil prices rose from five-year lows.Energy stocks helped the FTSE 100 index to close 1.3 percent higher at 6,742.10 points. It had fallen 1 percent in the previous session to a two-week low, its steepest one-day drop in 1 1/2 months.For a full report, click on- - - - TOKYO - Japan's Nikkei share average rose to a more than seven-year high on Wednesday after Wall Street gained and the dollar hit a fresh seven-year high against the yen, but Otsuka Holdings tumbled on news that it will buy a U.S. drugmaker for about $3.5 billion.The Nikkei 225 gained 1.2 percent to 17,881.76 points by mid-morning, the highest level since July 2007.For a full report, click on- - - - HONG KONG - Hang Seng Index is trading 0.64 percent higher. For a full report, click on- - - - FOREIGN EXCHANGE SYDNEY -  The dollar surged to a fresh seven-year high against the yen on Wednesday, after U.S. bond yields rose the previous day and as Federal Reserve officials this week painted a mostly rosy outlook for the U.S. economy.The dollar rose to 119.33 yen on trading platform EBS at one point, its highest level since August 2007. The greenback last traded at 119.30 yen, up 0.1 percent on the day.For a full report, click on- - - -  TREASURIES NEW YORK - U.S. Treasuries fell on Tuesday, with prices pressured by a Wall Street rally and institutional investors readying for a $6 billion corporate bond deal from leading retailer Amazon.U.S. equities pivoted from losses on Monday and were boosted by merger deals. Key indices were up about 0.5 percent in late New York trading on Tuesday.For a full report, click on- - - - COMMODITIES GOLD  SINGAPORE - Gold slipped for a second straight session on Wednesday to trade below $1,200 an ounce as weaker oil prices and a stronger dollar diminished the metal's appeal as a hedge.Spot gold had eased 0.2 percent to $1,196.60 an ounce by 0037 GMT, after falling 1 percent in the previous session.For a full report, click on- - - - BASE METALS SYDNEY - London copper was steady on Wednesday, holding above 4-1/2 year lows touched earlier this week as oil prices revived, but a stronger dollar and expectations of swelling supply kept gains in check.Three-month copper on the London Metal Exchange was trading unchanged at $6,415.50 a tonne by 0131 GMT, following small losses from the previous session. Copper prices sank to 4-1/2 year lows on Monday at $6,230.75 a tonne.For a full report, click on- - - - OIL NEW YORK -   Oil rebounded more than 1 percent on Wednesday, with Brent rising above $71 a barrel, recouping some of its losses from the previous session as a turbulent market struggled to find a price floor.Brent crude hit a high of $71.46 a barrel on Wednesday after falling $2 in the previous session. The January contract was up 75 cents at $71.29 by 0210 GMT.For a full report, click on    (Compiled by Indulal PM)",2014-12-03,BIIB,"Tue Dec 2, 2014 | 9:58pm EST",India Morning Call-Global Markets,http://www.reuters.com//article/morningcall-india-idUSL3N0TN1JB20141203?type=companyNews
69,"  Biogen Idec Inc said an experimental drug showed evidence of biological repair of the optic nerve in patients with acute inflammation of the optic nerve, but shares fell as analysts wondered how promising the mid-stage study results were.The drug is also being tested in patients with multiple sclerosis, an inflammatory disease that attacks the protective covers of nerve cells, and investors have been watching for the results of the acute optic neuritis study for an indication of how the treatment might fare in that study.The trial on the drug, called Anti-LINGO-1, demonstrated an improvement in recovery of optic nerve latency, or the time it takes for a signal to travel from the retina to the visual cortex, Biogen said. The company said it showed a 34 percent improvement versus a placebo treatment. The company said that in the intent-to-treat population, which includes patients who did not complete the study, there was a positive trend, but results did not reach statistical significance. The drug failed to meet the trial's secondary endpoint, including change in thickness of the retinal layers and visual function, Biogen said. ""These data certainly do not make us more positive that it will work in MS. If anything, the only clinical evidence we have on LINGO suggests it is less likely to work,"" UBS AG analyst Matthew Roden wrote in a research note. Biogen shares fell 2.4 percent to $345 after rising as much as 6 percent in premarket trading.Biogen described the study results as being positive.     This is the first clinical trial to provide evidence of biological repair in the central nervous system by facilitating remyelination following an acute inflammatory injury, Alfred Sandrock, Biogen chief medical officer said in a statement.  Remyelination is the regeneration of the insulating myelin sheath of a nerve. The most common cause of acute optic neuritis is multiple sclerosis, an area where Biogen has produced the leading drugs  Tecfidera and Tysabri.Wells Fargo analyst Brian Abrahams described the data as mixed but said that the signal of activity was encouraging.  Evercore ISI analyst Mark Schoenebaum said in a research note the data was ""encouraging, but certainly not definitive.""Biogen said there were 82 patients in the trial, that the drug was generally well tolerated and that three people experienced severe adverse effects. A Biogen spokeswoman described the number of people who did not finish the study as being low, but didn't provide a figure. (Reporting by Caroline Humer; Editing by Bernadette Baum)",2015-01-08,BIIB,"Thu Jan 8, 2015 | 10:38am EST",Biogen shares fall after optic nerve study results seen as mixed,http://www.reuters.com//article/us-biogen-pharmaceuticals-study-idUSKBN0KH17R20150108?type=companyNews
70,"  (Adds secondary endpoint, analyst comment)Jan 8 An experimental drug from Biogen Idec Inc  showed evidence of biological repair of the optic nerve in a mid-stage study in patients with acute optic neuritis, an inflammation of the optic nerve that can lead to vision loss.The drug is also being tested in patients with multiple sclerosis, an inflammatory disease that attacks the protective covers of nerve cells. Current treatments focus on decreasing inflammation rather than regenerating cells. That study's results are due in 2016, the company said.Biogen shares were up 2 percent at $361 in premarket trading, after rising as much as 6 percent.""This is the first clinical trial to provide evidence of biological repair in the central nervous system by facilitating remyelination following an acute inflammatory injury,"" Alfred Sandrock, Biogen chief medical officer said in a statement. Remyelination is the regeneration of the insulating myelin sheath of a nerve.The drug failed to meet the trial's secondary endpoint, including change in thickness of the retinal layers and visual function, Biogen said. The most common cause of acute optic neuritis is multiple sclerosis, an area where Biogen has produced the leading drugs  Tecfidera and Tysabri.""If successful, this could be a transformative therapeutic approach,"" Evercore ISI analyst Mark Schoenebaum said in a research note. ""The data are encouraging, but certainly not definitive."" The trial on the drug, called Anti-LINGO-1, demonstrated an improvement in recovery of optic nerve latency, or the time it takes for a signal to travel from the retina to the visual cortex. The company said it showed a 34 percent improvement versus a placebo treatment.The company said that in the intent-to-treat population, which includes patients who did not complete the study, there was a positive trend but results did not reach statistical significance.Biogen said there were 82 patients in the trial, that the drug was generally well tolerated and that three people experienced severe adverse effects.A Biogen spokeswoman described the number of people who did not finish the study as being low, but didn't provide a figure.   (Reporting by Caroline Humer; Editing by Bernadette Baum)",2015-01-08,BIIB,"Thu Jan 8, 2015 | 9:40am EST",UPDATE 2-Biogen experimental drug shows evidence of optic nerve repair,http://www.reuters.com//article/biogen-pharmaceuticals-study-idUSL1N0UN0UF20150108?type=companyNews
71,"  Jan 8 Biogen Idec Inc said on Thursday a mid-stage study of a new treatment for acute optic neuritis, an inflammation of the optic nerve that can lead to complete or partial loss of vision, showed evidence of biological repair of the visual system.Biogen shares rose 6 percent to $375 in premarket trading from a close of $353.24. The trial on the drug, called Anti-LINGO-1, demonstrated an improvement in recovery of optic nerve latency, or the time it takes for a signal to travel from the retina to the visual cortex. The company said it showed a 34 percent improvement versus a placebo treatment.  The biotech company said this was the first clinical trial to provide evidence of repair in the central nervous system through the use of remyelination, or regenerating the nerve's insulating myelin sheath. The most common cause of acute optic neuritis is multiple sclerosis.   (Reporting by Caroline Humer; Editing by Bernadette Baum)",2015-01-08,BIIB,"Thu Jan 8, 2015 | 7:54am EST",Biogen says mid-stage optic nerve treatment study succeeds,http://www.reuters.com//article/biogen-pharmaceuticals-study-idUSL1N0UN0SH20150108?type=companyNews
72,"  Biogen Idec Inc (BIIB.O) on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.The U.S. biotech company, known for its roster of multiple sclerosis medicines, said it would pay Convergence shareholders $200 million up front. Under the terms of the agreement, they would also be eligible to receive up to $475 million more for the achievement of future development milestones.The centerpiece of the acquisition is Convergence's drug for trigeminal neuralgia, a condition that causes episodes of debilitating facial pain. The drug, CVN1014802, recently had positive results from a midstage trial in which it reduced the severity of pain and number of episodes compared with a placebo. The drug is also being tested for the painful back condition commonly known as sciatica, and has potential as a treatment for other nerve pain conditions, Biogen said.Convergence, formed by investors in 2010 based on drug candidates acquired from GlaxoSmithKline (GSK.L), will continue to operate out of Cambridge, England, Biogen said. ""We believe their industry-leading talent, capabilities and pipeline of candidates, starting with CNV1014802, will provide a strong foundation upon which to expand our neuropathic pain portfolio,"" Biogen research chief Douglas Williams said in a statement.  (Reporting by Bill Berkrot; Editing by Christian Plumb)",2015-01-12,BIIB,"Sun Jan 11, 2015 | 8:06pm EST",Biogen to buy private U.K. company with chronic pain drug,http://www.reuters.com//article/us-biogen-idec-m-a-pain-idUSKBN0KL01N20150112?type=companyNews
73,"  Jan 11 Biogen Idec Inc on Sunday said it would buy small, privately-held Convergence Pharmaceuticals to acquire the U.K.-based company's portfolio of experimental drugs for chronic nerve pain.The U.S. biotech company, known for its roster of multiple sclerosis medicines, said it would pay Convergence shareholders $200 million up front. Under the terms of the agreement, they would also be eligible to receive up to $475 million more for the achievement of future development milestones.The centerpiece of the acquisition is Convergence's drug for trigeminal neuralgia, a condition that causes episodes of debilitating facial pain. The drug, CVN1014802, recently had positive results from a midstage trial in which it reduced the severity of pain and number of episodes compared with a placebo. The drug is also being tested for the painful back condition commonly known as sciatica, and has potential as a treatment for other nerve pain conditions, Biogen said. Convergence, formed by investors in 2010 based on drug candidates acquired from GlaxoSmithKline, will continue to operate out of Cambridge, England, Biogen said. ""We believe their industry-leading talent, capabilities and pipeline of candidates, starting with CNV1014802, will provide a strong foundation upon which to expand our neuropathic pain portfolio,"" Biogen research chief Douglas Williams said in a statement.   (Reporting by Bill Berkrot; Editing by Christian Plumb)",2015-01-12,BIIB,"Sun Jan 11, 2015 | 8:00pm EST",Biogen to buy private U.K. company with chronic pain drug,http://www.reuters.com//article/biogen-idec-ma-pain-idUSL1N0UO2G920150112?type=companyNews
74,"   By Bill Berkrot  Biogen Idec Inc (BIIB.O) on Thursday reported fourth-quarter profit and issued a 2015 earnings forecast that both sailed past Wall Street estimates, driven by strong sales of its oral multiple sclerosis drug Tecfidera, sending shares more than 7 percent higher. For 2015, Biogen sees adjusted earnings of $16.60 to $17 per share, compared with analysts' estimates for $16.37 per share, according to Thomson Reuters I/B/E/S.The U.S. biotechnology company forecast 2015 revenue growing 14 percent to 16 percent over 2014 revenue of $9.7 billion.After a quarter in which Tecfidera sales fell short of analysts' estimates for the first time, the drug topped expectations in the fourth quarter. The company reported  Tecfidera sales of $916 million, while Wall Street was looking for about $880 million.Biogen Chief Executive Officer George Scangos, on a call with analysts, said Tecfidera is now the most prescribed multiple sclerosis (MS) drug in Germany and most prescribed oral MS treatment in the United States. ""We believe Tecfidera will continue to grow in the U.S. and  grow substantially in Europe,"" Scangos said. The company said it has secured reimbursement for Tecfidera in the United Kingdom, Italy and Spain. It expects to gain full reimbursement across other major European markets this year.The biotechnology company posted a net profit of $883 million, or $3.74 per share, compared with a profit of $457.3 million, or $1.92 per share, a year ago.Excluding items, Biogen earned $4.09 per share, topping analysts' average expectations by 31 cents. Revenue rose 34 percent to $2.64 billion, matching Wall Street expectations.Sales of the injectable MS drug Tysabri of $484 million fell short of Wall Street estimates of $509 million. But sales of interferon-based MS drugs Avonex and the new longer-lasting Plegridy came in at $777 million, topping estimates of about $757 million.The company said about half of Plegridy patients were switching from Avonex with the rest new patients. The company's new hemophilia drugs, Alprolix and Eloctate, posted sales of $40 million and $37 million.Biogen shares rose to $379 in extended trading from a Nasdaq close at $353.25. (Reporting by Bill Berkrot in New York; Editing by Lisa Shumaker)",2015-01-29,BIIB,"Thu Jan 29, 2015 | 5:04pm EST",Biogen forecasts 2015 earnings well ahead of Street view,http://www.reuters.com//article/us-biogen-idec-results-idUSKBN0L22RX20150129?type=companyNews
75,"  Jan 29 Biogen Idec Inc on Thursday reported higher-than-expected fourth-quarter profit on strong demand for its oral multiple sclerosis drug Tecfidera and issued a forecast for 2015 earnings far higher than Wall Street forecasts.Tecfidera sales showed little sign of slowing after falling short of analysts' estimates for the first time in the previous quarter. The company reported fourth-quarter Tecfidera sales of $916 million, easily topping Wall Street projections of about $880 million.For 2015, Biogen sees adjusted earnings of $16.60 to $17 per share compared with analysts' estimates for $16.37 per share, according to Thomson Reuters I/B/E/S. The U.S. biotechnology company posted a net profit of $883 million, or $3.74 per share, compared with a profit of $457.3 million, or $1.92 per share, a year ago. Excluding items, Biogen earned $4.09 per share. Analysts on average expected $3.78 per share. Revenue rose 34 percent to $2.64 billion, matching Wall Street expectations.   (Reporting by Bill Berkrot in New York; Editing by Lisa Shumaker)",2015-01-29,BIIB,"Thu Jan 29, 2015 | 4:33pm EST",Biogen forecasts 2015 earnings well ahead of Street view,http://www.reuters.com//article/biogen-idec-results-idUSL1N0V738N20150129?type=companyNews
76,"  * Innovative method for financing dementia research* Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen* J.P. Morgan acted as financial adviser   (Adds plan for additional investment, J.P. Morgan role)By Ben HirschlerLONDON, March 17 The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised more than $100 million with the backing of the British government and several of the world's leading drugmakers.The global Dementia Discovery Fund is unique in focusing on a single difficult to treat disorder and in bringing together industry and government. Drug companies involved include GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Biogen Idec.The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight (G8) nations conference in London in December 2013 that set a goal of finding a cure or effective treatment for Alzheimer's and other forms of dementia by 2025.GSK's head of research and development Patrick Vallance told Reuters the 2025 goal was ""hugely ambitious"" but that pooling resources through the new fund to back promising ideas from academic groups and small biotech firms would help to accelerate research. ""It's tough to crack but the science is moving,"" Vallance said. ""People are now beginning to look at subsets of dementia and the genetics of neurodegeneration, so there are real opportunities.""Venture capital funds are a common source of finance for high-risk, early-stage life science research, but the new fund is the first to focus solely on dementia.The British government, which has worked with J.P. Morgan  as financial adviser in setting up the fund, said that additional interested investors would have an opportunity to participate at a later stage. As well as providing financial support, research projects that secure the fund's backing will gain expert advice during the critical early stages of research, with charity Alzheimer's Research UK also involved alongside industry.Individual pharmaceutical companies wanting to go on to  develop particular projects commercially will be able to bid for rights to do so, with money raised from the bidding process to be reinvested in the fund.The British government, as project leader, is contributing $22 million, while GSK is putting in $25 million and J&J $10 million, with further money coming from other companies.Dementia, of which Alzheimer's is the most common form, affects close to 50 million people worldwide and is set to reach 135 million by 2050, according to non-profit campaign group Alzheimer's Disease International.There is still no treatment that can slow the progression of Alzheimer's. Current drugs can do no more than ease some of the symptoms.     (Editing by David Goodman)",2015-03-17,BIIB,"Tue Mar 17, 2015 | 4:42am EDT",UPDATE 1-Dementia drug research aided by $100 mln venture capital fund,http://www.reuters.com//article/health-dementia-fund-idUSL6N0WJ1AT20150317?type=companyNews
77,"   By Bill Berkrot  An experimental drug from Biogen Idec Inc became the  first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment.Alzheimer's affects 15 million people worldwide, a number that is expected to grow to 75 million by 2030 without effective treatments, likely costing billions of dollars year.Any effective treatment is likely to become one of the world's most lucrative drugs, but the Biogen drug faces years of testing and would not reach the market much before 2020, even if all goes well, analysts said.Biogen shares were up 6.5 percent, or $27.97, at $461.92 in morning trading, after rising as high as $480.18.Biogen is entering a field littered with expensive failures from such drug makers as Pfizer Inc and Eli Lilly and Co. Lilly and Roche Holding AG are both conducting trials on drugs that work the same way as Biogen's, by blocking beta amyloid, a protein that forms toxic brain plaques that are theoretically an underlying cause of the degenerative brain disease.  It marks the first time an experimental drug demonstrated a statistically significant reduction in amyloid plaque as well as  a slowing of clinical impairment in patients with mild disease, said Alfred Sandrock, Biogen's chief medical officer.""It's a bigger treatment effect than we had hoped for,"" Sandrock said.The trial of the Biogen drug, aducanumab, tested 166 people divided into five groups, four of which each received a different dose, and a fifth that received a placebo.  The Biogen treatment led to reductions in brain amyloid, according to interim data presented at a medical meeting in Nice, France, on Friday. The plaque reduction was more pronounced as the dose of the drug increased and over time.Biogen will begin enrolling patients later this year for a large Phase III trial, whose results could be used to seek approval of its drug. Lilly's solanezumab, a drug for patients with mild Alzheimer's, has been in late-stage trials since 2013, with results expected late in 2016, according to Sanford Bernstein analyst Tim Anderson. He said the Biogen late-stage trial would not wrap up until 2019. Evercore ISI analyst Mark Schoenebaum said by email, ""The magnitude of the efficacy improvements is really striking."" The trial had safety issues and drop outs, particularly by those on high doses, he said, and he wondered if some comparative success to Lilly may be related to trial design.Biogen said it increased its chances of success by carefully screening patients to exclude those with other forms of dementia misdiagnosed as Alzheimer's, and by testing only those early in the disease.  ""We imaged every patient coming into study, so we knew that every patient had Alzheimer's disease and plaque,"" Biogen Chief Executive George Scangos said in an interview. ""It's hard to think of a reason why these data are not representative of the actual activity of the drug.""HIGHER DOSES, GREATER EFFECT Safety and tolerability were considered acceptable, the company said. There was a big jump in the incidence of amyloid-related imaging abnormalities-edema (ARIA-E), or water surrounding brain tissue, at the two higher doses among patients with a gene associated with the highest risk for developing Alzheimer's. These highest-risk patients also dropped out of the trial at a higher rate. Most of the ARIA-E was asymptomatic or mild and resolved over time, Sandrock said.   Using imaging to measure amyloid in six regions of the brain, researchers found plaque levels were virtually unchanged at 26 and 54 weeks into the study for the placebo group. Patients who received either 3 milligrams per kilogram of weight, 6 mg/kg or 10 mg/kg of aducanumab showed a significant and dose-dependent increase in plaque reduction at 26 weeks. There was an even greater reduction in plaque for patients at the 3 mg and 10 mg doses when they were tested at 54 weeks. Data for those in the 6 mg arm was not available at 54 weeks because that group started later. A fourth group of patients who received a 1 mg dose were not helped by the drug.    The trial also used two measures to test cognition: a questionnaire with a 30-point scale to test mental acuity and an 18-point Clinical Dementia Rating scale that also tests for loss of ability to function.On the first test, placebo patients worsened by 3.14 points after one year versus significantly smaller declines for patients receiving aducanumab 3 mg and 10 mg, of 0.75 and 0.58 points, respectively. On the second scale, the placebo group worsened by 2.04 points at one year. While the scores were better for all the drug groups, only the 10 mg dose reached statistical significance, with a decline of 0.59 points. The 6 mg dose could still show a significant slowing on both scales when more data becomes available. (Reporting by Bill Berkrot, additional reporting by Caroline Humer and Ransdell Pierson; Editing by Michele Gershberg and Leslie Adler)",2015-03-20,BIIB,"Fri Mar 20, 2015 | 2:42pm EDT",Biogen's Alzheimer's drug slows mental decline in early study,http://www.reuters.com//article/us-biogen-alzheimers-idUSKBN0MG1OU20150320?type=companyNews
78,"  (Adds outside comment, share price, background)By Bill BerkrotMarch 20 An experimental drug from Biogen Idec Inc became the  first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment.Alzheimer's affects 15 million people worldwide, a number that is expected to grow to 75 million by 2030 without effective treatments, likely costing billions of dollars year.Any effective treatment is likely to become one of the world's most lucrative drugs, but the Biogen drug faces years of testing and would not reach the market much before 2020, even if all goes well, analysts said.Biogen shares were up 6.5 percent, or $27.97, at $461.92 in morning trading, after rising as high as $480.18.Biogen is entering a field littered with expensive failures from such drug makers as Pfizer Inc and Eli Lilly and Co . Lilly and Roche Holding AG are both conducting trials on drugs that work the same way as Biogen's, by blocking beta amyloid, a protein that forms toxic brain plaques that are theoretically an underlying cause of the degenerative brain disease.It marks the first time an experimental drug demonstrated a statistically significant reduction in amyloid plaque as well as  a slowing of clinical impairment in patients with mild disease, said Alfred Sandrock, Biogen's chief medical officer.""It's a bigger treatment effect than we had hoped for,"" Sandrock said. The trial of the Biogen drug, aducanumab, tested 166 people divided into five groups, four of which each received a different dose, and a fifth that received a placebo.The Biogen treatment led to reductions in brain amyloid, according to interim data presented at a medical meeting in Nice, France, on Friday. The plaque reduction was more pronounced as the dose of the drug increased and over time.Biogen will begin enrolling patients later this year for a large Phase III trial, whose results could be used to seek approval of its drug.Lilly's solanezumab, a drug for patients with mild Alzheimer's, has been in late-stage trials since 2013, with results expected late in 2016, according to Sanford Bernstein analyst Tim Anderson. He said the Biogen late-stage trial would not wrap up until 2019. Evercore ISI analyst Mark Schoenebaum said by email, ""The magnitude of the efficacy improvements is really striking."" The trial had safety issues and drop outs, particularly by those on high doses, he said, and he wondered if some comparative success to Lilly may be related to trial design.Biogen said it increased its chances of success by carefully screening patients to exclude those with other forms of dementia misdiagnosed as Alzheimer's, and by testing only those early in the disease.""We imaged every patient coming into study, so we knew that every patient had Alzheimer's disease and plaque,"" Biogen Chief Executive George Scangos said in an interview. ""It's hard to think of a reason why these data are not representative of the actual activity of the drug."" HIGHER DOSES, GREATER EFFECT Safety and tolerability were considered acceptable, the company said. There was a big jump in the incidence of amyloid-related imaging abnormalities-edema (ARIA-E), or water surrounding brain tissue, at the two higher doses among patients with a gene associated with the highest risk for developing Alzheimer's. These highest-risk patients also dropped out of the trial at a higher rate. Most of the ARIA-E was asymptomatic or mild and resolved over time, Sandrock said.Using imaging to measure amyloid in six regions of the brain, researchers found plaque levels were virtually unchanged at 26 and 54 weeks into the study for the placebo group.Patients who received either 3 milligrams per kilogram of weight, 6 mg/kg or 10 mg/kg of aducanumab showed a significant and dose-dependent increase in plaque reduction at 26 weeks. There was an even greater reduction in plaque for patients at the 3 mg and 10 mg doses when they were tested at 54 weeks.Data for those in the 6 mg arm was not available at 54 weeks because that group started later. A fourth group of patients who received a 1 mg dose were not helped by the drug.The trial also used two measures to test cognition: a questionnaire with a 30-point scale to test mental acuity and an 18-point Clinical Dementia Rating scale that also tests for loss of ability to function.On the first test, placebo patients worsened by 3.14 points after one year versus significantly smaller declines for patients receiving aducanumab 3 mg and 10 mg, of 0.75 and 0.58 points, respectively.On the second scale, the placebo group worsened by 2.04 points at one year. While the scores were better for all the drug groups, only the 10 mg dose reached statistical significance, with a decline of 0.59 points. The 6 mg dose could still show a significant slowing on both scales when more data becomes available.   (Reporting by Bill Berkrot, additional reporting by Caroline Humer and Ransdell Pierson; Editing by Michele Gershberg and Leslie Adler)",2015-03-20,BIIB,"Fri Mar 20, 2015 | 11:11am EDT",UPDATE 1-Biogen's Alzheimer's drug slows mental decline in early study,http://www.reuters.com//article/biogen-alzheimers-idUSL2N0WM0OM20150320?type=companyNews
79,"  * Nike climbs in premarket after results, outlook* Biogen's Alzheimer's drug slows mental decline-study* Futures up: Dow 148 pts, S&P 15 pts, Nasdaq 36 pts   (Adds quote, updates prices)By Chuck MikolajczakMarch 20 U.S. stocks were poised for a higher open on Friday, with the S&P 500 on track to snap a three-week losing skid, buoyed by Nike earnings, as investors assessed the impact of a stronger dollar on corporate earnings.U.S. stocks fell on Thursday as a stronger dollar weighed on oil and other commodity prices, sending energy and materials sectors lower, to continue a recent pattern of trading sessions alternating between gains and losses that began at the start of the month.Dow component Nike's rose 5.2 percent to $103.42 in premarket after it posted a quarterly profit that beat market estimates. The world's largest sportswear maker sold more higher margin shoes and apparel, but the company warned Wall Street that the stronger dollar would take a toll on its current quarter. ""There is a tug-of-war going on between current valuations in our market and a lot of bad news being priced into a strong dollar with no good news being priced into a strong dollar,"" said Art Hogan, chief market strategist at Wunderlich Securities in New York.""We are taking the multinationals out to the woodshed and not moving consumer names higher.""Biotechs are likely to continue to rally as Biogen Idec  shares jumped 7.9 percent at $467.99 in premarket trading. The company said its experimental drug became the first Alzheimer's treatment to significantly slow cognitive decline and reduce brain plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. S&P 500 e-mini futures were up 15 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a higher open. Dow Jones industrial average e-mini futures rose 148 points and Nasdaq 100 e-mini futures added 36 points.The market may see heightened volatility heading into the close as a result of quadruple witching - the expiration of stock options, index options, index futures and single-stock futures.Tiffany & Co. shares lost 2.9 percent to $83.88 before the opening bell after the upscale jeweler reported quarterly sales fell for the first time in five years and are expected to decline further in the current quarter, hurt by the strong dollar. The dollar was off 0.8 percent against a basket of major currencies and was on track for its first weekly decline in five.Olive Garden owner Darden Restaurants reported a quarterly profit above analysts' estimates due to cost-cutting and better-than-expected sales at its chains such as LongHorn Steakhouse and Yard House. Its shares climbed 4.7 percent to $67.92 in premarket.Simon Property Group, the No.1 U.S. mall owner, raised its offer for Macerich Co three days after its smaller rival rejected its earlier offer, adopted a poison pill and changed board structure to prevent a hostile takeover. Simon Property advanced 1 percent to $194 while Macerich lost 7.5 percent to $86.50 before the opening bell.(Editing by Bernadette Baum)",2015-03-20,BIIB,"Fri Mar 20, 2015 | 9:17am EDT",US STOCKS-Wall St set for higher open as Nike provides lift,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0WM0IU20150320?type=companyNews
80,"   By Bill Berkrot | NEW YORK  NEW YORK Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.The Massachusetts-based company, which made headlines last week when it announced better-than-expected clinical trial results for its experimental Alzheimer's drug, aducanumab, said that it will drop Idec from its name as of Monday and adopt a new logo. The company merged with Idec Pharmaceuticals more than a decade ago.Chief Executive George Scangos says that going forward he will keep Biogen focused on developing drugs for some of the hardest-to-treat diseases.               ""Five years down the road, with some luck, we'll have an Alzheimer's drug that's getting approved, Scangos told Reuters. ""I hope we can transform the treatment of MS. By that time, we will have made substantial progress on ALS and other nerve degenerative diseases, spinal muscular atrophy in kids. All that stuff is on our plate,"" he said.""I am sure of two things,"" he added. ""Not all of it is going to work, and some of it will.""Investors, excited by the aducanumab news, sent Biogen shares up 9.7 percent on Friday, and the company's stock touched an all-time high of $480.18 during the session.The small trial showed the treatment significantly slowed cognitive impairment in patients with mild symptoms, a rare bit of good news in a field littered with high profile failures from the likes of Pfizer Inc and Eli Lilly and CoBut some patients, especially those with a gene predisposing them to Alzheimer's, developed localized brain swelling. The symptom was most common among patients with the gene who were receiving the highest doses of aducanumab, leading about 1/3 of the participants in that category to discontinue the treatment. The company said the swelling was generally ""asymptomatic or with mild, transient symptoms."" Biogen plans to begin a larger trial later this year. ""If they can replicate the Alzheimer's data in Phase III, they could conceivably have the biggest drug on the planet,"" JMP Securities analyst Michael King said. As many as 75 million people are expected to develop the disease by 2030.For Biogen, which is also working on Alzheimer's drugs that use other mechanisms of action, research on dementia drugs represents an expansion of the company's potential reach. ""If the Alzheimer's thing works, then we're not just an MS company. We are broadly focused on neuro-degenerative diseases,"" Scangos said.The company is also developing a drug it hopes will address not just symptoms but the cause of MS, potentially changing the way the disease is treated. ""The future looks pretty exciting for us,"" said Scangos, who became Biogen CEO in July 2010 following a period of upheaval in which activist investor Carl Icahn pushed for management changes and the sale of the company. Scangos, who previously led the tiny biotech firm Exelixis Inc, was recommended for the CEO post by Icahn lieutenants on the Biogen board.BIGGER MOVE INTO BIOSIMILARS As it works on new medicines for unmet needs, Biogen is also planning a bigger move into the fledgling field of biosimilars, manufacturing cheaper versions of older biotech drugs as they lose patent protection. Health regulators this month approved the first such drug for the U.S. market, a biosimilar version of Amgen Inc's white blood cell booster Neupogen. Biogen previously disclosed plans to develop six biosimilar drugs in collaboration with Samsung. ""We will expand that to include more,"" Scangos said.It has filed for European approval of biosimilars of two  blockbuster rheumatoid arthritis drugs, Amgen's Enbrel and Johnson & Johnson's Remicade.Scangos shrugged off the potential impact to Biogen of biosimilars that replicate its own products, even though such competition could result in far cheaper alternatives to its drugs.""I view biosimilars as a good thing,"" he said. ""When they come for our drugs, they come.""  Biogen's ambitions are not without risk. The company saw a ""spectacular failure,"" as Scangos put it, with a large trial of an ALS drug a few years ago, highlighting the challenge ahead.""There was no effect at all,"" Scangos said. ""We've gone back to the drawing board.""  (Reporting by Bill Berkrot; Editing by Michele Gershberg and Sue Horton)",2015-03-23,BIIB,"Mon Mar 23, 2015 | 12:51pm EDT","Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS",http://www.reuters.com//article/us-biogen-ceo-exclusive-idUSKBN0MJ0B520150323?type=companyNews
81,"  * Amazon shares touch life high after revenue beats estimates* Xerox slumps to year low as it cuts forecast* Biogen down 6 pct after key drug sales fall* Indexes up: Dow 0.2 pct, S&P 0.3 pct, Nasdaq 0.8 pct   (Updates to early afternoon)By Tanya AgrawalApril 24 The Nasdaq Composite extended its gains in early afternoon trading on Friday, hitting a 15-year intraday high, propelled by strong results from tech behemoths Google, Amazon and Microsoft.The S&P 500 also hit a record intraday high for the second session in a row. A majority of the ten S&P sectors rose, with the consumer discretionary index gaining 1.4 percent on the back of Amazon. The online retailer hit a lifetime high after its revenue beat estimates.Google gained 3.6 percent to $577.64 after reporting higher quarterly revenue and profit and Microsoft  added 9.4 percent to $47.42 after it topped Wall Street estimates.The S&P hit a high of 2,120.92. The Nasdaq rose to 5,100.371, the highest since touching a record of 5,132.52 in March 2000.""The difference today contrasting with back then is, you have a lot of mature companies like Microsoft, EMC and Intel that can be looked at as almost blue chip companies that pay relatively high dividends,"" said James Abate, chief investment officer of Centre Funds in New York, comparing the fresh Nasdaq highs with those in 2000, right before the Internet bubble burst. ""The froth really is in social media companies and when you compare it back then, the froth was pretty much everywhere.""At 1:03 p.m. EDT (1703 GMT) the Dow Jones industrial average  was up 30.25 points, or 0.17 percent, at 18,088.94, the S&P 500 was up 6.04 points, or 0.29 percent, at 2,118.97 and the Nasdaq Composite was higher 38.50 points, or 0.76 percent, at 5,094.56.Xerox slumped as much as 14 percent to a 52-week low of $11.32 after it cut its 2015 profit forecast, adding to a growing list of companies that have blamed a strong U.S. currency for weakened results or forecasts. Comcast abandoned its proposed $45 billion merger with Time Warner Cable after U.S. regulators said the deal would give Comcast an unfair advantage in the Internet-based services market. Time Warner rose 3.7 percent to $154.41 while Comcast was up 0.8 percent at $57.73.Mylan's shares rose 2.8 percent to $75.78 after the generic drugmaker said it would commence a formal offer to buy Perrigo. Perrigo was down 3 percent to $195.50 after it rejected the offer for the second time in a week.Aerie Pharmaceuticals dived 60.6 percent to $13.96 after the company's lead experimental drug failed to show that it was superior to commonly prescribed eye-drops.Biogen shares fell 5.8 percent to $405.10 after sales of its key oral multiple sclerosis drug fell on a sequential basis in the first quarter for the first time since its launch in 2013.Advancing issues outnumbered declining ones on the NYSE by 1,491 to 1,433, for a 1.04-to-1 ratio on the upside; on the Nasdaq, 1,452 issues fell and 1,197 advanced for a 1.21-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 16 new 52-week highs and 1 new lows; the Nasdaq Composite was recording 84 new highs and 16 new lows.    (Editing by Savio D'Souza and Rodrigo Campos)",2015-04-24,BIIB,"Fri Apr 24, 2015 | 1:16pm EDT","US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XL1FW20150424?type=companyNews
82,"   By Natalie Grover  Slowing sales of Biogen Inc's key oral multiple sclerosis (MS) drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday.The U.S. biotechnology company posted lower-than-expected quarterly profit and revenue, saying Tecfidera's ""challenging"" quarter was hit by an overall slowdown in the MS market, which has been weighed down by discounting, a single case of a serious brain infection, and the effect of a stronger dollar.A number of patients are switching to the Biogen's recently launched interferon-based MS drug Plegridy, which has also eaten into Tecfidera sales.If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief Financial Officer Paul Clancy said.Tecfidera sales rose to $824.9 million in the first quarter ended March 31 from $506 million a year earlier, but came in well below consensus projections of about $931 million, according to Deutsche Bank. Despite sales of the blockbuster treatment falling about 10 percent from the prior quarter, Clancy said Tecfidera would still be the largest contributor to the company's overall revenue growth.Biogen's market value has more than tripled in the last three years to more than $100 billion due to its lucrative roster of MS drugs.The company's attempts to diversify its pipeline received a boost last month when better-than-expected early-stage results for its drug to treat Alzheimer's sent its stock to an all-time high. The drug, aducanumab, is the first to significantly slow cognitive decline and reduce brain-destroying plaque in early-stage patients, rekindling hope of a cure for a disease that affects more than 15 million people worldwide.However, Biogen said on Friday that data on a 10 mg dose of the drug would not be available until next year, although data on a 6 mg dose would be available in July. Many investors are concerned that, given the 10 mg titration delay, the major 2015 catalyst has now been moved to 2016, Evercore ISI's Mark Schoenebaum said.Surprisingly, the company still plans to initiate late-stage development of aducanumab in the second half of 2015, RBC Capital Markets analyst Michael Yee said.Cambridge, Massachusetts-based Biogen's stock was down about 5.8 percent at $405.27 on the Nasdaq. (Editing by Simon Jennings)",2015-04-24,BIIB,"Fri Apr 24, 2015 | 11:52am EDT","Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug",http://www.reuters.com//article/us-biogen-results-idUSKBN0NF13E20150424?type=companyNews
83,"  * Stock falls as much at 8 pct* Tecfidera sales fall versus prior qtr* Co delays key data readout - executives   (Adds company, analyst comments on Alzheimer's drug data; Updates shares)By Natalie GroverApril 24 Slowing sales of Biogen Inc's  key oral multiple sclerosis (MS) drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday.The U.S. biotechnology company posted lower-than-expected quarterly profit and revenue, saying Tecfidera's ""challenging"" quarter was hit by an overall slowdown in the MS market, which has been weighed down by discounting, a single case of a serious brain infection, and the effect of a stronger dollar. A number of patients are switching to the Biogen's recently launched interferon-based MS drug Plegridy, which has also eaten into Tecfidera sales.If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief Financial Officer Paul Clancy said.Tecfidera sales rose to $824.9 million in the first quarter ended March 31 from $506 million a year earlier, but came in well below consensus projections of about $931 million, according to Deutsche Bank. Despite sales of the blockbuster treatment falling about 10 percent from the prior quarter, Clancy said Tecfidera would still be the largest contributor to the company's overall revenue growth.Biogen's market value has more than tripled in the last three years to more than $100 billion due to its lucrative roster of MS drugs.The company's attempts to diversify its pipeline received a boost last month when better-than-expected early-stage results for its drug to treat Alzheimer's sent its stock to an all-time high. The drug, aducanumab, is the first to significantly slow cognitive decline and reduce brain-destroying plaque in early-stage patients, rekindling hope of a cure for a disease that affects more than 15 million people worldwide.However, Biogen said on Friday that data on a 10 mg dose of the drug would not be available until next year, although data on a 6 mg dose would be available in July.Many investors are concerned that, given the 10 mg titration delay, the major 2015 catalyst has now been moved to 2016, Evercore ISI's Mark Schoenebaum said.Surprisingly, the company still plans to initiate late-stage development of aducanumab in the second half of 2015, RBC Capital Markets analyst Michael Yee said.Cambridge, Massachusetts-based Biogen's stock was down about 5.8 percent at $405.27 on the Nasdaq.   (Editing by Simon Jennings)",2015-04-24,BIIB,"Fri Apr 24, 2015 | 11:51am EDT","UPDATE 3-Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug",http://www.reuters.com//article/biogen-results-idUSL4N0XL4TM20150424?type=companyNews
84,"  * Amazon shares touch life high after revenue beats estimates* Xerox slumps to year low as it cuts forecast* Biogen down 6 pct after key drug sales fall* Indexes up: Dow 0.1 pct, S&P 0.2 pct, Nasdaq 0.8 pct   (Updates to late morning, adds details, changes comment)By Tanya AgrawalApril 24 The Nasdaq Composite extended its gains in late morning trading on Friday, hitting a 15-year intraday high, propelled by strong results from tech behemoths Google, Amazon and Microsoft.A majority of the ten S&P sectors rose, with the consumer discretionary index gaining 1.1 percent on the back of Amazon. The online retailer hit a lifetime high after its revenue beat estimates. Google gained 3.1 percent to $575 after reporting higher quarterly revenue and profit and Microsoft added 8 percent to $46.85 after it topped Wall Street estimates.The Nasdaq rose to 5,099.12, the highest since touching a record of 5,132.52 in March 2000.""The difference today contrasting with back then is, you have a lot of mature companies like Microsoft, EMC and Intel that can be looked at as almost blue chip companies that pay relatively high dividends,"" said James Abate, chief investment officer of Centre Funds in New York, comparing the fresh Nasdaq highs with those in 2000, right before the Internet bubble burst. ""The froth really is in social media companies and when you compare it back then, the froth was pretty much everywhere.""At 11:28 a.m. EDT (1528 GMT) the Dow Jones industrial average was up 12.38 points, or 0.07 percent, at 18,071.07, the S&P 500 was higher 4.92 points, or 0.23 percent, to 2,117.85 and the Nasdaq Composite was up 38.47 points, or 0.76 percent, to 5,094.53.Xerox slumped as much as 14 percent to a 52-week low of $11.32 after it cut its 2015 profit forecast, adding to a growing list of companies that have blamed a strong U.S. currency for weakened results or forecasts. Comcast abandoned its proposed $45 billion merger with Time Warner Cable after U.S. regulators said the deal would give Comcast an unfair advantage in the Internet-based services market. Time Warner rose 2.2 percent to $152 and Comcast was little changed.Aerie Pharmaceuticals dived 60 percent to $14.11 after the company's lead experimental drug failed to show that it was superior to commonly prescribed eye-drops.Biogen shares fell 6.1 percent to $403.91 after sales of its key oral multiple sclerosis drug fell on a sequential basis in the first quarter for the first time since its launch in 2013.Advancing issues outnumbered declining ones on the NYSE by 1,477 to 1,364, for a 1.08-to-1 ratio on the upside; on the Nasdaq, 1,314 issues fell and 1,249 advanced for a 1.05-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 15 new 52-week highs and 1 new lows; the Nasdaq Composite was recording 73 new highs and 14 new lows.   (Editing by Savio D'Souza and Rodrigo Campos)",2015-04-24,BIIB,"Fri Apr 24, 2015 | 11:39am EDT","US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft",http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XL5N020150424?type=companyNews
85,"  April 24 Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis (MS) drug, Tecfidera.The U.S. biotechnology company's net profit soared to $822.5 million, or $3.49 per share, in the first quarter ended March 31, from $480 million, or $2.02 per share, a year earlier. Excluding items, Biogen earned $3.82 per share.  Revenue rose about 20 percent to $2.55 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings)",2015-04-24,BIIB,"Fri Apr 24, 2015 | 7:07am EDT",Biogen 1st qtr profit jumps 71 pct as MS drug Tecfidera shines,http://www.reuters.com//article/biogen-results-idUSL4N0XL4NZ20150424?type=companyNews
86,"  Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company's entry into opthalmology.Shares of AGTC, formally known as Applied Genetic Technologies Corp, surged 21 percent to $19.75 in morning trading on the Nasdaq after the announcement. Biogen shares were little changed at $406.08.Biogen, a leader in treatments for multiple sclerosis, said under terms of the deal that it would pay $124 million upfront, including a $30 million investment in AGTC shares.AGTC would also be entitled to milestone payments and royalties in the high single-digit to mid-teen percentages of annual net sales of any approved products that come out of the collaboration.""AGTC is an exceptional partner to help us advance our gene therapy capabilities by targeting diseases of the eye,"" Olivier Danos, Biogen's head of cell and gene therapy, said in a statement.The initial work targets rare diseases of the retina that can lead to blindness, including one drug already being tested in people, and one still in pre-clinical development. Biogen will obtain commercial rights for the programs, the companies said. The therapy involves replacing the faulty gene that causes each condition.  The treatment already being used in human trials is for a disease called X-linked Retinoschisis. The condition primarily affects young males beginning during the teenage years and can lead to serious complications, such as vitreous hemorrhage or retinal detachment.The pre-clinical treatment is for X-Linked Retinitis Pigmentosa, which typically causes night blindness by the age of ten and progresses to legal blindness.The agreement also includes Biogen options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.   (Reporting by Bill Berkrot; additional reporting by Ransdell Pierson)",2015-07-02,BIIB,"Thu Jul 2, 2015 | 10:04am EDT",Biogen enters eye-treatment arena with AGTC deal,http://www.reuters.com//article/us-biogen-agtc-idUSKCN0PC1KR20150702?type=companyNews
87,"  July 2 Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company's entry into opthalmology.Shares of AGTC, formally known as Applied Genetic Technologies Corp, surged 21 percent to $19.75 in morning trading on the Nasdaq after the announcement. Biogen shares were little changed at $406.08.Biogen, a leader in treatments for multiple sclerosis, said under terms of the deal that it would pay $124 million upfront, including a $30 million investment in AGTC shares.AGTC would also be entitled to milestone payments and royalties in the high single-digit to mid-teen percentages of annual net sales of any approved products that come out of the collaboration.""AGTC is an exceptional partner to help us advance our gene therapy capabilities by targeting diseases of the eye,"" Olivier Danos, Biogen's head of cell and gene therapy, said in a statement.The initial work targets rare diseases of the retina that can lead to blindness, including one drug already being tested in people, and one still in pre-clinical development. Biogen will obtain commercial rights for the programs, the companies said. The therapy involves replacing the faulty gene that causes each condition.The treatment already being used in human trials is for a disease called X-linked Retinoschisis. The condition primarily affects young males beginning during the teenage years and can lead to serious complications, such as vitreous hemorrhage or retinal detachment.The pre-clinical treatment is for X-Linked Retinitis Pigmentosa, which typically causes night blindness by the age of ten and progresses to legal blindness. The agreement also includes Biogen options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition. (Reporting by Bill Berkrot; additional reporting by Ransdell Pierson)",2015-07-02,BIIB,"Thu Jul 2, 2015 | 10:01am EDT",Biogen enters eye-treatment arena with AGTC deal,http://www.reuters.com//article/biogen-agtc-idUSL2N0ZF1OR20150702?type=companyNews
88,"   By Ransdell Pierson and Bill Berkrot  Disappointing data for Biogen Inc's experimental Alzheimer's drug dragged shares of the company lower on Wednesday, while investors took a slightly more positive view of new findings for a treatment from Eli Lilly and Co.Shares of Biogen traded 3.9 percent lower in midafternoon after falling as much as 4.9 percent, while Lilly was up slightly, recovering from a decline of 4.7 percent after the two companies released study data at the Alzheimer's Association International Conference in Washington. Wall Street analysts said the initial Lilly drop may have been influenced by the negative take on Biogen, since both of their drugs work by blocking formation of the protein beta amyloid, which is believed to cause brain plaques that are the hallmark of Alzheimer's.Alzheimer's experts said there were signs for hope for both treatments, but they will wait for results of much larger confirmatory trials before getting excited.""Developments are moving in the right direction, but are not of the magnitude that will change the world tomorrow,"" said Dr. David Knopman, a Mayo Clinic neurologist and deputy editor of the journal Neurology. ""There are hints of genuine benefits.""  Biogen's drug aducanumab had been hailed as a potential breakthrough in March, when a small study showed that 3 milligram and 10 mg doses slowed cognitive decline and reduced brain plaques.Investors had hoped that a 6 mg dose could be a safer and effective alternative to the 10 mg dose, which had also produced high rates of a type of brain swelling. On Wednesday, researchers said the 6 mg dose failed to significantly slow mental decline even though it clearly demonstrated an amyloid reduction.    ""If they're getting brain swelling at 10 mgs and their 6 mg dose is showing limited efficacy, it draws into question Biogen's program,"" said John Boris, an analyst with Suntrust Robinson Humphrey, who is attending the Alzheimer's meeting. Lilly researchers said on Wednesday that patients with mild Alzheimer's disease who took the company's solanezumab early in the course of their disease preserved more of their cognitive and functional ability than patients who received the treatment at a later stage.Boris said Lilly's solanezumab, if successful in a new large-scale study, is likely to be approved by 2017. That would bring it to the market at least two years before aducanumab, and represent the first medicine to slow progression of the disease affecting 5 million Americans. Morningstar analyst Damien Conover said the Lilly data was only ""slightly encouraging"" because it did not compare solanezumab with a placebo.Other analysts said Biogen's aducanumab could still prove a potent treatment when tested in a larger population.""The benefit still looks robust to us and better than Lilly's solanezumab,"" said Evercore ISI analyst Mark Schoenebaum. He stuck to his estimate of a 50 percent chance for success in planned late-stage trials. (Reporting by Ransdell Pierson and Bill Berkrot in New York; Editing by Chris Reese and Matthew Lewis)",2015-07-22,BIIB,"Wed Jul 22, 2015 | 2:40pm EDT","Biogen Alzheimer's data disappoints, Lilly gets slight bump",http://www.reuters.com//article/us-health-alzheimers-rivals-idUSKCN0PW1UZ20150722?type=companyNews
89,"   By Ransdell Pierson | July 22  July 22 Disappointing data for Biogen Inc's  experimental Alzheimer's drug dragged shares in the company lower on Wednesday, while investors took a slightly more positive view of new findings for a treatment from Eli Lilly and Co.Shares in Biogen traded 2.7 percent lower after falling as much as 4.9 percent, while Lilly was up 0.3 percent, recovering from a decline of 4.7 percent after the two companies released study data at the Alzheimer's Association International Conference in Washington.Wall Street analysts said the initial Lilly drop may have been influenced by the negative take on Biogen, since both companies' drugs work by blocking formation of the protein beta amyloid, which is believed to cause brain plaques that are the hallmark of Alzheimer's.Biogen's drug aducanumab had been hailed as a potential breakthrough in March, when a small study showed that 3 milligram and 10 mg doses appeared to slow cognitive decline and reduce toxic brain plaques associated with Alzheimer's. Investors had hoped that a 6 mg dose could be a safer and effective alternative to the 10 mg dose, which had also produced a type of brain swelling. On Wednesday, researchers said the 6 mg dose failed to significantly slow mental decline. ""If they're getting brain swelling at 10 mgs and their 6 mg dose is showing limited efficacy, it draws into question Biogen's program,"" said John Boris, an analyst with Suntrust Robinson Humphrey, who is attending the Alzheimer's meeting.Evercore ISI analyst Mark Schoenebaum said the fact that the 6 mg dose of aducanumab was less effective than the 3 milligram raised some concern. But he stuck to his estimate that planned late-stage trials of the drug have a 50 percent chance of success. Lilly researchers on Wednesday said that patients with mild Alzheimer's disease who took the company's experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability than patients who received the treatment at a later stage.Although the findings suggest that solanezumab may slow down disease progression among those with mild Alzheimer's, the hypothesis must be proven in a new and larger Phase III study that is now in progress.Morningstar analyst Damien Conover said the Lilly data was only ""slightly encouraging"" because it did not compare solanezumab with a placebo.Boris said solanezumab, if successful in the new study, is likely to be approved by 2017, at least two years before aducanumab, and become the first medicine to slow progression of the disease affecting 5 million Americans.   (Reporting by Ransdell Pierson; Editing by Chris Reese)",2015-07-22,BIIB,"Wed Jul 22, 2015 | 11:43am EDT","Biogen Alzheimer's drug data falls flat, Lilly gets slight bump",http://www.reuters.com//article/health-alzheimers-rivals-idUSL1N10216K20150722?type=companyNews
90,"  * Nidec jumps 10 pct on strong April-June results     * Eisai tanks after Biogen drug data disappoints     * Komatsu, Hitachi Construction Machinery fall before Caterpillar's earnings      By Ayai Tomisawa     TOKYO, July 23 Japan's Nikkei share average rose on Thursday morning on domestic earnings optimism after electric motor maker Nidec Corp reported strong quarterly results.     Shares of Nidec jumped 10 percent after it posted a 24.1 percent rise in operating profit to 31 billion yen  ($249.92 million) for April-June, a record quarterly profit.       Bucking the strength, Eisai Co fell nearly 10 percent and was the third most traded stock by turnover after news of disappointing research data for partner Biogen Inc's  experimental Alzheimer's drug.      The Nikkei share average gained 0.3 percent to 20,661.19 in midmorning trade.     With worries about international risks such as volatility in China shares receding, investors started to shift their focus to domestic catalysts, traders said.     ""Expectations for strong earnings have always been there, and people finally can focus on them,"" said Isao Kubo, equity strategist at Nissay Asset Management, adding that the Japanese market will likely gradually rise back to its 18-1/2-year high of 20,952.71 hit in June.     Stocks related to rising inbound tourism outperformed after the Japan National Tourism Organization said on Wednesday a record number of foreigners travelled to Japan during the first half of this year. The number jumped 46 percent on year to 9.14 million, it said.     Department store stocks climbed, with Isetan Mitsukoshi Holdings rising 2.1 percent and Takashimaya Co   2.5 percent. Disney Resort operator Oriental Land Co  rose 2.3 percent.     Caterpillar Inc's weak sales data took a toll on Japanese construction machinery makers' shares.     Ahead of its scheduled earnings report, Caterpillar said  retail sales statistics of machines were down by 2 percent to 50 percent in all regions for the three-month rolling period ended June.      Komatsu Ltd fell 2.8 percent and Hitachi Construction Machinery Co dropped 1.8 percent.     The broader Topix gained 0.3 percent to 1,659.48 and the JPX-Nikkei Index 400 advanced 0.2 percent to 14,973.39.  ($1 = 124.0400 yen)   (Editing by Richard Borsuk)   ",2015-07-23,BIIB,"Wed Jul 22, 2015 | 10:20pm EDT",Nikkei rises on earnings optimism; Nidec jumps on quarterly results,http://www.reuters.com//article/markets-japan-stocks-idUSL3N1031A020150723?type=companyNews
91,"  TOKYO Shares in Japanese drug maker Eisai Co fell nearly 10 percent early on Thursday after news of disappointing data for partner Biogen Inc's experimental Alzheimer's drug.Eisai was down 7 percent at 8,228 yen at 0109 GMT, after falling to as low as 7975.0 yen. Its shares had jumped to a record high in March driven by promising results of Biogen's experimental drug.   (Reporting by Ayai Tomisawa; Editing by Chang-Ran Kim)",2015-07-23,BIIB,"Wed Jul 22, 2015 | 9:18pm EDT",Eisai shares tank after partner Biogen's Alzheimer's data disappoints,http://www.reuters.com//article/us-eisai-stocks-idUSKCN0PX03520150723?type=companyNews
92,"  * Amazon joins club of 10 largest U.S. companies* Biogen's fall weighs on Nasdaq, S&P* Clinton to propose raising capital gains tax - report* Indexes down: Dow 0.9 pct, S&P 1.1 pct, Nasdaq 1.1 pct   (Updates to close)By Rodrigo CamposJuly 24 The S&P 500 and Nasdaq posted their largest weekly drops since March on Friday as slowing global growth dragged commodity-related stocks lower while an earnings-fueled drop in Biogen took down the biotech sector.Biogen more than halved its revenue growth forecast for 2015 and its stock lost 22 percent to close just above $300.Stocks in the energy and materials sectors weighed heavily on the market after weaker-than-expected economic data from China and the euro zone raised concerns about global growth. Oil prices hit their lowest since March. ""You got underwhelming revenue growth on balance and then you layer on top of that concern over a global economic slowdown, that becomes self-fulfilling,"" Art Hogan, chief market strategist at Wunderlich Securities in New York, said of the stock market weakness.Amazon was the bright spot on Friday, rising more than 20 percent at one point and closing up 10 percent at $530.50. The online retailer posted an unexpected quarterly profit and its market cap ballooned to $247 billion, making it the tenth-largest U.S. company by market value.However, Amazon's spike highlighted the thinning of leadership in the S&P 500. Gains on the index so far this year can be attributed to Amazon and just three more companies. At the close of trading on Friday, the Dow Jones industrial average fell 163.39 points, or 0.92 percent, to 17,568.53, the S&P 500 lost 22.5 points, or 1.07 percent, to 2,079.65 and the Nasdaq Composite dropped 57.78 points, or 1.12 percent, to 5,088.63.For the week, the S&P fell 2.2 percent and the Nasdaq slid 2.3 percent in their largest weekly drops since the last week of March. The 2.9 percent fall on the Dow was the largest for any week since January.Selling in stocks accelerated after a report from the Wall Street Journal said Democratic presidential candidate Hillary Clinton will propose nearly doubling the U.S. capital gains tax rate on short-term investments. Second-quarter S&P 500 earnings have been mixed, with 74 percent of companies beating analysts' profit expectations but just 52 percent surpassing revenue expectations, according to Thomson Reuters data.Adding to the concerns regarding lukewarm earnings, the S&P 500 is relatively expensive, trading at 16.9 times forward 12 months' earnings, above the 10-year median of 14.7 times, according to StarMine data.Dow component Visa ended up 4.3 percent at $74.80 after the credit and debit card company's results handily beat expectations.Declining issues outnumbered advancing ones on the NYSE by 2,246 to 831, for a 2.70-to-1 ratio on the downside; on the Nasdaq, 2,144 issues fell and 660 advanced for a 3.25-to-1 ratio favoring decliners.The benchmark S&P 500 index posted 13 new 52-week highs and 54 new lows; the Nasdaq Composite recorded 50 new highs and 200 new lows.Some 7.3 billion shares changed hands on U.S. exchanges, above the daily average of 6.6 billion so far this month.   (Reporting by Rodrigo Campos; Editing by Meredith Mazzilli)",2015-07-24,BIIB,"Fri Jul 24, 2015 | 4:46pm EDT","US STOCKS-Wall St slides to end rough week on macro, earnings concerns",http://www.reuters.com//article/markets-stocks-usa-idUSL1N1042C920150724?type=companyNews
93,"   By Natalie Grover  Biogen Inc (BIIB.O) more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis (MS) drug, Tecfidera, to continue slowing this year in the United States.Tecfidera has been Biogen's main growth driver since its launch in 2013, but a saturated U.S. market and reports linking the drug to brain infections meant that sales rose less than analysts expectations for the second straight quarter.Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the company's weak forecast and lackluster second-quarter results on Friday.The company also reported disappointing sales for its other MS drugs. Sales of injectable MS drug Tysabri and interferon-based MS drug Avonex fell more than analysts expected, while sales of the longer-lasting Plegridy also missed estimates.Biogen needs ""fixing"", and it does not have the luxury of time to build out its pipeline gradually like Celgene Corp (CELG.O) does, Piper Jaffray's Joshua Schimmer said. Biogen plans to continue investing in its pipeline, while controlling costs, the biotech company's executives said on a conference call.""I don't think we're in any panic situation but as we see good opportunities we will be aggressive about bringing them in,"" CEO George Scangos said after analysts on the call suggested Biogen consider acquisitions to rejuvenate growth.Biogen said it now assumes ""extremely limited"" U.S. patient growth for Tecfidera sequentially for the rest of 2015, and also highlighted lower-than-anticipated reimbursements in Europe. With Tecfidera's sales slowing, Biogen chopped its full-year sales growth forecast to 6-8 percent from 14-16 percent. The company's sales had risen 40 percent in 2014 and 25.7 percent in 2013.Cambridge, Massachusetts-based Biogen's second-quarter sales rose 7 percent to $2.6 billion, but missed analysts' average estimate of $2.7 billion, according to Thomson Reuters I/B/E/S.Biogen's stock hit a record high in March when tests showed the company's experimental Alzheimer's drug significantly slowed mental decline  a potential breakthrough in treating the incurable disease. But that enthusiasm was tempered on Wednesday, after longer term data showed that a particular dose of the drug failed to significantly slow mental decline.Relying on the Alzheimer's program is too risky, said Schimmer, who hacked his price target on the stock by $49 to $361.Biogen's stock was down 18.5 percent at $315, easing slightly from its session low of $312.50. (Editing by Savio D'Souza)",2015-07-24,BIIB,"Fri Jul 24, 2015 | 12:14pm EDT",Biogen halves sales growth forecast as Tecfidera demand stalls,http://www.reuters.com//article/us-biogen-results-idUSKCN0PY1CL20150724?type=companyNews
94,"  * Tecfidera U.S. growth to be flat for rest of 2015* Q2 MS drug sales miss estimates* Cuts FY sales growth view to 6-8 pct from 14-16 pct* ""I don't think we're in any panic situation""-CEO* Shares fall as much as 18.8 percent   (Recasts, analyst and executive comment, shares)By Natalie GroverJuly 24 Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis (MS) drug, Tecfidera, to continue slowing this year in the United States. Tecfidera has been Biogen's main growth driver since its launch in 2013, but a saturated U.S. market and reports linking the drug to brain infections meant that sales rose less than analysts expectations for the second straight quarter.Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the company's weak forecast and lackluster second-quarter results on Friday.The company also reported disappointing sales for its other MS drugs. Sales of injectable MS drug Tysabri and interferon-based MS drug Avonex fell more than analysts expected, while sales of the longer-lasting Plegridy also missed estimates.Biogen needs ""fixing"", and it does not have the luxury of time to build out its pipeline gradually like Celgene Corp  does, Piper Jaffray's Joshua Schimmer said. Biogen plans to continue investing in its pipeline, while controlling costs, the biotech company's executives said on a conference call.""I don't think we're in any panic situation but as we see good opportunities we will be aggressive about bringing them in,"" CEO George Scangos said after analysts on the call suggested Biogen consider acquisitions to rejuvenate growth.Biogen said it now assumes ""extremely limited"" U.S. patient growth for Tecfidera sequentially for the rest of 2015, and also highlighted lower-than-anticipated reimbursements in Europe. With Tecfidera's sales slowing, Biogen chopped its full-year sales growth forecast to 6-8 percent from 14-16 percent. The company's sales had risen 40 percent in 2014 and 25.7 percent in 2013.Cambridge, Massachusetts-based Biogen's second-quarter sales rose 7 percent to $2.6 billion, but missed analysts' average estimate of $2.7 billion, according to Thomson Reuters I/B/E/S.Biogen's stock hit a record high in March when tests showed the company's experimental Alzheimer's drug significantly slowed mental decline - a potential breakthrough in treating the incurable disease.But that enthusiasm was tempered on Wednesday, after longer term data showed that a particular dose of the drug failed to significantly slow mental decline.Relying on the Alzheimer's program is too risky, said Schimmer, who hacked his price target on the stock by $49 to $361.Biogen's stock was down 18.5 percent at $315, easing slightly from its session low of $312.50.   (Editing by Savio D'Souza)",2015-07-24,BIIB,"Fri Jul 24, 2015 | 11:54am EDT",UPDATE 3-Biogen halves sales growth forecast as Tecfidera demand stalls,http://www.reuters.com//article/biogen-results-idUSL3N10448Y20150724?type=companyNews
95,"  * Amazon jumps to record high after posting unexpected profit* June home sales fall to lowest level in seven months* Hillary Clinton to propose raising capital gains tax - report* Biogen's fall weighs on Nasdaq, S&P* Indexes down: Dow 0.41 pct, S&P 0.39 pct, Nasdaq 0.1 pct   (Adds details, changes comment, updates prices)By Tanya AgrawalJuly 24 Wall Street was lower in late morning trading on Friday for the fourth straight day after a mixed bag of earnings from big companies and the downward spiral of commodities.Metal prices hit multi-year lows as weaker-than-expected data from China and the euro zone raised concerns about global growth while oil prices neared four-month lows.The three major indexes were poised to end the week in the red after disappointing corporate results and forecasts added to concerns about the U.S. profit outlook. Adding to the day's pressure, Democratic presidential candidate Hillary Clinton will propose nearly doubling the U.S. capital gains tax rate on short-term investments, the Wall Street Journal reported.Data on Friday showed new U.S. single-family home sales fell in June to their lowest level in seven months and May's sales were revised sharply lower. Other data showed manufacturing activity nudged up in July after slowing for three straight months.""We are not going to see a lot of earnings growth in the second half of the year as the economic data hasn't been very strong,"" said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago.""The fall in commodities is also a concerns that global growth is slowing and that ties into U.S. growth too.""Amazon.com shares jumped as much as 20.4 percent to a record high of $580.57, a day after the online retailer posted an unexpected quarterly profit. Dow component Visa was up 5.4 percent at $75.61 after the credit and debit card company's results handsomely beat  expectations.Starbucks rose 1.9 percent to $57.65 after the world's biggest coffee chain reported a higher quarterly profit.At 11:04 a.m. ET (1504 GMT), the Dow Jones industrial average was down 72.93 points, or 0.41 percent, at 17,658.99, the S&P 500 was down 8.23 points, or 0.39 percent, at 2,093.92 and the Nasdaq Composite was down 4.97 points, or 0.1 percent, at 5,141.44.Biogen's 16.9 percent slump weighed the most on the Nasdaq and the S&P 500 after the biotechnology company cut its 2015 forecast. Six of the 10 major S&P 500 indexes were lower with the health index's 1.37 percent fall leading the decliners.Second-quarter S&P 500 earnings have been mixed, with 74 percent of companies so far beating analysts' profit expectations but just 52 percent surpassing revenue expectations, according to Thomson Reuters data.RBC Capital Markets said investors were treating disappointing stocks harshly. While only 20 percent of companies have missed expectations, below the 23 percent over the past three years, there was a 3.5 percent selloff versus the 2.4 percent seen historically, a note said.Adding to the concerns regarding lukewarm earnings, the S&P 500 is relatively expensive, trading at 16.9 times forward 12 months' earnings, above the 10-year median of 14.7 times, according to StarMine data.Stancorp Financial Group soared 48.2 percent to $113.70 after Japan's Meiji Yasuda Life Insurance said it has agreed to buy the company for $5 billion.Truecar slumped 37 percent to $6.73 after the online car-shopping service provider cut full-year revenue forecast.Declining issues outnumbered advancers on the NYSE by 1,943 to 939. On the Nasdaq, 1,629 issues fell and 945 advanced.The S&P 500 index showed 12 new 52-week highs and 42 new lows, while the Nasdaq recorded 38 new highs and 125 new lows.   (Editing by Don Sebastian)",2015-07-24,BIIB,"Fri Jul 24, 2015 | 11:22am EDT","US STOCKS-Wall Street lower amid mixed earnings, fall in commodities",http://www.reuters.com//article/markets-stocks-usa-idUSL3N1045A720150724?type=companyNews
96,"  July 24 Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera.Net profit attributable to Biogen rose to $927.3 million, or $3.93 per share, in the second quarter ended June 30, from $714.5 million, or $3.01 per share, a year earlier.  The U.S. biotechnology company's revenue rose about 7 percent to $2.59 billion.    (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza) ",2015-07-24,BIIB,"Fri Jul 24, 2015 | 6:59am EDT",Biogen profit rises 30 pct on higher Tecfidera sales,http://www.reuters.com//article/biogen-results-idUSL3N10448720150724?type=companyNews
97,"   By Ransdell Pierson and Bill Berkrot  Aug 5 CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight loss treatment Qsymia, which last week was excluded from the 2016 formulary of rival PBM Express Scripts Holding Co. Vivus officials could not immediately be reached for comment.Pharmacy benefit managers, or PBMs, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications. When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing.Viagra, the world's first approved pill for erectile dysfunction, has annual sales of $1.8 billion, including $1.3 billion in the United States. Cheaper generic versions are expected to be launched by December 2017. ""Pfizer is committed to ensuring patient access to our medicines,"" the drugmaker said in an emailed statement.The CVS formulary, however, does include Eli Lilly and Co's  rival Cialis anti-impotence treatment.Next year's formulary will also exclude two interferon-based multiple sclerosis treatments from Biogen, big-selling Avonex and its new longer-acting Plegridy. Avonex, Biogen's second-biggest product, has annual sales of almost $2.5 billion. ""Avonex and Plegridy have broad insurance coverage,"" Biogen said in an emailed statement. ""We are confident that patients will continue to have access to our medicines.""Johnson & Johnson's two-year-old diabetes treatment, Invokana, and a related combination treatment called Invokamet, will also be stripped from CVS coverage. Combined sales of the medicines have been growing by leaps and bounds, reaching $318 million in the second quarter. J&J did not have an immediate comment. Another diabetes drug to be excluded from the CVS formulary is Bydureon, a once-weekly treatment from AstraZeneca Plc . CVS will favor instead similar treatments from Lilly and Novo Nordisk.""Bydureon continues to have excellent access across commercial and non-commercial plans, including (Medicare) Part D,"" AstraZeneca said.Express Scripts, the nation's biggest PBM, last week said it would boot about 20 additional medicines from its formulary in 2016 <ID:nL1N10B2JM>.Express Scripts said it can negotiate lower drug prices through its ability to exclude drugs from its coverage list. The formulary determines whether tens of millions of people with private insurance can easily use an insurance co-pay to buy  prescription drugs.   (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Jonathan Oatis)",2015-08-05,BIIB,"Wed Aug 5, 2015 | 5:37pm EDT","CVS strips Viagra, other top drugs, from insurance coverage",http://www.reuters.com//article/cvs-health-coverage-idUSL1N10G3HE20150805?type=companyNews
98,"   By Andrew Chung and Bill Berkrot  In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.Last month the patent office also declined reviews requested by Bass and his Coalition for Affordable Drugs on two Acorda Therapeutics Inc patents. The Biogen patent covered a dosing regimen for Tecfidera, which had $2.9 billion in sales last year.Despite recent slowing demand, Tecfidera is the top-selling oral MS drug and widely considered to be Biogen's most important near-term growth driver. Biogen shares were up 2.8 percent at $300.65 at midday on Wednesday.The Bass group had argued that the Tecfidera patent, which covered a specific dosing regimen for patients, was obvious in light of previously known treatment methods. The USPTO Patent Trial and Appeal Board disagreed. ""It is ordered that the Petition is denied as to all challenged claims, and a trial will not be instituted,"" the 16-page ruling concluded. In February, Bass began to file reviews to eliminate drug patents through his Coalition for Affordable Drugs. His group claims that drugmakers were improperly extending patent protection in questionable ways, such as changing dosage or delivery methods in order to delay entry to the market of cheaper generic versions of the medicines.The pharmaceutical industry has raised concerns about hedge fund challenges to drug patents, saying they are intended to make money through short-selling by driving stock prices lower.In July, Celgene Corp asked the patent agency to sanction Bass and the coalition for ""abuse"" of the review process. The coalition has challenged patents on Celgene's flagship multiple myeloma drug Revlimid.",2015-09-02,BIIB,"Wed Sep 2, 2015 | 12:49pm EDT",Biogen patent survives challenge by hedge fund manager Bass,http://www.reuters.com//article/biogen-patent-idUSL1N1181I320150902?type=companyNews
99,"  NEW YORK In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera.Last month the patent office also declined reviews requested by Bass and his Coalition for Affordable Drugs on two Acorda Therapeutics Inc patents. The Biogen patent covered a dosing regimen for Tecfidera, which had $2.9 billion in sales last year.Despite recent slowing demand, Tecfidera is the top-selling oral MS drug and widely considered to be Biogen's most important near-term growth driver.Biogen shares were up 2.8 percent at $300.65 at midday on Wednesday. The Bass group had argued that the Tecfidera patent, which covered a specific dosing regimen for patients, was obvious in light of previously known treatment methods.The USPTO Patent Trial and Appeal Board disagreed. ""It is ordered that the Petition is denied as to all challenged claims, and a trial will not be instituted,"" the 16-page ruling concluded.  In February, Bass began to file reviews to eliminate drug patents through his Coalition for Affordable Drugs. His group claims that drugmakers were improperly extending patent protection in questionable ways, such as changing dosage or delivery methods in order to delay entry to the market of cheaper generic versions of the medicines.The pharmaceutical industry has raised concerns about hedge fund challenges to drug patents, saying they are intended to make money through short-selling by driving stock prices lower. In July, Celgene Corp asked the patent agency to sanction Bass and the coalition for ""abuse"" of the review process. The coalition has challenged patents on Celgene's flagship multiple myeloma drug Revlimid. (Reporting by Andrew Chung and Bill Berkrot; Editing by Alexia Garamfalvi and Matthew Lewis)",2015-09-02,BIIB,"Wed Sep 2, 2015 | 12:38pm EDT",Biogen patent survives challenge by hedge fund manager Bass,http://www.reuters.com//article/us-biogen-patent-idUSKCN0R21RL20150902?type=companyNews
100,"  NEW YORK, Sept 2 In another setback for prominent hedge fund manager Kyle Bass and his campaign to eliminate some drug patents, the U.S. Patent and Trademark Office on Wednesday declined to hold a trial on the validity of a patent on Biogen Inc's multiple sclerosis drug Tecfidera. Last month the patent office also declined reviews requested by Bass and his Coalition for Affordable Drugs on two Acorda Therapeutics Inc patents. The Biogen patent covered a dosing regimen for Tecfidera, which had $2.9 billion in sales last year.   (Reporting by Andrew Chung; Editing by Alexia Garamfalvi)  ",2015-09-02,BIIB,"Wed Sep 2, 2015 | 11:24am EDT",Biogen patent survives challenge by hedge fund manager Kyle Bass,http://www.reuters.com//article/biogen-patent-idUSL1N11816S20150902?type=companyNews
101,"   By Bill Berkrot  Biogen Inc (BIIB.O), whose shares have tumbled since it slashed growth forecasts for its top-selling multiple sclerosis drug in July, said it will cut 11 percent of its workforce and eliminate development of several drugs to focus on high-priority medicines in its pipeline.Wall Street signaled its approval of the belt-tightening as well as better-than-expected third-quarter sales of Biogen's multiple sclerosis drugs, sending its shares up as much as 9.5 percent. But most of the gains evaporated by midday. The restructuring, announced on Wednesday, will reduce operating expenses by about $250 million this year, it said.The U.S. biotech's stock had fallen about 35 percent over the past three months over concerns about slowing sales of Tecfidera, its oral multiple sclerosis drug.Biogen will stop developing a drug for lupus and end some immunology and fibrosis research to concentrate on high-risk programs that promise high reward if successful.They include late-stage development of its high-profile Alzheimer's disease drug aducanumab, two other Alzheimer's programs, its anti-Lingo drug that aims to repair nerve damage caused by MS, and one for spinal muscular atrophy. The company will also pour some of the savings into direct-to-consumer marketing of Tecfidera in an effort to reignite growth in the United States and elsewhere. It cut a Tecfidera program in secondary progressive multiple sclerosis after disappointing trial results. Chief Executive Officer George Scangos said, even with mounting pressures to rein in prices of U.S. prescription drugs, medicines like aducanumab and others on which it will focus will justify ""attractive pricing"" if approved.""In the end, things are going to be priced according to the value they bring to patients,"" Scangos said. RBC Capital Markets analyst Michael Yee said investors had been concerned after the second-quarter disappointment. ""What's most important for people is that things did not get worse, things could get a little bit better, and management's tone about the pipeline remains positive,"" Yee said. ""These are really huge opportunities."" The company said it may have found a way to reduce a type of brain swelling that had been the most concerning side effect seen with aducanumab by adjusting dosing during treatment.  Biogen, which has about 7,550 employees, will take a charge of $85 million to $95 million, primarily in the fourth quarter relating to the jobs cuts. It also plans to announce other non-labor related cost savings by year end.With strong third-quarter sales, cost savings, and a $5 billion share repurchase campaign well underway, Biogen raised its full-year sales and earnings forecasts. It expects revenue growth of 8 percent to 9 percent, up from 6 percent to 8 percent, and sees adjusted earnings of $16.20 to $16.50 per share versus its prior view of $15.50 to $15.95.The company reported adjusted third-quarter earnings of $4.48 per share, sailing past analysts' tempered expectations of $3.80, according to Thomson Reuters I/B/E/S.Tecfidera sales of $937 million in the quarter, helped by inventory stocking, topped expectations of about $895 million.The stock rose 2.2 percent to $271.70 at midday after rising as high as $291.01. (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian, Clive McKeef and Jeffrey Benkoe)",2015-10-21,BIIB,"Wed Oct 21, 2015 | 12:59pm EDT","Biogen to cut 11 percent of staff, cancel some drug programs; stock jumps",http://www.reuters.com//article/us-biogen-restructuring-idUSKCN0SF1DH20151021?type=companyNews
102,"  (Adds analyst comment, updates shares)By Bill BerkrotOct 21 Biogen Inc, whose shares have tumbled since it slashed growth forecasts for its top-selling multiple sclerosis drug in July, said it will cut 11 percent of its workforce and eliminate development of several drugs to focus on high-priority medicines in its pipeline.Wall Street signaled its approval of the belt-tightening as well as better-than-expected third-quarter sales of Biogen's multiple sclerosis drugs, sending its shares up as much as 9.5 percent. But most of the gains evaporated by midday.The restructuring, announced on Wednesday, will reduce operating expenses by about $250 million this year, it said.The U.S. biotech's stock had fallen about 35 percent over the past three months over concerns about slowing sales of Tecfidera, its oral multiple sclerosis drug.Biogen will stop developing a drug for lupus and end some immunology and fibrosis research to concentrate on high-risk programs that promise high reward if successful. They include late-stage development of its high-profile Alzheimer's disease drug aducanumab, two other Alzheimer's programs, its anti-Lingo drug that aims to repair nerve damage caused by MS, and one for spinal muscular atrophy.The company will also pour some of the savings into direct-to-consumer marketing of Tecfidera in an effort to reignite growth in the United States and elsewhere. It cut a Tecfidera program in secondary progressive multiple sclerosis after disappointing trial results.Chief Executive Officer George Scangos said, even with mounting pressures to rein in prices of U.S. prescription drugs, medicines like aducanumab and others on which it will focus will justify ""attractive pricing"" if approved.""In the end, things are going to be priced according to the value they bring to patients,"" Scangos said. RBC Capital Markets analyst Michael Yee said investors had been concerned after the second-quarter disappointment.""What's most important for people is that things did not get worse, things could get a little bit better, and management's tone about the pipeline remains positive,"" Yee said. ""These are really huge opportunities.""The company said it may have found a way to reduce a type of brain swelling that had been the most concerning side effect seen with aducanumab by adjusting dosing during treatment. Biogen, which has about 7,550 employees, will take a charge of $85 million to $95 million, primarily in the fourth quarter relating to the jobs cuts. It also plans to announce other non-labor related cost savings by year end.With strong third-quarter sales, cost savings, and a $5 billion share repurchase campaign well underway, Biogen raised its full-year sales and earnings forecasts.It expects revenue growth of 8 percent to 9 percent, up from 6 percent to 8 percent, and sees adjusted earnings of $16.20 to $16.50 per share versus its prior view of $15.50 to $15.95.The company reported adjusted third-quarter earnings of $4.48 per share, sailing past analysts' tempered expectations of $3.80, according to Thomson Reuters I/B/E/S.Tecfidera sales of $937 million in the quarter, helped by inventory stocking, topped expectations of about $895 million.The stock rose 2.2 percent to $271.70 at midday after rising as high as $291.01.   (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Don Sebastian, Clive McKeef and Jeffrey Benkoe)",2015-10-21,BIIB,"Wed Oct 21, 2015 | 12:58pm EDT","UPDATE 3-Biogen to cut 11 pct of staff, cancel some drug programs; stock jumps",http://www.reuters.com//article/biogen-restructuring-idUSL3N12L3WX20151021?type=companyNews
103,"  Oct 21 Drugmaker Biogen Inc said it would cut 11 pct of its global workforce by the end of this year. Biogen also reported an 11 percent rise in quarterly revenue, driven by higher demand for its multiple sclerosis drug Tecfidera.    (Reporting by Rosmi Shaji in Bengaluru)  ",2015-10-21,BIIB,"Wed Oct 21, 2015 | 7:43am EDT",Biogen to cut 11 pct of global workforce,http://www.reuters.com//article/biogen-restructuring-idUSL3N12L33D20151021?type=companyNews
104,"  * EMA considers recommendation of biosimilar copy of Enbrel* Drug copy developed by Samsung, Biogen joint venture   (Adds detail on discounts, application process)By Ben HirschlerLONDON, Nov 18 Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel.Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their use than the United States, and their potential to take business from companies making the original products is being monitored closely by investors.AbbVie, which sells the market-leading rheumatoid arthritis drug Humira, is viewed as being particularly at risk.Antibody drugs are the big prize for biosimilars because these products are among the world's top-selling drugs. Worldwide sales of Amgen's Enbrel, which is marketed outside North America by Pfizer, totalled $9 billion last year, with Europe accounting for about $2.5 billion.Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim at that business with its version of etanercept, as Enbrel is known scientifically.A marketing application for biosimilar etanercept is being assessed by experts at the European Medicines Agency (EMA) this week, according to an EMA agenda. There is currently only one such application pending at the EMA and a Biogen spokeswoman confirmed the assessment referred to its product.Because biosimilars are made inside living cells they can never be exact duplicates of the original medicine, so manufacturers need to conduct clinical trials to show their products work as intended.That makes them more difficult to produce than conventional generic medicines but potentially more profitable. Biosimilar etanercept, which was recently approved in South Korea, would be the second such antibody product to reach the market in Europe and its arrival is likely to intensify competition. European doctors are already able to prescribe biosimilar infliximab, a copy of Merck's Remicade.The infliximab biosimilar is gaining ground in certain European countries after some surprisingly steep price discounts. In some cases these have reached nearly 70 percent, though overall the discounts have been nearer 45 percent.Assuming biosimilar etanercept is given a green light from the EMA this week, its approval will still have to be formally ratified by the European Commission, a process that normally takes a couple of months.Biogen will market the drug in Europe and manufacture it at a factory in Denmark.In a further boost for biosimilars, Novartis's  Sandoz unit said on Friday that the U.S. Food and Drug Administration had accepted its submission for approval of a biosimilar version of Amgen's Neulasta, which fights infections in cancer patients.(Editing by David Goodman)",2015-11-18,BIIB,"Wed Nov 18, 2015 | 7:11am EST",UPDATE 1-Europe could recommend second biosimilar arthritis drug this week,http://www.reuters.com//article/biotech-europe-biosimilars-idUSL8N13D2E820151118?type=companyNews
105,"  (Makes clear that 10th and 11th paragraphs refer to biosimilar versions of infliximab and etanercept)* EMA considers recommendation of biosimilar copy of Enbrel* Drug copy developed by Samsung, Biogen joint ventureBy Ben HirschlerLONDON, Nov 18 Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel.Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their use than the United States, and antibodies are the big prize because these products are among the world's top-selling drugs.Worldwide sales of Amgen's Enbrel, which is marketed outside North America by Pfizer, totalled $9 billion last year, with Europe accounting for about $2.5 billion. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim at that business with its version of etanercept, as Enbrel is known scientifically.A marketing application for biosimilar etanercept is being assessed by experts at the European Medicines Agency (EMA) this week, according to an EMA agenda. A Biogen spokeswoman confirmed the assessment referred to its product.Because biosimilars are made inside living cells they can never be exact duplicates of the original medicine, so manufacturers need to conduct clinical trials to show their products work as intended. That makes them more difficult to produce than conventional generic medicines but potentially more profitable.Biosimilar etanercept, which was recently approved in South Korea, would be the second such antibody product to reach the market in Europe and its arrival is likely to intensify competition. European doctors are already able to prescribe biosimilar infliximab, a copy of Merck's Remicade.The potential for cheaper biosimilars to take business from expensive brands is worrying investors in companies making the original products. AbbVie, which sells the market-leading rheumatoid arthritis drug Humira, is viewed as particularly at risk. Biosimilar infliximab is gaining ground in certain European countries after some surprisingly steep price discounts.Assuming biosimilar etanercept is given a green light from the EMA this week, its approval will still have to be formally ratified by the European Commission, a process that normally takes a couple of months.Biogen will market the drug in Europe and manufacture it at a factory in Denmark.In a further boost for biosimilars, Novartis's  Sandoz unit said on Friday that the U.S. Food and Drug Administration had accepted its submission for approval of a biosimilar version of Amgen's Neulasta, which fights infections in cancer patients.(Editing by David Goodman)",2015-11-18,BIIB,"Wed Nov 18, 2015 | 5:22am EST",REFILE-Europe could recommend second biosimilar arthritis drug this week,http://www.reuters.com//article/biotech-europe-biosimilars-idUSL8N13C44Q20151118?type=companyNews
106,  Nov 24 Swedish Orphan Biovitrum* Says Sobi and Biogen's Elocta (rfviiifc) approved in Europe for the treatment of haemophilia a  * Says product to launch in initial EU countries in early 2016  Source text for Eikon:  Further company coverage:    (Stockholm Newsroom) ,2015-11-24,BIIB,"Tue Nov 24, 2015 | 2:06am EST",BRIEF-Sobi and Biogen's Elocta approved in Europe for the treatment of haemophilia A,http://www.reuters.com//article/idUSFWN13I02020151124?type=companyNews
107,"   By Bill Berkrot and Natalie Grover  Biogen Inc eased investor nerves on Wednesday and its shares surged more than 9 percent after the company reported better-than-expected sales of its most important multiple sclerosis drug, Tecfidera, and issued a 2016 outlook in line with Wall Street estimates.Biogen's quarterly results should help put a difficult 2015 in the rear view mirror and allow for a renewed focus on potentially important drugs the U.S. biotech company is developing.""Investors were quite nervous going into guidance,"" RBC Capital Markets analyst Michael Yee said.""Things aren't getting worse. There's some signs of light at end of the tunnel. There is a lot of huge pipeline opportunities to come,"" Yee said.Analysts had been concerned Biogen would provide a forecast below expectations after cautious comments by management at the recent JP Morgan Healthcare conference. That followed a 2015 in which the company slashed Tecfidera's growth forecast midyear and later announced a cost-saving restructuring.On Wednesday, Biogen said U.S. Tecfidera demand had stabilized, while sales were growing in Europe, allowing for a renewed focus on the company's promising stable of drugs in development. Biogen is enrolling patients in two late stage trials of aducanumab, the Alzheimer's disease drug that generated  excitement last year with early data that demonstrated reduction in amyloid plaque in the brain and some cognitive improvement.Data on other drugs expected this year, including two other Alzheimer's treatments earlier in development, could boost shares if positive, analysts said.Biogen is expecting data this year on a closely watched medicine known as anti-Lingo that could become the first to restore nerve damage caused by multiple sclerosis. Based on the Phase II data, Biogen will decide whether to proceed to a pivotal registration trial. It is also moving into Phase III trials with partner Ionis Pharmaceuticals, formerly Isis, of nusinersen for spinal muscular atrophy, a leading genetic cause of infant mortality.Fourth-quarter Tecfidera sales of $993 million, helped by about $30 million in inventory stocking, topped Wall Street estimates of about $930 million.Biogen executives told analysts on a call that the company hoped its ongoing direct-to-consumer Tecfidera television campaign will reaccelerate U.S. growth, but it will be difficult to gauge the impact until later this year. Biogen forecast 2016 adjusted earnings of $18.30 to $18.60 per share and revenue of $11.1 billion to $11.3 billion.Excluding special items, such as restructuring costs, Biogen earned $4.50 per share, handily beating Wall Street expectations of $4.08.Biogen shares rose $24.31, or 9.4 percent, to $284.18. (Editing by David Gregorio)",2016-01-27,BIIB,"Wed Jan 27, 2016 | 1:03pm EST",Biogen focuses on drugs in pipeline after strong quarter,http://www.reuters.com//article/us-biogen-results-idUSKCN0V51HH?type=companyNews
108,"   By Bill Berkrot and Natalie Grover  Biogen Inc eased investor nerves on Wednesday and its shares surged more than 9 percent after the company reported better-than-expected sales of its most important multiple sclerosis drug, Tecfidera, and issued a 2016 outlook in line with Wall Street estimates.Biogen's quarterly results should help put a difficult 2015 in the rear view mirror and allow for a renewed focus on potentially important drugs the U.S. biotech company is developing.""Investors were quite nervous going into guidance,"" RBC Capital Markets analyst Michael Yee said.""Things aren't getting worse. There's some signs of light at end of the tunnel. There is a lot of huge pipeline opportunities to come,"" Yee said.Analysts had been concerned Biogen would provide a forecast below expectations after cautious comments by management at the recent JP Morgan Healthcare conference. That followed a 2015 in which the company slashed Tecfidera's growth forecast midyear and later announced a cost-saving restructuring.On Wednesday, Biogen said U.S. Tecfidera demand had stabilized, while sales were growing in Europe, allowing for a renewed focus on the company's promising stable of drugs in development. Biogen is enrolling patients in two late stage trials of aducanumab, the Alzheimer's disease drug that generated  excitement last year with early data that demonstrated reduction in amyloid plaque in the brain and some cognitive improvement.Data on other drugs expected this year, including two other Alzheimer's treatments earlier in development, could boost shares if positive, analysts said.Biogen is expecting data this year on a closely watched medicine known as anti-Lingo that could become the first to restore nerve damage caused by multiple sclerosis. Based on the Phase II data, Biogen will decide whether to proceed to a pivotal registration trial. It is also moving into Phase III trials with partner Ionis Pharmaceuticals, formerly Isis, of nusinersen for spinal muscular atrophy, a leading genetic cause of infant mortality.Fourth-quarter Tecfidera sales of $993 million, helped by about $30 million in inventory stocking, topped Wall Street estimates of about $930 million.Biogen executives told analysts on a call that the company hoped its ongoing direct-to-consumer Tecfidera television campaign will reaccelerate U.S. growth, but it will be difficult to gauge the impact until later this year. Biogen forecast 2016 adjusted earnings of $18.30 to $18.60 per share and revenue of $11.1 billion to $11.3 billion.Excluding special items, such as restructuring costs, Biogen earned $4.50 per share, handily beating Wall Street expectations of $4.08.Biogen shares rose $24.31, or 9.4 percent, to $284.18. (Editing by David Gregorio)",2016-01-27,BIIB,"Wed Jan 27, 2016 | 1:03pm EST",UPDATE 3-Biogen focuses on drugs in pipeline after strong quarter,http://www.reuters.com//article/biogen-results-idUSL3N15B4HF?type=companyNews
109,"  Jan 27 Biogen Inc's fourth-quarter revenue rose 7.5 percent, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.Net income attributable to the U.S. biotechnology company fell to $831.6 million, or $3.77 per share, in the fourth-quarter ended December 31, from $883.5 million, or $3.74 per share, a year earlier. On a per share basis net income rose due to fewer shares outstanding.  Total revenue rose to $2.84 billion from $2.64 billion.   (Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)",2016-01-27,BIIB,"Wed Jan 27, 2016 | 7:28am EST",Biogen's quarterly sales rise 7.5 percent,http://www.reuters.com//article/biogen-results-idUSL3N15B4AP?type=companyNews
110,"   By Carl O'Donnell  Biogen Inc, one of the world's largest biotechnology companies, is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter. The potential sale of the assets, long seen as unusual fits relative to the company's broader portfolio, come as Biogen implements a sweeping restructuring program announced in October to cut costs and focus on core areas such as neurology and autoimmune diseases.Biogen is working with an investment bank on the sale of the hemophilia assets, the people said this week. There is no guarantee that the discussions will lead to a sale, the people added. These drugs collectively produced sales of about $500 million in 2015, the first full year in which they have been for sale.  The sources asked not to be identified because the sale process is confidential. Biogen declined to comment.""With the majority of the restructuring now completed, there's a palpable reinvigorated focus on our key commercial initiatives and high-potential pipeline candidate,"" Biogen Chief Executive Officer George Scangos told analysts on the company's latest earnings call in January. The potential divestment marks somewhat of an about-face for Biogen. In a February interview with trade publication Xconomy, Scangos said that he had decided to hold on to the products and try to build a platform around them.  Biogen now has two hemophilia products that have already obtained approval from the U.S. Food and Drug Administration, Alprolix and Eloctate. ""If all we were going to do was market those two compounds and let them run their life cycle then we should probably just sell them,"" Scangos said. ""If we are gonna be in it we need to be making investments for the future and the next generation of products, and care about this. Last year, Biogen made a small investment in its hemophilia platform, partnering with two Italian research institutions to develop gene therapies that treat the root causes of some types of hemophilia. The hemophilia drugs' revenues could continue to grow significantly in coming years due to their potential for international expansion. In November, Eloctate was launched in Europe for the treatment of one type of hemophilia. (Reporting by Carl O'Donnell; Editing by Bernard Orr)",2016-04-08,BIIB,"Fri Apr 8, 2016 | 2:56pm EDT",Biogen explores sale of hemophilia assets: sources,http://www.reuters.com//article/us-biogen-hemophilia-idUSKCN0X52AF?type=companyNews
111,"   By Carl O'Donnell  Biogen Inc, one of the world's largest biotechnology companies, is exploring a sale of its hemophilia treatments, as it increases its focus on core therapeutic areas, according to people familiar with the matter. The potential sale of the assets, long seen as unusual fits relative to the company's broader portfolio, come as Biogen implements a sweeping restructuring program announced in October to cut costs and focus on core areas such as neurology and autoimmune diseases.Biogen is working with an investment bank on the sale of the hemophilia assets, the people said this week. There is no guarantee that the discussions will lead to a sale, the people added. These drugs collectively produced sales of about $500 million in 2015, the first full year in which they have been for sale.  The sources asked not to be identified because the sale process is confidential. Biogen declined to comment.""With the majority of the restructuring now completed, there's a palpable reinvigorated focus on our key commercial initiatives and high-potential pipeline candidate,"" Biogen Chief Executive Officer George Scangos told analysts on the company's latest earnings call in January. The potential divestment marks somewhat of an about-face for Biogen. In a February interview with trade publication Xconomy, Scangos said that he had decided to hold on to the products and try to build a platform around them.  Biogen now has two hemophilia products that have already obtained approval from the U.S. Food and Drug Administration, Alprolix and Eloctate. ""If all we were going to do was market those two compounds and let them run their life cycle then we should probably just sell them,"" Scangos said. ""If we are gonna be in it we need to be making investments for the future and the next generation of products, and care about this. Last year, Biogen made a small investment in its hemophilia platform, partnering with two Italian research institutions to develop gene therapies that treat the root causes of some types of hemophilia. The hemophilia drugs' revenues could continue to grow significantly in coming years due to their potential for international expansion. In November, Eloctate was launched in Europe for the treatment of one type of hemophilia. (Reporting by Carl O'Donnell; Editing by Bernard Orr)",2016-04-08,BIIB,"Fri Apr 8, 2016 | 2:56pm EDT",Biogen explores sale of hemophilia assets -sources,http://www.reuters.com//article/biogen-hemophilia-idUSL2N17B1F5?type=companyNews
112,  April 15 Biogen Inc * CEO George Scangos' FY 2015 total compensation $16.9 million versus. $18.6 million in fy 2014 - sec filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-04-15,BIIB,"Fri Apr 15, 2016 | 9:16am EDT",BRIEF-Biogen CEO George Scangos FY 2015 compensation was $16.9 mln vs $18.6 mln in 2014,http://www.reuters.com//article/idUSFWN17I0DN?type=companyNews
113,"   By Bill Berkrot and Amrutha Penumudi  Aggressive cost cutting propelled Biogen Inc to a better-than-expected first quarter profit as the biotechnology company's reorganization moves began to pay off, and its shares rose nearly 5 percent.Sales of Biogen's most important products came in shy of Wall Street estimates, but the company slashed expenses, with selling, general and administrative costs down 11.3 percent and  research and development spending down 5 percent.Biogen last year announced a restructuring that involved cutting jobs and development of some medicines to focus on more high-risk, high-reward therapies, such as for Alzheimer's disease.The company, in a conference call with analysts, said the benefits of the restructuring were realized in the first quarter and that it would continue to focus on further spending reductions, while supporting advance of its drugs in development.Excluding one-time items, Biogen earned $4.79 per share, topping analysts' average expectations by 32 cents, according to Thomson Reuters I/B/E/S.""They're definitely taking costs out of the system and watching their pennies,"" said Cowen and Co analyst Eric Schmidt.""The commercial business is treading water at best. We're crossing our fingers and hoping that something in the pipeline works,"" he said. The company is enrolling patients for two Phase III trials of its high-profile Alzheimer's drug, aducanumab, and has high hopes for an experimental treatment for spinal muscular atrophy in partnership with Ionis Pharmaceuticals.  Sales of its most important multiple sclerosis drug Tecfidera rose 15 percent from a year ago to $946 million in the  quarter, missing Wall Street estimates of about $960 million. Sales of the oral drug were hurt somewhat by inventory drawdown, which was partially offset by a price increase.Biogen said its Tecfidera television ads had raised patient awareness of the drug and that it planned to halt the campaign in the middle of this year. Biogen management refused to discuss reports, including by Reuters, that it was looking for a buyer for its relatively new two-drug hemophilia franchise, saying it was pleased with the performance of the medicines.""If they weren't selling the hemophilia business, they'd have said so. They would have put this (rumor) to bed and they didn't,"" said Leerink Partners analyst Geoffrey Porges.Given all their cash and borrowing capacity, Porges said,   ""you have to wonder what they're preparing to buy. They're obviously making room in their balance sheet for a material acquisition.""Biogen Chief Executive George Scangos said the company was indeed in the market for potential deals, including looking at drugs in late-stage development.  ""We continue to track companies and compounds that are interesting to us,"" he said.Total revenue for the quarter rose 6.7 percent to $2.73 billion, just short of analyst estimates of $2.75 billion.Net income rose 18 percent to $970.9 million, or $4.43 per share, from $822.5 million, or $3.49 a share, a year ago.Biogen shares were up $12.78, or 4.8 pct at $278.67 on Nasdaq. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey and Meredith Mazzilli)",2016-04-21,BIIB,"Thu Apr 21, 2016 | 11:24am EDT",Cost cutting helps Biogen top Wall Street estimates for quarter,http://www.reuters.com//article/us-biogen-results-idUSKCN0XI1CJ?type=companyNews
114,"   By Bill Berkrot and Amrutha Penumudi  Aggressive cost cutting propelled Biogen Inc to a better-than-expected first quarter profit as the biotechnology company's reorganization moves began to pay off, and its shares rose nearly 5 percent.Sales of Biogen's most important products came in shy of Wall Street estimates, but the company slashed expenses, with selling, general and administrative costs down 11.3 percent and  research and development spending down 5 percent.Biogen last year announced a restructuring that involved cutting jobs and development of some medicines to focus on more high-risk, high-reward therapies, such as for Alzheimer's disease.The company, in a conference call with analysts, said the benefits of the restructuring were realized in the first quarter and that it would continue to focus on further spending reductions, while supporting advance of its drugs in development.Excluding one-time items, Biogen earned $4.79 per share, topping analysts' average expectations by 32 cents, according to Thomson Reuters I/B/E/S.""They're definitely taking costs out of the system and watching their pennies,"" said Cowen and Co analyst Eric Schmidt.""The commercial business is treading water at best. We're crossing our fingers and hoping that something in the pipeline works,"" he said. The company is enrolling patients for two Phase III trials of its high-profile Alzheimer's drug, aducanumab, and has high hopes for an experimental treatment for spinal muscular atrophy in partnership with Ionis Pharmaceuticals.  Sales of its most important multiple sclerosis drug Tecfidera rose 15 percent from a year ago to $946 million in the  quarter, missing Wall Street estimates of about $960 million. Sales of the oral drug were hurt somewhat by inventory drawdown, which was partially offset by a price increase.Biogen said its Tecfidera television ads had raised patient awareness of the drug and that it planned to halt the campaign in the middle of this year. Biogen management refused to discuss reports, including by Reuters, that it was looking for a buyer for its relatively new two-drug hemophilia franchise, saying it was pleased with the performance of the medicines.""If they weren't selling the hemophilia business, they'd have said so. They would have put this (rumor) to bed and they didn't,"" said Leerink Partners analyst Geoffrey Porges.Given all their cash and borrowing capacity, Porges said,   ""you have to wonder what they're preparing to buy. They're obviously making room in their balance sheet for a material acquisition.""Biogen Chief Executive George Scangos said the company was indeed in the market for potential deals, including looking at drugs in late-stage development.  ""We continue to track companies and compounds that are interesting to us,"" he said.Total revenue for the quarter rose 6.7 percent to $2.73 billion, just short of analyst estimates of $2.75 billion.Net income rose 18 percent to $970.9 million, or $4.43 per share, from $822.5 million, or $3.49 a share, a year ago.Biogen shares were up $12.78, or 4.8 pct at $278.67 on Nasdaq. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey and Meredith Mazzilli)",2016-04-21,BIIB,"Thu Apr 21, 2016 | 11:24am EDT",UPDATE 3-Cost cutting helps Biogen top Wall Street estimates for quarter,http://www.reuters.com//article/biogen-results-idUSL3N17O3O5?type=companyNews
115,  April 21 Biogen Inc* Biogen reports first quarter 2016 revenues of $2.7 billion* Q1 non-gaap earnings per share $4.79* Q1 gaap earnings per share $4.43 * Q1 revenue $2.7 billion versus i/b/e/s view $2.75 billion* Q1 earnings per share view $4.47 -- Thomson Reuters I/B/E/S * Qtrly Tecfidera revenue $945.9 million (not $744.3 million) versus $824.9 million last year * Q1 Tysabri revenue $288.2 million versus. $462.6 million* Qtrly total Avonex revenue $564 million versus $693 million* Qtrly Plegridy revenue $106 million versus $62 million  Source text for Eikon:  Further company coverage:,2016-04-21,BIIB,"Thu Apr 21, 2016 | 7:29am EDT",BRIEF-Biogen Q1 adj shr $4.79,http://www.reuters.com//article/idUSL5N17O3XY?type=companyNews
116,"  April 21 Biogen Inc's quarterly sales rose 6.7 percent, helped by growing demand for its key oral multiple sclerosis (MS) drug, Tecfidera.Net income attributable to the U.S. biotechnology company rose to $970.9 million, or $4.43 per share, in the first quarter ended March 31, from $822.5 million, or $3.49 per share, a year earlier. On an adjusted basis, the company earned $4.79 per share.  Total revenue rose to $2.73 billion from $2.56 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-04-21,BIIB,"Thu Apr 21, 2016 | 7:27am EDT",Biogen first-quarter sales rise 6.7 percent,http://www.reuters.com//article/biogen-results-idUSL3N17O3NC?type=companyNews
117,"  April 27 Biogen Inc : * Biogen appoints Michael Ehlers executive vice president, research and development  Source text for Eikon:  Further company coverage:  ",2016-04-27,BIIB,"Wed Apr 27, 2016 | 11:14am EDT","BRIEF-Biogen appoints Michael Ehlers, executive VP of R&D",http://www.reuters.com//article/idUSASC08LS5?type=companyNews
118,"  April 27 Sobi CEO at Q1 earnings call:* CEO, asked about interest in Biogen's hemophilia assets, says ""this is not a time to bet the company on something that is at the outer limits of our capacity"" * Says focused on transactions that allow us to absorb, integrate them in a way that doesn't distract us * Says for me, means size within reach of current debt capacity and maybe to lesser degree the use of equity * Sources told Reuters earlier this month Biogen is exploring a sale of hemophilia assets   Further company coverage:",2016-04-27,BIIB,"Wed Apr 27, 2016 | 9:07am EDT","BRIEF-Sobi CEO on Biogen assets: ""not a time to bet the company""",http://www.reuters.com//article/idUSFWN17U0W9?type=companyNews
119,"  April 29 Biogen Inc* Biogen and abbvie receive positive opinion from the chmp on zinbryta(tm) (daclizumab) for treatment of multiple sclerosis * Positive benefit-risk profile of zinbryta supported by large head-to-head phase 3 decide study  * Says in decide study, overall incidence of adverse events was similar in zinbryta and avonex groups.  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-04-29,BIIB,"Fri Apr 29, 2016 | 8:03am EDT",BRIEF-Biogen and Abbvie receive positive opinion from the CHMP on zinbryta,http://www.reuters.com//article/idUSFWN17W0O3?type=companyNews
120,"  Biogen Inc plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases, the company said on Tuesday.Biogen said it considered a number of alternatives including a sale before deciding to split the business in a tax-free transaction, which it said would deliver the most value to     its shareholders.The new company will include treatments Eloctate and Alprolix for hemophilia A and B, which had total sales of $554.2 million in 2015, about 5 percent of Biogen's revenue. Hemophilia is a group of hereditary genetic disorders that impairs the body's ability to control blood clotting. Biogen began a sweeping restructuring program in October to cut costs and focus on core areas such as neurology and autoimmune diseases. In April, Reuters reported that it was looking at selling the hemophilia assets.After that report, Citi analyst Robyn Karnauskas said the business could be worth $4.8 billion to $6.4 billion. Biogen expects the transaction to occur by the end of this year or early next year.Biogen will focus on developing drugs for neurodegenerative diseases such as multiple sclerosis, spinal muscular atrophy (SMA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and neuropathic pain. It will keep its bestselling MS drug, Tecfidera. The company's promising Alzheimer's drug candidate generated excitement last year after early data showed a reduction in amyloid plaque in the brain and some cognitive improvement.Biogen's collaboration on Eloctate and Alproprix with Swedish Orphan Biovitrum AB will continue, CEO George Scangos said during a conference call with analysts. The move to spin off the hemophilia drugs would have been premature 6 or 12 months ago, he said.    ""It's not really a shift in strategy. It is the fact that the business has matured. It is doing very well. It is profitable. It can stand on its own,"" Scangos said. The area of the company focused on hemophilia also has a pipeline of experimental products that need to be ""aggressively"" developed, he said. Biogen's executive vice president, pharmaceutical operations and technology, John Cox, will be the chief executive officer of the new company, which will be based in the Boston area, Biogen said.Biogen shares were largely unchanged in early trading at $274.52, versus their Monday close of $273.67.  (Reporting by Amrutha Penumudi and Rosmi Shaji in Bengaluru and Caroline Humer in New York; Editing by Savio D'Souza and Frances Kerry)",2016-05-03,BIIB,"Tue May 3, 2016 | 11:26am EDT",Biogen to spin off hemophilia drugs and focus on core neuro business,http://www.reuters.com//article/us-biogen-hemophilia-idUSKCN0XU15E?type=companyNews
121,"  May 3 Biogen Inc :* Biogen announces intent to spin off its hemophilia business* Intends to spin off its hemophilia business as an independent, publicly traded company* New company to be named at a later date* New company is expected to be headquartered in boston area * Biogen is expected to provide transition services to new company for some period of time* Spin-Off is expected to be accomplished through a distribution of shares of new publicly traded company to biogen stockholders * Spin-Off expected to be done through distribution of shares of new publicly traded company to biogen stockholders, in a tax-free deal* New co expected to continue to develop and commercialize eloctate,alprolix under biogen's existing collaboration agreement with biovitrum ab * Spin-Off is planned to be completed by end of 2016 or early 2017* New company will retain commercial rights for eloctate and alprolix for north america* To focus on novel therapies for neurology  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-05-03,BIIB,"Tue May 3, 2016 | 8:02am EDT",BRIEF-Biogen announces intent to spin off its hemophilia business,http://www.reuters.com//article/idUSASC08M60?type=companyNews
122,"  May 16 Regenxbio Inc* Regenxbio and Biogen enter exclusive license agreement for the development of gene therapy treatments for rare genetic vision disorders * Under terms, Biogen granted worldwide research license to co's NAV AAV8,AAV9 vectors for development of gene therapy product candidates  * Co will receive undisclosed upfront payment, ongoing fees, milestone payments and royalties on net sales of products  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-16,BIIB,"Mon May 16, 2016 | 7:16am EDT",BRIEF-Regenxbio and Biogen enter agreement for development of gene therapy treatments,http://www.reuters.com//article/idUSASC08PQB?type=companyNews
123,"  The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning. The self-administered, under-the-skin injection, Zinbryta, is designed to treat adults with relapsing forms of the disease. Zinbryta should generally be used in patients who have not benefited from at least two prior therapies as the drug poses serious safety risks, the FDA said. (1.usa.gov/1TILwDg)Accordingly, the approval comes with a boxed warning - the most severe issued by the FDA - to underscore risks, including liver injury and immune conditions.  Zinbryta, or daclizumab, was recommended for approval by European regulators in April. MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.  The drug's effectiveness was shown in two clinical trials, the FDA said. In one trial, patients were given either Zinbryta or Biogen's Avonex. Data showed that those on Zinbryta had fewer clinical relapses.  The second trial compared Zinbryta against a placebo, with data again showing that those on Zinbryta had fewer relapses. (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)",2016-05-27,BIIB,"Fri May 27, 2016 | 6:45pm EDT","Biogen, AbbVie once-monthly MS injection wins U.S. approval",http://www.reuters.com//article/us-biogen-fda-idUSKCN0YI2LI?type=companyNews
124,"  The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning. The self-administered, under-the-skin injection, Zinbryta, is designed to treat adults with relapsing forms of the disease. Zinbryta should generally be used in patients who have not benefited from at least two prior therapies as the drug poses serious safety risks, the FDA said. (1.usa.gov/1TILwDg)Accordingly, the approval comes with a boxed warning - the most severe issued by the FDA - to underscore risks, including liver injury and immune conditions.  Zinbryta, or daclizumab, was recommended for approval by European regulators in April. MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.  The drug's effectiveness was shown in two clinical trials, the FDA said. In one trial, patients were given either Zinbryta or Biogen's Avonex. Data showed that those on Zinbryta had fewer clinical relapses.  The second trial compared Zinbryta against a placebo, with data again showing that those on Zinbryta had fewer relapses. (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)",2016-05-27,BIIB,"Fri May 27, 2016 | 6:45pm EDT","UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval",http://www.reuters.com//article/biogen-fda-idUSL3N18O51P?type=companyNews
125,  June 1 Biogen Inc* Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Accepted Into European Medicines Agency's Prime Program  * Through Prime Program Biogen Will Have Access To Enhanced Support From EMA  Source text for Eikon:  Further company coverage: ,2016-06-01,BIIB,"Wed Jun 1, 2016 | 11:51am EDT",BRIEF-Biogen's Alzheimer drug Aducanumab Accepted into EMA's PRIME Program,http://www.reuters.com//article/idUSFWN18T0KQ?type=companyNews
126,"  Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.The drug, opicinumab, did not improve overall physical and cognitive function and the progression of disability in patients, the company said on Tuesday.However, Biogen said the drug showed evidence of a clinical effect in patients, and that it would continue to analyze the data to decide on the next steps for the program.Though Biogen clearly has not ruled out further exploration, moving into a late-stage study at this point seems highly unlikely, Jefferies analyst Brian Abrahams wrote in a note.""We see increased risk to the program overall from the mixed results,"" he added.Analysts have previously said the drug represents a multi-billion opportunity for Biogen given its potential to repair nerve damage caused by multiple sclerosis, a nervous system disease affecting the brain and the spinal cord. Biogen is targeting high-priority medicines in its pipeline after concerns over stalling demand for its key MS drug, Tecfidera, in recent quarters.The company has embarked on a restructuring program, shifted focus to its much-anticipated Alzheimer's disease drug and announced plans to spin off its hemophilia drug business as a publicly traded entity.Biogen must do more to extend its core competencies beyond MS, given that the disease has faced a pause in medical advances, Piper Jaffray analyst Joshua Schimmer said on Tuesday. ""A new approach to R&D and asset allocation in our view would be prudent,"" he said.The study, which enrolled 418 patients, was the second mid-stage trial testing opicinumab.  The first study was designed to evaluate the effect of opicinumab following a first episode of acute optic neuritis, or inflammation of the optic nerve.  Biogen's shares were down 8.57 percent at $264.99 before the bell. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty and Sriraj Kalluvila)",2016-06-07,BIIB,"Tue Jun 7, 2016 | 9:33am EDT",Biogen's MS drug misses main goal in mid-stage study,http://www.reuters.com//article/us-biogen-study-idUSKCN0YT1FZ?type=companyNews
127,"   By Caroline Valetkevitch  The S&P 500 ended at its best level since July on Tuesday, helped by a big jump in energy shares and investor confidence that higher interest rates will not derail the economy.The index finished below its best levels of the session, though, while the Nasdaq ended lower. Biotech shares dropped following disappointing news from several key companies including Biogen. The Nasdaq Biotech Index .NBI was down 2.5 percent, its biggest daily percentage decline since May 11.Giving the S&P 500 its biggest boost, the S&P energy index .SPNY jumped 2.1 percent as oil prices reached 2016 highs due to supply constraints and a weak dollar. Exxon Mobil (XOM.N) gained 1.5 percent to $90.71.Gains this week have once again put the S&P 500 within striking distance of record highs reached in May 2015. Comments from Fed Chair Janet Yellen on Monday seemed to ease some worries about the economy, while underscoring views the Fed may be in no rush to raise rates.""The big story for the market right now is, do we break out to all-time highs,"" said Michael Sheldon, chief investment officer at Northstar Wealth Partners in West Hartford, Connecticut. ""If we do so in the near term, we could see a rush of money jump into the market from investors who had been sitting out on the sidelines, in fear missing out on further market gains.""The Dow Jones industrial average .DJI ended up 17.95 points, or 0.1 percent, to 17,938.28, and earlier broke above 18,000, while the S&P 500 .SPX gained 2.72 points, or 0.13 percent, to 2,112.13, its highest close since July 22. The benchmark index now sits less than 19 points from its all-time closing high of 2130.82.The Nasdaq Composite .IXIC dipped 6.96 points, or 0.14 percent, to 4,961.75.Navistar International (NAV.N) shares jumped 19.6 percent to $14.54 after it posted a surprise second-quarter profit. On the downside, the S&P 500 healthcare index .SPXHC dropped 0.7 percent, dragged down by Biogen (BIIB.O) and Alexion (ALXN.O).Biogen tumbled 12.8 percent to $252.86 after its multiple sclerosis drug failed in a mid-stage study.Alexion dropped 10.9 percent to $138.13 after its drug failed a trial, while Valeant (VRX.N) slumped 14.6 percent to $24.64 after the drugmaker cut its full-year forecast.About 6.4 billion shares changed hands on U.S. exchanges, below the 6.9 billion daily average for the past 20 trading days, according to Thomson Reuters data. Advancing issues outnumbered declining ones on the NYSE by 1,896 to 1,136, for a 1.67-to-1 ratio on the upside; on the Nasdaq, 1,462 issues rose and 1,364 fell for a 1.07-to-1 ratio favoring advancers.The S&P 500 posted 43 new 52-week highs and one new low; the Nasdaq recorded 82 new highs and 22 new lows.   (additional reporting by Yashaswini Swamynathan in Bengaluru; Editing by Nick Zieminski)",2016-06-07,BIIB,"Tue Jun 7, 2016 | 6:51pm EDT",US STOCKS-S&P edges closer to record high; energy shares lead,http://www.reuters.com//article/usa-stocks-idUSL1N18Z24J?type=companyNews
128,"  * S&P 500 nears 2015 record high* Oil prices hit 2016 highs* Biogen, Alexion drop after drug trial failures* Dow up 0.3 pct, S&P up 0.3 pct, Nasdaq down 0.04 pct   (Updates to late afternoon)By Caroline ValetkevitchJune 7 The S&P 500 rose to within 15 points of its record high on Tuesday, helped by a big jump in energy shares and enthusiasm following Federal Reserve Chair Janet Yellen's speech this week.Volume was relatively light, though, and the Nasdaq was slightly lower. Biotech shares dropped following disappointing news from several key companies including Biogen. The Nasdaq Biotech Index was down 2.2 percent. Giving the S&P 500 its biggest boost, the S&P energy index  jumped 2.3 percent and was on track for its best two-day percentage gain since March. Oil prices reached 2016 highs due to supply constraints and a weak dollar.Gains this week have once again put the S&P 500 within striking distance of record highs reached in May 2015. Comments from Yellen on Monday seemed to ease some worries about the economy while underscoring views the Fed may be in no rush to raise rates.""The big story for the market right now is, do we break out to all-time highs,"" said Michael Sheldon, chief investment officer at Northstar Wealth Partners in West Hartford, Connecticut. ""If we do so in the near term, we could see a rush of money jump into the market from investors who had been sitting out on the sidelines, in fear missing out on further market gains."" At 3:18 p.m., the Dow Jones industrial average was up 48.39 points, or 0.27 percent, to 17,968.72, the S&P 500  gained 5.74 points, or 0.27 percent, to 2,115.15 and the Nasdaq Composite dropped 2.12 points, or 0.04 percent, to 4,966.59.The Dow earlier in the day traded above 18,000, while the S&P hit its highest level since late July.On the downside, the healthcare index dropped 0.5 percent, dragged down by Biogen and Alexion. Biogen tumbled 12.3 percent to $254.08, and was the biggest drag on the Nasdaq and the S&P 500, after its multiple sclerosis drug failed in a mid-stage study.Alexion dropped 10.7 percent to $138.18 after its drug failed a trial, while Valeant slumped 13 percent to $25.12 after the drugmaker cut its full-year forecast.One of the few bright spots among biotechs was Sarepta , which surged 25 percent on hopes that its muscle-wasting treatment could yet win U.S. approval.Advancing issues outnumbered declining ones on the NYSE by 1,930 to 1,085, for a 1.78-to-1 ratio on the upside; on the Nasdaq, 1,532 issues rose and 1,286 fell for a 1.19-to-1 ratio favoring advancers.The S&P 500 posted 43 new 52-week highs and 1 new low; the Nasdaq recorded 80 new highs and 19 new lows.      (additional reporting by Yashaswini Swamynathan in Bengaluru; Editing by Savio D'Souza)",2016-06-07,BIIB,"Tue Jun 7, 2016 | 3:39pm EDT",US STOCKS-S&P edges closer to record high; energy shares lead,http://www.reuters.com//article/usa-stocks-idUSL1N18Z1XN?type=companyNews
129,"  * Oil prices touch 2016 highs* Biogen, Alexion drop after drugs fail in trials* Valeant slumps on weak results, forecast cut* Indexes up: Dow 0.4 pct, S&P 0.19 pct, Nasdaq 0.04 pct   (Updates to open)By Yashaswini SwamynathanJune 7 Gains in energy and technology stocks helped the S&P 500 and the Dow move higher on Tuesday morning, but a steep fall in healthcare shares capped gains on the Nasdaq.Eight of the 10 major S&P sectors were higher, led by the energy index's 0.8 percent rise as oil prices hovered around 2016 highs. However, the healthcare index tumbled 0.75 percent, led by Biogen and Alexion, both of which reported that their drugs failed in trials.The other sectors were mostly higher a day after Federal Reserve Chair Janet Yellen expressed confidence in the health of the economy, but was vague on when the Fed would raise interest rates.""There is a good possibility we may see the S&P make a new 52-week high as enthusiasm continues to build."" said Peter Cardillo, chief market economist at First Standard Financial in New York. At 9:39 a.m. ET (1339 GMT) the Dow Jones Industrial Average  was up 71.77 points, or 0.4 percent, at 17,992.1.The S&P 500 was up 4.07 points, or 0.19 percent, at 2,113.48 and the Nasdaq Composite was up 2.02 points, or 0.04 percent, at 4,970.73.Gains in technology stocks were led by Apple and Microsoft, which were up about 1 percent. The financial index was the only other index beside healthcare to post losses as the chances of a rate hike in June faded.Biogen tumbled 10 percent after its multiple sclerosis drug failed in a mid-stage study, while Alexion dropped 10 percent after its drug failed a late-stage trial.Valeant's shares slumped 19 percent to $23.47 after the drugmaker posted a lower-than-expected quarterly profit and cut its full-year forecasts.Ralph Lauren dropped 7.3 percent after the retailer said it would cut jobs, close stores and reduce its real estate as part of a plan to lower costs and revive sales growth.Advancing issues outnumbered decliners on the NYSE by 1,735 to 872. On the Nasdaq, 1,138 issues rose and 1,094 fell.The S&P 500 index showed 20 new 52-week highs and no new lows, while the Nasdaq recorded 28 new highs and six new lows.   (Reporting by Yashaswini Swamynathan in Bengaluru; Editing by Savio D'Souza)",2016-06-07,BIIB,"Tue Jun 7, 2016 | 9:59am EDT","US STOCKS-Oil, tech boost S&P and Dow, healthcare caps Nasdaq gains",http://www.reuters.com//article/usa-stocks-idUSL4N18Z400?type=companyNews
130,"  Biogen Inc's keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study, sending the company's shares down as much as 9 percent in premarket trading.The drug, opicinumab, did not improve overall physical and cognitive function and the progression of disability in patients, the company said on Tuesday.However, Biogen said the drug showed evidence of a clinical effect in patients, and that it would continue to analyze the data to decide on the next steps for the program.Though Biogen clearly has not ruled out further exploration, moving into a late-stage study at this point seems highly unlikely, Jefferies analyst Brian Abrahams wrote in a note.""We see increased risk to the program overall from the mixed results,"" he added.Analysts have previously said the drug represents a multi-billion opportunity for Biogen given its potential to repair nerve damage caused by multiple sclerosis, a nervous system disease affecting the brain and the spinal cord. Biogen is targeting high-priority medicines in its pipeline after concerns over stalling demand for its key MS drug, Tecfidera, in recent quarters.The company has embarked on a restructuring program, shifted focus to its much-anticipated Alzheimer's disease drug and announced plans to spin off its hemophilia drug business as a publicly traded entity.Biogen must do more to extend its core competencies beyond MS, given that the disease has faced a pause in medical advances, Piper Jaffray analyst Joshua Schimmer said on Tuesday. ""A new approach to R&D and asset allocation in our view would be prudent,"" he said.The study, which enrolled 418 patients, was the second mid-stage trial testing opicinumab.  The first study was designed to evaluate the effect of opicinumab following a first episode of acute optic neuritis, or inflammation of the optic nerve.  Biogen's shares were down 8.57 percent at $264.99 before the bell. (Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty and Sriraj Kalluvila)",2016-06-07,BIIB,"Tue Jun 7, 2016 | 9:33am EDT",UPDATE 2-Biogen's MS drug misses main goal in mid-stage study,http://www.reuters.com//article/biogen-study-idUSL4N18Z3RH?type=companyNews
131,"  June 7 Biogen Inc said its experimental drug for treating multiple sclerosis, a nervous system disease affecting the brain and the spinal cord, did not meet the main goal of improving some symptoms in a mid-stage study.The drug, opicinumab, did not improve overall physical and cognitive function and the progression of disability in patients, the company said.  Biogen's shares fell 9 percent to $263.59 in premarket trading on Tuesday.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty) ",2016-06-07,BIIB,"Tue Jun 7, 2016 | 7:59am EDT",Biogen's MS drug misses main goal in mid-stage study,http://www.reuters.com//article/biogen-study-idUSL4N18Z3QX?type=companyNews
132,"  July 5 Biogen Inc :* Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis * Zinbryta significantly reduced multiple measures of disease activity in patients with relapsing forms of MS  * Targeted mechanism of action of zinbryta did not cause broad, prolonged depletion of studied immune cell types  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-05,BIIB,"Tue Jul 5, 2016 | 8:19am EDT",BRIEF-Biogen and AbbVie's drug approved in EU,http://www.reuters.com//article/idUSFWN19R0F6?type=companyNews
133,  July 5 Abbvie Inc * Biogen and Abbvie's once-monthly Zinbryta (Daclizumab) approved in European Union for treatment of multiple sclerosis  Source text for Eikon:  Further company coverage:  ,2016-07-05,BIIB,"Tue Jul 5, 2016 | 8:03am EDT",BRIEF-Biogen and Abbvie's multiple sclerosis drug approved in EU,http://www.reuters.com//article/idUSFWN19R0F4?type=companyNews
134,  July 18 Biogen Inc * Biogen and Sobi to showcase long-term efficacy and safety data from extended half-life hemophilia therapies at world federation of hemophilia 2016 world congress  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780)  ,2016-07-18,BIIB,"Mon Jul 18, 2016 | 7:46am EDT","BRIEF-Biogen, Sobi to present long-term data on hemophilia drugs at conference",http://www.reuters.com//article/idUSFWN1A409Q?type=companyNews
135,"  July 18 Biogen Inc * Sb5, an adalimumab biosimilar referencing humira, accepted for review by european medicines agency   Further company coverage:    (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)  ",2016-07-18,BIIB,"Mon Jul 18, 2016 | 5:59am EDT",BRIEF-Biogen SB5 accepted for review by European Medicines Agency,http://www.reuters.com//article/idUSFWN1A10FV?type=companyNews
136,"  SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar of Humira, the world's best-selling drug that generated $14 billion in sales last year. The company did not say when it submitted the application for its Humira copy.Interest in biosimilars, a cheaper copy of complex biotech drugs, has soared in recent years as copies of some of the world's best-selling prescription medicines have hit the market. Medical officials and insurers in the United States and Europe hope biosimilars will significantly reduce healthcare costs.Samsung Group hopes its biosimilar company can emerge as a new growth driver as the global smartphone industry matures, clouding long-term earnings prospects for flagship Samsung Electronics Co Ltd. Samsung Bioepis, which seeks to be first or second to market with its products, already received regulatory approval earlier this year to sell its copies of Amgen Inc's Enbrel and Johnson & Johnson's Remicade - two rheumatoid arthritis drugs that are also among the world's best-selling medicines.  It was not immediately clear how quickly Samsung Bioepis can bring its Humira biosimilar to market even after regulatory approval from the European Union, as AbbVie's composition patent for Humira will not expire in Europe until October 2018. The U.S.-based company, which earned 61 percent of its 2015 net revenue from Humira, has been filing new patents in a bid to push back sales of biosimilars of the drug.Samsung Bioepis, along with partner and minority shareholder Biogen Inc, filed a lawsuit against AbbVie in Britain on March 24 to stop the U.S. company from blocking the launch of the Humira biosimilar.  (Reporting by Se Young Lee; Editing by Christopher Cushing)",2016-07-18,BIIB,"Sun Jul 17, 2016 | 9:38pm EDT",Samsung Bioepis seeks Europe approval for its Humira copy,http://www.reuters.com//article/us-samsung-bioepis-humira-europe-idUSKCN0ZY022?type=companyNews
137,"  SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar of Humira, the world's best-selling drug that generated $14 billion in sales last year. The company did not say when it submitted the application for its Humira copy.Interest in biosimilars, a cheaper copy of complex biotech drugs, has soared in recent years as copies of some of the world's best-selling prescription medicines have hit the market. Medical officials and insurers in the United States and Europe hope biosimilars will significantly reduce healthcare costs.Samsung Group hopes its biosimilar company can emerge as a new growth driver as the global smartphone industry matures, clouding long-term earnings prospects for flagship Samsung Electronics Co Ltd. Samsung Bioepis, which seeks to be first or second to market with its products, already received regulatory approval earlier this year to sell its copies of Amgen Inc's Enbrel and Johnson & Johnson's Remicade - two rheumatoid arthritis drugs that are also among the world's best-selling medicines.  It was not immediately clear how quickly Samsung Bioepis can bring its Humira biosimilar to market even after regulatory approval from the European Union, as AbbVie's composition patent for Humira will not expire in Europe until October 2018. The U.S.-based company, which earned 61 percent of its 2015 net revenue from Humira, has been filing new patents in a bid to push back sales of biosimilars of the drug.Samsung Bioepis, along with partner and minority shareholder Biogen Inc, filed a lawsuit against AbbVie in Britain on March 24 to stop the U.S. company from blocking the launch of the Humira biosimilar.  (Reporting by Se Young Lee; Editing by Christopher Cushing)",2016-07-18,BIIB,"Sun Jul 17, 2016 | 9:38pm EDT",UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy,http://www.reuters.com//article/samsung-bioepis-humira-europe-idUSL4N1A40FZ?type=companyNews
138,"   By Bill Berkrot and Natalie Grover  Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.Shares of Biogen, whose board also authorized a $5 billion share repurchase program, rose more than 7 percent.""This is the right time for a new leader to take the reins and lead Biogen through its next stage of development,"" Scangos said in a statement.The biotechnology company said it will begin a search for a new CEO immediately, considering both internal and external candidates.""When you look at what the growth of this company has been under him by any metric, it's been a terrific overall six-year run, even if the last 12 months weren't up to the par of the first five,"" said Cowen and Co analyst Eric Schmidt.  Biogen now expects 2016 adjusted earnings of $19.70 to $20 per share and revenue of $11.2 billion to $11.4 billion, up from its previous forecast of $18.30 to $18.60 per share and revenue of $11.1 billion to $11.3 billion.  Excluding special items, Biogen earned $5.21 per share, topping analysts' average expectations by 54 cents, according to Thomson Reuters I/B/E/S.Net income rose to $1.05 billion, or $4.79 per share, from $927.3 million, or $3.93 per share, a year earlier.Sales of Tecfidera, the market leading oral multiple sclerosis drug, rose 12 percent to $987 million for the quarter, slightly ahead of Wall Street estimates. Sales of Biogen's other MS drugs, including Tysabri and Avonex, were in line or ahead of Wall Street estimates. Biogen said it expects to begin selling a new once-monthly MS treatment, Zinbryta, in the United States and Europe next month.Hemophilia drugs Eloctate and Alprolix posted sales of $125 million and $80 million, respectively, above estimates of $190 million for both drugs.Biogen in May announced plans to spin off its hemophilia business into a publicly traded entity and said it now expects that to be completed in early 2017. Amid slowing Tecfidera growth, the company last year embarked on a sweeping restructuring program to cut costs and focus on core areas, such as neurology, with high risk, potentially high reward, experimental treatments for Alzheimer's disease under development.Total revenue rose 12 percent to $2.89 billion, exceeding Wall Street estimate of $2.79 billion.Biogen shares rose $18.23 to $280.69 on Nasdaq.  (Reporting by Bill Berkrot in New York and Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila and Phil Berlowitz)",2016-07-21,BIIB,"Thu Jul 21, 2016 | 10:25am EDT",Biogen's profit easily beats Street view; CEO to leave,http://www.reuters.com//article/us-biogen-results-idUSKCN1011F8?type=companyNews
139,"   By Bill Berkrot and Natalie Grover  Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.Shares of Biogen, whose board also authorized a $5 billion share repurchase program, rose more than 7 percent.""This is the right time for a new leader to take the reins and lead Biogen through its next stage of development,"" Scangos said in a statement.The biotechnology company said it will begin a search for a new CEO immediately, considering both internal and external candidates.""When you look at what the growth of this company has been under him by any metric, it's been a terrific overall six-year run, even if the last 12 months weren't up to the par of the first five,"" said Cowen and Co analyst Eric Schmidt.  Biogen now expects 2016 adjusted earnings of $19.70 to $20 per share and revenue of $11.2 billion to $11.4 billion, up from its previous forecast of $18.30 to $18.60 per share and revenue of $11.1 billion to $11.3 billion.  Excluding special items, Biogen earned $5.21 per share, topping analysts' average expectations by 54 cents, according to Thomson Reuters I/B/E/S.Net income rose to $1.05 billion, or $4.79 per share, from $927.3 million, or $3.93 per share, a year earlier.Sales of Tecfidera, the market leading oral multiple sclerosis drug, rose 12 percent to $987 million for the quarter, slightly ahead of Wall Street estimates. Sales of Biogen's other MS drugs, including Tysabri and Avonex, were in line or ahead of Wall Street estimates. Biogen said it expects to begin selling a new once-monthly MS treatment, Zinbryta, in the United States and Europe next month.Hemophilia drugs Eloctate and Alprolix posted sales of $125 million and $80 million, respectively, above estimates of $190 million for both drugs.Biogen in May announced plans to spin off its hemophilia business into a publicly traded entity and said it now expects that to be completed in early 2017. Amid slowing Tecfidera growth, the company last year embarked on a sweeping restructuring program to cut costs and focus on core areas, such as neurology, with high risk, potentially high reward, experimental treatments for Alzheimer's disease under development.Total revenue rose 12 percent to $2.89 billion, exceeding Wall Street estimate of $2.79 billion.Biogen shares rose $18.23 to $280.69 on Nasdaq.  (Reporting by Bill Berkrot in New York and Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila and Phil Berlowitz)",2016-07-21,BIIB,"Thu Jul 21, 2016 | 10:25am EDT",UPDATE 2-Biogen's profit easily beats Street view; CEO to leave,http://www.reuters.com//article/biogen-results-idUSL4N1A73Q4?type=companyNews
140,"  July 21 Biogen Inc said on Thursday Chief Executive George Scangos will leave the U.S. drugmaker in the coming months and that its board approved a $5 billion share repurchase program.The company said total revenue rose about 12 percent to $2.47 billion in its second-quarter ended June 30.  Net income attributable to the company rose to $1.05 billion, or $4.79 per share, from $927.3 million, or $3.93 per share, a year earlier.    (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila) ",2016-07-21,BIIB,"Thu Jul 21, 2016 | 7:19am EDT",Biogen CEO to leave; company plans $5 bln share buyback,http://www.reuters.com//article/biogen-results-idUSL4N1A73P9?type=companyNews
141,"  July 26 Enigma Biomedical Group Inc:* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240  * Announced a research collaboration agreement with Biogen Inc and Merck  Source text for Eikon: ",2016-07-25,BIIB,"Mon Jul 25, 2016 | 5:28pm EDT",BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck,http://www.reuters.com//article/idUSFWN1AB0S6?type=companyNews
142,"   By Natalie Grover  Biogen Inc said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement.The drug, nusinersen, was being developed by Biogen in collaboration with Ionis Pharmaceuticals Inc, to treat spinal muscular atrophy (SMA).The genetic disease disrupts the part of the nervous system that controls voluntary muscle movement, eventually taking away an individual's ability to walk, eat, or breathe.Currently, there exists no approved treatment for the condition, which is the leading genetic cause of death in infants. It affects about 1 in 10,000 babies, and some 1 in every 50 Americans is a genetic carrier, according to Illinois-based Cure SMA.Shares of Biogen, which plans to file marketing applications for the potential blockbuster in the coming months, rose about 5.2 percent to $304.95. In the interim analysis of the late-stage trial in infants with a form of SMA, nusinersen met the main goal of improving motor symptoms. Based on this data, the trial will be stopped, and patients can receive the drug in a follow-on study, the companies said.Biogen also said it had paid Ionis a $75 million license fee to take responsibility for the product's development, regulatory and commercialization activities and costs going forward.Facing slowing growth of its flagship drug Tecfidera, Biogen last year embarked on a sweeping restructuring program to focus on core areas, such as neurology, with high-risk, potentially high-reward experimental treatments for Alzheimer's among others. Nusinersen could provide a new growth opportunity for Biogen, which hasn't seen big organic growth since the launch of Tecfidera and has faced several late-stage setbacks over the past year, analysts said.Nusinersen is also being evaluated in two other studies in different SMA patient groups that will continue as planned. If approved, analysts expect the drug to generate between $1 billion to $2 billion in peak sales.Ionis is eligible to receive tiered royalties on any potential sales of nusinersen up to a certain percentage, and up to $150 million in milestone payments.Carlsbad, California-based Ionis' shares jumped about 33.4 percent to $38.95. (Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)",2016-08-01,BIIB,"Mon Aug 1, 2016 | 11:06am EDT",Biogen exercises option to develop muscle drug after trial success,http://www.reuters.com//article/us-biogen-study-idUSKCN10C29B?type=companyNews
143,"   By Natalie Grover  Biogen Inc said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement.The drug, nusinersen, was being developed by Biogen in collaboration with Ionis Pharmaceuticals Inc, to treat spinal muscular atrophy (SMA).The genetic disease disrupts the part of the nervous system that controls voluntary muscle movement, eventually taking away an individual's ability to walk, eat, or breathe.Currently, there exists no approved treatment for the condition, which is the leading genetic cause of death in infants. It affects about 1 in 10,000 babies, and some 1 in every 50 Americans is a genetic carrier, according to Illinois-based Cure SMA.Shares of Biogen, which plans to file marketing applications for the potential blockbuster in the coming months, rose about 5.2 percent to $304.95. In the interim analysis of the late-stage trial in infants with a form of SMA, nusinersen met the main goal of improving motor symptoms. Based on this data, the trial will be stopped, and patients can receive the drug in a follow-on study, the companies said.Biogen also said it had paid Ionis a $75 million license fee to take responsibility for the product's development, regulatory and commercialization activities and costs going forward.Facing slowing growth of its flagship drug Tecfidera, Biogen last year embarked on a sweeping restructuring program to focus on core areas, such as neurology, with high-risk, potentially high-reward experimental treatments for Alzheimer's among others. Nusinersen could provide a new growth opportunity for Biogen, which hasn't seen big organic growth since the launch of Tecfidera and has faced several late-stage setbacks over the past year, analysts said.Nusinersen is also being evaluated in two other studies in different SMA patient groups that will continue as planned. If approved, analysts expect the drug to generate between $1 billion to $2 billion in peak sales.Ionis is eligible to receive tiered royalties on any potential sales of nusinersen up to a certain percentage, and up to $150 million in milestone payments.Carlsbad, California-based Ionis' shares jumped about 33.4 percent to $38.95. (Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)",2016-08-01,BIIB,"Mon Aug 1, 2016 | 11:06am EDT",UPDATE 2-Biogen exercises option to develop muscle drug after trial success,http://www.reuters.com//article/biogen-study-idUSL3N1AI447?type=companyNews
144,"  Aug 1 Biogen Inc* Biogen Inc And Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint At Interim Analysis Of Phase 3 Endear Study In Infantile Onset spinal muscular atrophy* Biogen exercises option to develop and commercialize Nusinersen globally * Infants receiving Nusinersen experienced a statistically significant improvement in achievement of motor milestones versus those who didn't* Biogen is now responsible for all Nusinersen development, regulatory and commercialization activities and costs. * Ionis will complete phase 3 studies and work with Biogen on regulatory filings for Nusinersen* Intends to file marketing applications for Nusinersen with regulatory authorities in coming months * Biogen has exercised its option to develop and commercialize Nusinersen globally and paid Ionis a $75 million license fee* Ionis is eligible to receive tiered royalties on any potential sales of Nusineren up to a percentage in mid-teens* Ionis is eligible to receive up to $150 million in milestone payments based on regulatory approvals for  nusinersen  Source text for Eikon:  Further company coverage:",2016-08-01,BIIB,"Mon Aug 1, 2016 | 7:46am EDT",BRIEF-Biogen and Ionis say Nusinersen meets primary endpoint at interim analysis of phase 3 Endear study,http://www.reuters.com//article/idUSASC08ZO7?type=companyNews
145,"  Biotechnology companyBiogenInc(BIIB.O) has drawn takeover interest from drug companies includingMerck& Co Inc (MRK.N) andAllerganPlc (AGN.N), The Wall Street Journal reported on Tuesday, citing people familiar with the matter.The talks were informal and preliminary, the Journal said, adding they may might not result in a deal, in part because Biogen may not be interested. Allergan was unlikely to pursue the deal, CNBC said, citing a source.Biogen shares closed up 9.4 percent at $330.11 on Tuesday, valuing the company at about $72.33 billion. The stock fell 1.3 percent in extended trade following the CNBC report. Officials at Cambridge, Massachusetts-based Biogen could not be reached for comment. Allergan spokesman Mark Marmur and Merck spokeswoman Lainie Keller said they do not comment on speculation.The WSJ report came less than two weeks after Biogen reported surprisingly strong second-quarter earnings but said Chief Executive George Scangos, 68, would step down in coming months after a successor is found. Although Biogen significantly raised its full-year earnings forecast, growth for its flagship Tecfidera treatment for multiple sclerosis has been slowing. The slowdown prompted the company last year to embark on a sweeping restructuring program to cut costs and focus on core areas, such as neurology, including treatments for Alzheimer's disease.Leerink Partners analyst Geoffrey Porges said Merck, Allergan or other large drugmakers would benefit from acquiring Biogen and its experimental drugs in late-stage trials, which include treatments for Alzheimer's, multiple sclerosis and spinal muscular atrophy. ""There's a scarcity of assets in the industry,"" Porges said. ""The industry needs to bulk up and consolidate and neither Merck nor Allergan have a multiple sclerosis business today,"" he said, while Biogen is leading the field. (Reporting by Anya George Tharakan in Bengaluru and Ransdell Pierson in New York; Editing by Richard Chang and Savio D'Souza)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 6:13pm EDT","Biogen draws takeover interest from Merck, Allergan: WSJ",http://www.reuters.com//article/us-biogen-m-a-idUSKCN10D25T?type=companyNews
146,"  Biotechnology companyBiogenInc(BIIB.O) has drawn takeover interest from drug companies includingMerck& Co Inc (MRK.N) andAllerganPlc (AGN.N), The Wall Street Journal reported on Tuesday, citing people familiar with the matter.The talks were informal and preliminary, the Journal said, adding they may might not result in a deal, in part because Biogen may not be interested. Allergan was unlikely to pursue the deal, CNBC said, citing a source.Biogen shares closed up 9.4 percent at $330.11 on Tuesday, valuing the company at about $72.33 billion. The stock fell 1.3 percent in extended trade following the CNBC report. Officials at Cambridge, Massachusetts-based Biogen could not be reached for comment. Allergan spokesman Mark Marmur and Merck spokeswoman Lainie Keller said they do not comment on speculation.The WSJ report came less than two weeks after Biogen reported surprisingly strong second-quarter earnings but said Chief Executive George Scangos, 68, would step down in coming months after a successor is found. Although Biogen significantly raised its full-year earnings forecast, growth for its flagship Tecfidera treatment for multiple sclerosis has been slowing. The slowdown prompted the company last year to embark on a sweeping restructuring program to cut costs and focus on core areas, such as neurology, including treatments for Alzheimer's disease.Leerink Partners analyst Geoffrey Porges said Merck, Allergan or other large drugmakers would benefit from acquiring Biogen and its experimental drugs in late-stage trials, which include treatments for Alzheimer's, multiple sclerosis and spinal muscular atrophy. ""There's a scarcity of assets in the industry,"" Porges said. ""The industry needs to bulk up and consolidate and neither Merck nor Allergan have a multiple sclerosis business today,"" he said, while Biogen is leading the field. (Reporting by Anya George Tharakan in Bengaluru and Ransdell Pierson in New York; Editing by Richard Chang and Savio D'Souza)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 6:13pm EDT","UPDATE 4-Biogen draws takeover interest from Merck, Allergan-WSJ",http://www.reuters.com//article/biogen-ma-idUSL3N1AJ554?type=companyNews
147,"  Aug 2 (Reuters) - * Allergan unlikely to pursue Biogen deal- CNBC,citing source    (Bengaluru Newsroom: +1-646-223-8780)  ",2016-08-02,BIIB,"Tue Aug 2, 2016 | 5:34pm EDT","BRIEF-Allergan unlikely to pursue Biogen deal- CNBC,citing source",http://www.reuters.com//article/idUSFWN1AJ11R?type=companyNews
148,"  (Adds Merck response)Aug 2 Biotechnology company Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, The Wall Street Journal reported on Tuesday, citing people familiar with the matter.The talks were informal and preliminary, the Journal said, adding they may might not result in a deal, in part because Biogen may not be interested. (on.wsj.com/2aKYrnp)Shares of Biogen, which is based in Cambridge, Massachusetts, closed up 9.4 percent at $330.11. Officials at Biogen could not be reached for comment. Allergan spokesman Mark Marmur and Merck spokeswoman Lainie Keller said they do not comment on speculation. The report came less than two weeks after Biogen reported surprisingly strong second-quarter earnings but said Chief Executive George Scangos, 68, would step down in coming months after a successor is found.Although Biogen significantly raised its full-year earnings forecast, growth for its flagship Tecfidera treatment for multiple sclerosis has been slowing. The slowdown prompted the company last year to embark on a sweeping restructuring program to cut costs and focus on core areas, such as neurology, including treatments for Alzheimer's disease. Leerink Partners analyst Geoffrey Porges said Merck, Allergan or other large drugmakers would benefit from acquiring Biogen and its experimental drugs in late-stage trials, which include treatments for Alzheimer's, multiple sclerosis and spinal muscular atrophy.""There's a scarcity of assets in the industry,"" Porges said. ""The industry needs to bulk up and consolidate and neither Merck nor Allergan have a multiple sclerosis business today,"" he said, while Biogen is leading the field.   (Reporting by Anya George Tharakan in Bengaluru and Ransdell Pierson in New York; Editing by James Dalgleish and Richard Chang)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 5:10pm EDT","UPDATE 3-Biogen draws takeover interest from Merck, Allergan -WSJ",http://www.reuters.com//article/biogen-ma-idUSL3N1AJ4NN?type=companyNews
149,"   By Chuck Mikolajczak | NEW YORK  NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.Shares of Ford (F.N) and General Motors (GM.N) dropped more than 4 percent each after the two major U.S. automakers reported July vehicle sales slightly below expectations.The automakers' declines pulled the S&P consumer discretionary sector .SPLRCD down 1.5 percent as the worst- performing of the 10 major S&P groups. Data showed U.S. consumer spending rose more than expected in June as households bought a range of goods and services.However, personal income rose only 0.2 percent, missing estimates of 0.3 percent, while inflation remained below the Federal Reserve's 2 percent target. That could keep the central bank on a cautious path to hiking interest rates. ""People are starting to see that things arent quite as rosy as they might have thought in the month of July with that big run up,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois. The S&P 500 climbed 3.6 percent in July, its best month since March.   Another drop in U.S. crude CLc1 below $40 a barrel also weighed on sentiment, as the commodity settled down 1.4 percent at $39.51. Pfizer (PFE.N), was the biggest percentage decliner on the Dow, after the largest U.S. drugmaker reported better-than-expected quarterly results but revenue from its branded patent-protected medicines was disappointing.       The Dow Jones industrial average .DJI fell 90.74 points, or 0.49 percent, to 18,313.77, the S&P 500 .SPX lost 13.81 points, or 0.64 percent, to 2,157.03 and the Nasdaq Composite .IXIC dropped 46.46 points, or 0.9 percent, to 5,137.73. CVS (CVS.N) jumped more than 5 percent to $98.57 after the drugstore chain operator's quarterly profit beat estimates.Of the 353 companies in the S&P 500 that have reported earnings through Tuesday morning, 71 percent have topped analyst expectations, according to Thomson Reuters data. Earnings for the second quarter are expected to show a decline of 2.6 percent, an improvement from the expected 4.5 percent decline on July 1. Equities pared early losses after a report in the Wall Street Journal that biotechnology giant Biogen Inc (BIIB.O) has drawn takeover interest from drug companies, including Merck & Co Inc (MRK.N) and Allergan Plc (AGN.N). Biogen shares surged 9.4 percent to $330.11 and the Nasdaq biotechnology index .NBI climbed 0.2 percent after falling as much as 1.8 percent.    Declining issues outnumbered advancing ones on the NYSE by a 3.35-to-1 ratio; on Nasdaq, a 2.97-to-1 ratio favored decliners.The S&P 500 posted 14 new 52-week highs and 1 new low; the Nasdaq Composite recorded 54 new highs and 38 new lows.  About 7.45 billion shares changed hands on U.S. exchanges, compared with the 6.64 billion daily average over the last 20 sessions.  (Reporting by Chuck Mikolajczak; Editing by Chris Reese and Dan Grebler)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 4:32pm EDT",Wall St. falls as weak auto sales spur growth jitters,http://www.reuters.com//article/us-usa-stocks-idUSKCN10D14A?type=companyNews
150,"   By Chuck Mikolajczak | NEW YORK  NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.Shares of Ford (F.N) and General Motors (GM.N) dropped more than 4 percent each after the two major U.S. automakers reported July vehicle sales slightly below expectations.The automakers' declines pulled the S&P consumer discretionary sector .SPLRCD down 1.5 percent as the worst- performing of the 10 major S&P groups. Data showed U.S. consumer spending rose more than expected in June as households bought a range of goods and services.However, personal income rose only 0.2 percent, missing estimates of 0.3 percent, while inflation remained below the Federal Reserve's 2 percent target. That could keep the central bank on a cautious path to hiking interest rates. ""People are starting to see that things arent quite as rosy as they might have thought in the month of July with that big run up,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois. The S&P 500 climbed 3.6 percent in July, its best month since March.   Another drop in U.S. crude CLc1 below $40 a barrel also weighed on sentiment, as the commodity settled down 1.4 percent at $39.51. Pfizer (PFE.N), was the biggest percentage decliner on the Dow, after the largest U.S. drugmaker reported better-than-expected quarterly results but revenue from its branded patent-protected medicines was disappointing.       The Dow Jones industrial average .DJI fell 90.74 points, or 0.49 percent, to 18,313.77, the S&P 500 .SPX lost 13.81 points, or 0.64 percent, to 2,157.03 and the Nasdaq Composite .IXIC dropped 46.46 points, or 0.9 percent, to 5,137.73. CVS (CVS.N) jumped more than 5 percent to $98.57 after the drugstore chain operator's quarterly profit beat estimates.Of the 353 companies in the S&P 500 that have reported earnings through Tuesday morning, 71 percent have topped analyst expectations, according to Thomson Reuters data. Earnings for the second quarter are expected to show a decline of 2.6 percent, an improvement from the expected 4.5 percent decline on July 1. Equities pared early losses after a report in the Wall Street Journal that biotechnology giant Biogen Inc (BIIB.O) has drawn takeover interest from drug companies, including Merck & Co Inc (MRK.N) and Allergan Plc (AGN.N). Biogen shares surged 9.4 percent to $330.11 and the Nasdaq biotechnology index .NBI climbed 0.2 percent after falling as much as 1.8 percent.    Declining issues outnumbered advancing ones on the NYSE by a 3.35-to-1 ratio; on Nasdaq, a 2.97-to-1 ratio favored decliners.The S&P 500 posted 14 new 52-week highs and 1 new low; the Nasdaq Composite recorded 54 new highs and 38 new lows.  About 7.45 billion shares changed hands on U.S. exchanges, compared with the 6.64 billion daily average over the last 20 sessions.  (Reporting by Chuck Mikolajczak; Editing by Chris Reese and Dan Grebler)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 4:32pm EDT",US STOCKS-Wall St falls as weak auto sales spur growth jitters,http://www.reuters.com//article/usa-stocks-idUSL1N1AJ1W0?type=companyNews
151,"  (Adds dropped word 'percent' in third paragraph)Aug 2 Biotechnology giant Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, the Wall Street Journal reported, citing people familiar with the matter. The talks were informal and preliminary, the Journal said, adding the talks might not result in a deal, in part because Biogen may not be interested. (on.wsj.com/2aKYrnp) Biogen's shares shot up nearly 9 percent on Tuesday. Biogen, Merck and Allergan were not immediately available for comment.   (Reporting by Anya George Tharakan in Bengaluru; Editing by Savio D'Souza)",2016-08-02,BIIB,"Tue Aug 2, 2016 | 2:58pm EDT","REFILE-Biogen draws takeover interest from Merck, Allergan - WSJ",http://www.reuters.com//article/biogen-ma-idUSL3N1AJ4MM?type=companyNews
152,"   By Greg Roumeliotis  U.S. biotechnology company Biogen Inc (BIIB.O) has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter. While some of Biogen's peers have approached individual board directors of the company over time, nothing has been presented to Biogen's board for consideration recently, the person said on Wednesday.One reason that no formal offer has materialized is that Biogen values its portfolio of neurology drugs highly, and would expect any proposal to come with a significant premium, the person added.The Wall Street Journal reported on Tuesday, citing sources, that Allergan Plc (AGN.N) and Merck & Co Inc (MRK.N) had sounded out Biogen on the possibility of a takeover. Merck expressed more of an interest in Biogen than Allergan, but this did not result in any offer, the source said.The source asked not to be identified because Biogen's  deliberations are confidential. Biogen, Allergan and Merck offered no comment. Cambridge, Massachusetts-based Biogen has a market value of $70 billion. The company's $11 billion in annual revenue comes primarily from its multiple sclerosis portfolio, about $4 billion of which may be subject to generic competition in coming years.Earlier this week, Biogen said it would develop and commercialize an experimental genetic muscle-disorder drug called nusinersen after an interim analysis of late-stage data showed patients experienced statistically significant improvement.Facing slowing growth of its flagship multiple sclerosis drug Tecfidera, Biogen last year embarked on a sweeping restructuring program to focus on core areas, such as neurology, with high-risk, potentially high-reward experimental treatments for Alzheimer's disease, among others. Last month, the company's chief executive, George Scangos, announced plans to step down once a successor is named.Meanwhile, Allergan recently announced the closing of a deal to sell its generics business to Teva Pharmaceutical Industries Ltd (TEVA.TA) for more than $40 billion, providing Allergan with a substantial war chest that could be deployed for acquisitions. In April, Allergan, which is based in Dublin, Ireland, terminated its planned merger with U.S.-based rival Pfizer Inc (PFE.N) after new U.S. Treasury rules reduced the tax benefits of the deal. In earnings calls, Merck, based in Kenilworth, New Jersey, has expressed an interest in growing aggressively through deals, calling business development ""a top priority."" In 2015, it closed an acquisition of Cubist Pharmaceuticals for $9.5 billion. (Reporting by Greg Roumeliotis in New York; Additional reporting by Carl O'Donnell in New York; Editing by Tom Brown)",2016-08-03,BIIB,"Thu Aug 4, 2016 | 1:35pm EDT",Biogen not pursuing a sale - source,http://www.reuters.com//article/biogen-ma-allergan-idUSL1N1AK18Y?type=companyNews
153,"  Aug 3 (Reuters) -* Allergan has no interest in a Biogen deal - CNBC, citing sources  Source text: (bit.ly/2aupGnD)   (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780) ",2016-08-03,BIIB,"Wed Aug 3, 2016 | 9:38am EDT","BRIEF-Allergan has no interest in a Biogen deal - CNBC, citing sources",http://www.reuters.com//article/idUSFWN1AK10L?type=companyNews
154,  Aug 3 Amyris Inc :* Collaboration will explore use of Amyris's microbe engineering technology  * Amyris enters partnership with Biogen to develop alternative cell lines supporting production of therapeutics  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-08-03,BIIB,"Wed Aug 3, 2016 | 8:44am EDT",BRIEF-Amyris enters partnership with Biogen,http://www.reuters.com//article/idUSFWN1AK0VG?type=companyNews
155,"   By Greg Roumeliotis  U.S. biotechnology company Biogen Inc (BIIB.O) has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter. While some of Biogen's peers have approached individual board directors of the company over time, nothing has been presented to Biogen's board for consideration recently, the person said on Wednesday.One reason that no formal offer has materialized is that Biogen values its portfolio of neurology drugs highly, and would expect any proposal to come with a significant premium, the person added.The Wall Street Journal reported on Tuesday, citing sources, that Allergan Plc (AGN.N) and Merck & Co Inc (MRK.N) had sounded out Biogen on the possibility of a takeover. Merck expressed more of an interest in Biogen than Allergan, but this did not result in any offer, the source said.The source asked not to be identified because Biogen's  deliberations are confidential. Biogen, Allergan and Merck offered no comment. Cambridge, Massachusetts-based Biogen has a market value of $70 billion. The company's $11 billion in annual revenue comes primarily from its multiple sclerosis portfolio, about $4 billion of which may be subject to generic competition in coming years.Earlier this week, Biogen said it would develop and commercialize an experimental genetic muscle-disorder drug called nusinersen after an interim analysis of late-stage data showed patients experienced statistically significant improvement.Facing slowing growth of its flagship multiple sclerosis drug Tecfidera, Biogen last year embarked on a sweeping restructuring program to focus on core areas, such as neurology, with high-risk, potentially high-reward experimental treatments for Alzheimer's disease, among others. Last month, the company's chief executive, George Scangos, announced plans to step down once a successor is named.Meanwhile, Allergan recently announced the closing of a deal to sell its generics business to Teva Pharmaceutical Industries Ltd (TEVA.TA) for more than $40 billion, providing Allergan with a substantial war chest that could be deployed for acquisitions. In April, Allergan, which is based in Dublin, Ireland, terminated its planned merger with U.S.-based rival Pfizer Inc (PFE.N) after new U.S. Treasury rules reduced the tax benefits of the deal. In earnings calls, Merck, based in Kenilworth, New Jersey, has expressed an interest in growing aggressively through deals, calling business development ""a top priority."" In 2015, it closed an acquisition of Cubist Pharmaceuticals for $9.5 billion. (Reporting by Greg Roumeliotis in New York; Additional reporting by Carl O'Donnell in New York; Editing by Tom Brown)",2016-08-04,BIIB,"Thu Aug 4, 2016 | 1:35pm EDT",Biogen not pursuing a sale: source,http://www.reuters.com//article/us-biogen-m-a-allergan-idUSKCN10E28M?type=companyNews
156,  Aug 9 Biogen Inc :* Initial form 10 filing expected later this week * Biogen announces Bioverativ as name of new hemophilia-focused company  * On track for separation into two publicly traded companies in early 2017  Source text for Eikon:  Further company coverage:,2016-08-09,BIIB,"Tue Aug 9, 2016 | 9:19am EDT",BRIEF-Biogen announces Bioverativ as name of new hemophilia-focused company,http://www.reuters.com//article/idUSFWN1AQ0D3?type=companyNews
157,  Sept 6 Biogen Inc : * BioMotiv and Biogen expand strategic partnership into ophthalmology  Source text for Eikon:  Further company coverage:  ,2016-09-06,BIIB,"Tue Sep 6, 2016 | 7:40am EDT",BRIEF-BioMotiv and Biogen expand strategic partnership,http://www.reuters.com//article/idUSASC095BV?type=companyNews
158,  Sept 14 Biogen Inc :* New Data Affirm Strong Efficacy And well characterized safety profile of TECFIDERA in both clinical studies and real-world setting  * Risk profile of TECFIDERA remains favorable up to nine years  Source text for Eikon:  Further company coverage: ,2016-09-14,BIIB,"Wed Sep 14, 2016 | 7:52am EDT",BRIEF-Biogen Inc affirms strong efficacy of TECFIDERA in both clinical studies and real-world setting,http://www.reuters.com//article/idUSFWN1BQ04J?type=companyNews
159,"   By Carl O'Donnell  Allergan Plc (AGN.N) CEO Brent Saunders calls them ""stepping stones"" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.Allergan's agreement on Tuesday to acquire liver drug developer Tobira Therapeutics Inc (TBRA.O) for $1.7 billion may seem trivial compared to the proposed $160 billion deal Allergan crafted last year to sell itself to Pfizer Inc (PFE.N).But that deal was torpedoed in April by the U.S. Treasury's latest curbs on tax inversions. Now the company, domiciled in Ireland, is taking a new tack, preparing to spend a war chest of more than $20 billion on stepping-stone deals. The small deals are aimed at filling gaps in its core therapeutic areas, which range from the central nervous system and gastrointestinal diseases, to dermatology and eye care.Allergan has added four other small companies to its portfolio this year, three of which sold for less than $100 million upfront, plus performance payments. Two, ForSight Vision and Retrosense Therapeutics, treat eye disorders. The others, Topokine Therapeutics and Vitae Pharmaceuticals Inc. VTAE.O, focus on dermatology. Allergan agreed to acquire Vitae last week for $639 million.The fact that Allergan is paying top dollar for some of these companies - including a nearly 600 percent premium for Tobira, excluding performance payments - has investors and dealmakers speculating about the company's next stepping stone.Logical acquisition targets for Allergan would include Acadia Pharmaceuticals Inc (ACAD.O), a maker of treatments for Parkinsons disease; Intra-Cellular Therapies Inc (ITCI.O), a developer of psychiatric medications; Neurocrine Biosciences Inc (NBIX.O), which focuses on neurology and womens health; and Dermira Inc (DERM.O), a dermatology company, according to investment bankers and industry investors. In an interview with Reuters, Saunders declined to comment on any specific companies that Allergan may want to acquire next. But he said that stepping stones will play a key role in helping the company continue to meet its ambitious annual revenue growth target of 10 percent for years to come. ""I needed to do big deals to get where we are, but the strategic vision was always to get to a point where we could use stepping stones,"" Saunders said. 	 Allergan has relied heavily on M&A because it views inventing its own drugs in-house as too risky. Saunders, 46, has attempted or executed mergers and acquisitions totaling more than $300 billion in the last three years. Allergan now has the money to embark on a major acquisition spree thanks to the sale of its generic drug portfolio to Teva Pharmaceutical Industries Ltd (TEVA.TA). Allergan received $33.4 billion in cash and $5.1 billion in Teva stock last month as a result of that deal. While Allergan has pledged to spend some of those dollars on share buybacks, it will still have cash reserves of more than $20 billion it can spend on deals.	Allergan wants to build out its central nervous system franchise, which is one of the largest in the industry and treats diseases including Alzheimer's, depression, migraines and schizophrenia, Saunders said.     He added that he would like to branch out into other types of neurological treatments, including multiple sclerosis, attention deficit hyperactivity disorder and Parkinson's disease.     One of Allergan's successful endeavors in the central nervous system space, its Namenda Alzheimer's franchise, took a hit over the past year after one of its key drugs, Namenda IR, lost patent protection. Namenda IR generated more than $500 million in 2015.   Allergan is hoping that a ramp-up of its newly commercialized anti-psychotic drug, Vraylar, can help offset that decline.BOTOX AS A GATEWAY DRUG Saunders said he also is optimistic about opportunities in dermatology and eye care, adding that he would be open to a medium-sized deal to build out its opthalmic products.      In dermatology, Allergan has the world's biggest franchise by sales, largely due to its flagship drug, Botox, for wrinkle-smoothing.Last year, in a stepping-stone acquisition, Allergan bought a publicly traded dermatology company called Kythera for $2.1 billion, and it has been ramping up sales of its key drug, Kybella, which treats double chins.""There's definitely potential for more deals like that in dermatology,"" said Randall Stanicky, an analyst at RBC Capital Markets. ""Botox is a gateway product into the entire world of aesthetics.""In the interview, Saunders left open the possibility of a transformative acquisition or merger for Allergan, which has a market capitalization of $95 billion.He said a company with a cutting-edge treatment that reversed Alzheimer's was an example of the type of big deal Allergan would consider making.    Biogen Inc BIIB.N and Eli Lilly and Co (LLY.N) both have late stage drugs that promise to reverse the effects of the degenerative neurological disease. Biogen and Eli Lilly have market capitalizations of $65 billion and $86 billion, respectively.Reuters reported in August that Allergan had held informal conversations with some members of Biogen's board before deciding against any acquisition offer.  (Reporting by Carl O'Donnell in New York; Editing by Greg Roumeliotis and Brian Thevenot)",2016-09-20,BIIB,"Tue Sep 20, 2016 | 10:32am EDT",Allergan pays top dollar for 'stepping stones' from neurology to dermatology,http://www.reuters.com//article/us-allergan-m-a-idUSKCN11Q1XB?type=companyNews
160,  Sept 26 Biogen Inc* Biogen completes rolling submission of new drug application to FDA for nusinersen as a treatment for spinal muscular atrophy * Biogen completes rolling submission of new drug application to FDA for nusinersen as a treatment for spinal muscular atrophy * Submission of marketing authorization application to European medicines agency planned in coming weeks * Has also applied for priority review for nusinersen  Source text for Eikon:  Further company coverage:,2016-09-26,BIIB,"Mon Sep 26, 2016 | 7:45am EDT",BRIEF-Biogen completes submission of new drug application,http://www.reuters.com//article/idUSASC0996H?type=companyNews
161,"  Sept 28 Anavex Life Sciences * Signed material transfer agreement with Biogen  under which Biogen will test Anavex's lead drug candidate, Anavex 2-73  Source text for Eikon:  Further company coverage:  ",2016-09-28,BIIB,"Wed Sep 28, 2016 | 7:28am EDT",BRIEF-Anavex signs material transfer agreement with Biogen,http://www.reuters.com//article/idUSFWN1C40AV?type=companyNews
162,"   By Bill Berkrot  Biogen Inc (BIIB.O) on Wednesday reported better-than-expected third quarter profit, driven by higher sales of its lead multiple sclerosis drug and lower costs, and its shares rose more than 4 percent.However, investor focus is likely to turn to promising new drugs in late-stage development, including a potential blockbuster Alzheimer's treatment, and the company's search for a successor to Chief Executive George Scangos, who in July said he would step down once his replacement is found.Scangos, on a conference call with analysts, said the CEO search was progressing and that ""very high quality"" candidates were being interviewed, but he declined to provide a timeline.""The sooner we have a new CEO come in, the better it is for all of us,"" Scangos said.The company expressed encouragement over early data it has seen for the Alzheimer's drug aducanumab, currently in Phase III testing, and said more data would be presented at a medical meeting in December. ""What was most important was comments around Alzheimer's, noting again their view of consistent efficacy and safety from the prior data, referring to cognitive endpoints as well as biomarker data,"" said RBC Capital Markets analyst Michael Yee, calling aducanumab ""potentially the most exciting Alzheimer's drug in late stage development.""Any successful Alzheimer's treatment is virtually assured of becoming a multibillion-dollar product, given the huge need.Biogen also said it filed its application with U.S.  regulators seeking priority review for nusinersen, which would be the first treatment for spinal muscular atrophy, a leading genetic cause of death in infants. Priority review for the drug, being developed with Ionis Pharmaceuticals (IONS.O), would bring an approval decision within six months. ""Many investors are debating whether or not this could get a very, very fast approval given the unmet medical need. There's a lot of enthusiasm over that,"" Yee said. ""The are filing for a broad label, which could be significant upside if that occurs."" Biogen also sees biosimilars as an important growth opportunity. It has begun selling cheaper versions of Amgen's (AMGN.O) Enbrel and Johnson & Johnson's (JNJ.N) Remicade rheumatoid arthritis drugs in Europe.Excluding items, Biogen earned $5.19 per share in the quarter, topping analysts' expectations by 22 cents, according to Thomson Reuters I/B/E/S.       Sales of the biotechnology company's market-leading oral MS drug Tecfidera of $1.03 billion, edged past analysts' estimates of $1 billion.     Total revenue rose 6 percent to $2.96 billion, ahead of Wall Street estimates of $2.91 billion.Biogen shares were up $13 at $299.22 on Nasdaq. (Reporting by Bill Berkrot in New York and Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta and Nick Zieminski)",2016-10-26,BIIB,"Wed Oct 26, 2016 | 10:47am EDT","Biogen profit tops expectations; focus on CEO search, new drugs",http://www.reuters.com//article/us-biogen-results-idUSKCN12Q1D2?type=companyNews
163,  Oct 26 Biogen* Says expects reimbursement for new MS drug Zinbryta throughout Europe within 12-18 months  * Biogen CEO says board search to find new CEO progressing  Source text for Eikon:  Further company coverage:    (Reporting By Bill Berkrot) ,2016-10-26,BIIB,"Wed Oct 26, 2016 | 9:33am EDT",BRIEF-Biogen CEO says search to find successor progressing,http://www.reuters.com//article/idUSL1N1CW0K0?type=companyNews
164,"  Oct 26 Biogen Inc reported a 7 percent rise in quarterly profit, helped by higher sales of its multiple sclerosis drugs.Net income attributable rose to $1.03 billion, or $4.71 per share, in the third quarter ended Sept. 30, from $965.6 million, or $4.15 per share, a year earlier.  Total revenue rose to $2.96 billion from $2.78 billion.     (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta) ",2016-10-26,BIIB,"Wed Oct 26, 2016 | 7:06am EDT",Drugmaker Biogen quarterly profit rises 7 pct,http://www.reuters.com//article/biogen-results-idUSL4N1CW3LA?type=companyNews
165,  Oct 28 Biogen Inc :* Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA and EMA* Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA and EMA * Says nusinersen granted priority review by FDA* Biogen Inc - EMA plans to follow accelerated assessment timeline for nusinersen * Biogen Inc - Biogen exercised its option to worldwide rights to nusinersen in august 2016 * Says intends to market nusinersen under brand name spinraza* Says is initiating regulatory filings in other countries in coming months  Source text for Eikon:  Further company coverage:,2016-10-28,BIIB,"Fri Oct 28, 2016 | 7:49am EDT","BRIEF-Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA, EMA",http://www.reuters.com//article/idUSASC09E4B?type=companyNews
166,"  * Biogen says potential U.S. launch by 2016-end or Q1 2017* Drug may get $1 bln-$2 bln in peak annual sales - Piper Jaffray* Shares of Ionis jump as much as 28.16 pct* Biogen shares up as much as 7.32 pct   (Adds details)Nov 7 Biogen Inc and Ionis Pharmaceuticals said a second late-stage study testing their drug for a rare genetic muscular disorder, the leading genetic cause of death in infants, was successful, prompting them to stop the trial early.Ionis Pharmaceutical's stock jumped up as much as 28.16 percent to $34.77 while Biogen shares rose as much as 7.32 percent to $297.27 in trading on Monday. An interim analysis found that patients with a less-severe form of spinal muscular atrophy (SMA) who received the drug, Spinraza (nusinersen), experienced significant improvement in motor function compared with those who didn't.A separate late-stage study in August evaluating the drug in patients with the most-severe form of SMA was stopped early after the drug was found effective.SMA disrupts the part of the nervous system that controls voluntary muscle movement, eventually taking away an individual's ability to walk, eat or breathe. Currently, there is no approved treatment for the condition and it affects about 1 in 10,000 babies, and some 1 in 50 Americans is a genetic carrier, according to Illinois-based Cure SMA.Monday's announcement increases the probability of Spinraza obtaining a broad initial label, analysts said. Biogen, which agreed to pay Ionis a $75 million license fee to take responsibility for the drug's development, regulatory and commercialization activities in August, is preparing for a potential U.S. launch of Spinraza, possibly by the end of the year or the first quarter of 2017.This timeline is shorter than what most analysts had forecast, and Ionis is eligible to receive royalties on potential sales of the drug and up to $150 million in milestone payments.Spinraza could provide a new growth opportunity for Biogen, which hasn't seen big organic growth since the launch of multiple sclerosis drug, Tecfidera and has faced several late-stage setbacks over the past year.This data gives Biogen and Ionis a head start over rival gene therapy developer Avexis Inc, which is also working on an SMA treatment.""Even with gene therapy competition we still think Spinraza can achieve more than $1 billion-$2 billion in peak annual revenue,"" Piper Jaffray & Co analysts said.   (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto)",2016-11-07,BIIB,"Mon Nov 7, 2016 | 2:33pm EST","UPDATE 3-Ionis, Biogen drug for fatal infant disorder succeeds in key study",http://www.reuters.com//article/ionis-study-idUSL4N1D84EE?type=companyNews
167,  Nov 7 Ionis Pharmaceuticals Inc* Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 cherish study in later-onset spinal muscular atrophy * Spinraza demonstrated a favorable safety profile in study * Biogen is preparing for potential launch of SPINRAZA in U.S. possibly as early as end of 2016 or q1 of 2017 * Ionis pharmaceuticals says analysis found children receiving SPINRAZA experienced highly statistically significant improvement in motor function versus those who didn't receive treatment  Source text for Eikon:  Further company coverage:,2016-11-07,BIIB,"Mon Nov 7, 2016 | 8:52am EST",BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study,http://www.reuters.com//article/idUSASC09GKX?type=companyNews
168,"  Nov 7 Biogen Inc and Ionis Pharmaceuticals said their investigational treatment for a type of rare genetic muscular disorder met its main goal in an interim analysis of a late-stage study.The interim analysis found that children receiving this treatment experienced significant improvement in motor function compared with those who didn't receive the treatment, the companies said in a statement. The drug, nusinersen, is being developed to treat spinal muscular atrophy (SMA). SMA disrupts the part of the nervous system that controls voluntary muscle movement, eventually taking away an individual's ability to walk, eat or breathe. Biogen said in August it would exercise an option to develop and commercialize nusinersen after the drug met the main goal of improving motor symptoms in an interim analysis of another late-stage study.    (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto)",2016-11-07,BIIB,"Mon Nov 7, 2016 | 8:04am EST",Ionis and Biogen's muscular disorder treatment meets main goal,http://www.reuters.com//article/ionis-study-idUSL4N1D844X?type=companyNews
169,"  Nov 15 Biogen Inc* Biogen Inc - Appoints Rogerio Vivaldi, M.D. EVP and chief global therapeutic operations officer, and John T. Greene, EVP and chief financial officer * Says spin-off of Bioverativ is on track to be completed in early 2017  * Biogen announces additional members of management team of hemophilia spin-off company Bioverativ  Source text for Eikon:  Further company coverage:",2016-11-15,BIIB,"Tue Nov 15, 2016 | 7:42am EST",BRIEF-Biogen announces additional members of management team of hemophilia spin-off company Bioverativ,http://www.reuters.com//article/idUSASC09IZL?type=companyNews
170,"   By Lewis Krauskopf | NEW YORK  NEW YORK Eli Lilly & Co's massive setback for its experimental Alzheimer's disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc.Lilly shares tumbled 10.5 percent, and fell to their lowest point in two years during the session, after the company said its drug failed to slow loss of cognitive ability in patients with mild symptoms. The shares were on pace for their biggest one-day percentage decline since the 2008 financial crisis, shaving about $9 billion of market value.Biogen shares were down 4 percent, but had reduced their initial losses by more than half from premarket trading as investors assessed the damage to the prospects of the company's drug that works in a similar way to Lilly's.The results for Lilly's solanezumab were a highly anticipated event on Wall Street, with some analysts saying the company's shares could have leapt 20 percent or more had the clinical trial succeeded.Although Alzheimer's disease has been a notoriously difficult area for drug development, some investors were clearly optimistic that the drug would meet the study goals. A buy-side investor survey by Evercore ISI at the end of September found that 56 percent had expected the study to meet its main goal.Morningstar analyst Damien Conover had been factoring in a 50-percent chance of solanezumab approval, with peak probability sales of nearly $4 billion a year.  ""Therefore, the negative trial results have a large impact on our fair value estimate.""Lilly's shares had traded at just over 19 times earnings estimates for the next 12 months ahead of the study results, making their shares more expensive than other large U.S. and European drugmakers. Wednesday's decline left shares trading at about 17 times estimates, below Bristol-Myers Squibb Co but still well ahead of those of Pfizer and GlaxoSmithKline.PHARMA CUPBOARD NOT BARE  The stock valuation shows investor confidence that Lilly's cupboard is not bare without solanezumab, as medicines for diabetes, rheumatoid arthritis and psoriasis are expected to propel its business.Lilly's earnings per share are expected to rise by 14 percent a year on average over five years, said Sanford Bernstein analyst Tim Anderson, making the company ""among the very best growers in our coverage universe."" According to Starmine data, Lilly's average annual earnings per share growth is expected to be 7.8 percent over the next five years, nearly double that of peers.Lilly executives themselves have told analysts on recent quarterly conference calls they project average annual revenue growth of at least 5 percent a year through 2020, even without solanezumab.    ""They are telling you that their business can work regardless, so in many ways they provided some prophylaxis to the market,"" said Tony Butler, an analyst with Guggenheim Securities.The results nonetheless will sting for Lilly investors. Balyasny Asset Management, Franklin Advisers, Wellington Management and Vanguard Group made large additions to their Lilly holdings as of Sept 30, according to securities filings tracked by Thomson Reuters. Lilly's setback raised questions in the strategy of targeting the beta amyloid protein, believed to cause brain plaques, which Biogen's aducanumab also targets.But Biogen's drug is different, including data showing it could be more effective in targeting beta amyloid, according to Raymond James analyst Chris Raymond. While ""the risk has gone up with respect to aducanumab,"" Raymond said, part of the reason the stock recovered the bulk of its initial losses on Wednesday was that investors did not completely discount the chance aducanumab could still succeed.Investors should learn more about aducanumab's potential at an Alzheimer's conference starting Dec. 8.Another possible support for shares of Biogen, which has a leading franchise of multiple sclerosis drugs: the company, with a market value of about $66 billion, has been the subject of takeover speculation.With more data expected in the near term, Raymond said, ""we anticipate greater clarity and think this could actually help to resolve questions around how to value aducanumab as it relates to a potential Biogen takeout."" (Reporting by Lewis Krauskopf; Editing by Dan Burns and Nick Zieminski)",2016-11-23,BIIB,"Wed Nov 23, 2016 | 3:36pm EST","Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks",http://www.reuters.com//article/us-health-alzheimer-s-stocks-idUSKBN13I2G2?type=companyNews
171,"   By Lewis Krauskopf | NEW YORK  NEW YORK Nov 23 Eli Lilly & Co's  massive setback for its experimental Alzheimer's disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc .Lilly shares tumbled 10.5 percent, and fell to their lowest point in two years during the session, after the company said its drug failed to slow loss of cognitive ability in patients with mild symptoms.The shares were on pace for their biggest one-day percentage decline since the 2008 financial crisis, shaving about $9 billion of market value.Biogen shares were down 4 percent, but had reduced their initial losses by more than half from premarket trading as investors assessed the damage to the prospects of the company's drug that works in a similar way to Lilly's.The results for Lilly's solanezumab were a highly anticipated event on Wall Street, with some analysts saying the company's shares could have leapt 20 percent or more had the clinical trial succeeded.Although Alzheimer's disease has been a notoriously difficult area for drug development, some investors were clearly optimistic that the drug would meet the study goals. A buy-side investor survey by Evercore ISI at the end of September found that 56 percent had expected the study to meet its main goal.Morningstar analyst Damien Conover had been factoring in a 50-percent chance of solanezumab approval, with peak probability sales of nearly $4 billion a year.  ""Therefore, the negative trial results have a large impact on our fair value estimate.""Lilly's shares had traded at just over 19 times earnings estimates for the next 12 months ahead of the study results, making their shares more expensive than other large U.S. and European drugmakers. Wednesday's decline left shares trading at about 17 times estimates, below Bristol-Myers Squibb Co but still well ahead of those of Pfizer and GlaxoSmithKline.PHARMA CUPBOARD NOT BARE The stock valuation shows investor confidence that Lilly's cupboard is not bare without solanezumab, as medicines for diabetes, rheumatoid arthritis and psoriasis are expected to propel its business. Lilly's earnings per share are expected to rise by 14 percent a year on average over five years, said Sanford Bernstein analyst Tim Anderson, making the company ""among the very best growers in our coverage universe.""According to Starmine data, Lilly's average annual earnings per share growth is expected to be 7.8 percent over the next five years, nearly double that of peers.Lilly executives themselves have told analysts on recent quarterly conference calls they project average annual revenue growth of at least 5 percent a year through 2020, even without solanezumab.""They are telling you that their business can work regardless, so in many ways they provided some prophylaxis to the market,"" said Tony Butler, an analyst with Guggenheim Securities. The results nonetheless will sting for Lilly investors. Balyasny Asset Management, Franklin Advisers, Wellington Management and Vanguard Group made large additions to their Lilly holdings as of Sept 30, according to securities filings tracked by Thomson Reuters.Lilly's setback raised questions in the strategy of targeting the beta amyloid protein, believed to cause brain plaques, which Biogen's aducanumab also targets.But Biogen's drug is different, including data showing it could be more effective in targeting beta amyloid, according to Raymond James analyst Chris Raymond.While ""the risk has gone up with respect to aducanumab,"" Raymond said, part of the reason the stock recovered the bulk of its initial losses on Wednesday was that investors did not completely discount the chance aducanumab could still succeed.Investors should learn more about aducanumab's potential at an Alzheimer's conference starting Dec. 8.Another possible support for shares of Biogen, which has a leading franchise of multiple sclerosis drugs: the company, with a market value of about $66 billion, has been the subject of takeover speculation.With more data expected in the near term, Raymond said, ""we anticipate greater clarity and think this could actually help to resolve questions around how to value aducanumab as it relates to a potential Biogen takeout.""   (Reporting by Lewis Krauskopf; Editing by Dan Burns and Nick Zieminski)",2016-11-23,BIIB,"Wed Nov 23, 2016 | 3:30pm EST","Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks",http://www.reuters.com//article/health-alzheimers-stocks-idUSL1N1DO1CB?type=companyNews
172,"  (Corrects name of Dr. Gandy in paragraphs 16 and 18)By Ransdell PiersonNov 23 Eli Lilly and Co said its experimental Alzheimer's treatment failed to slow the loss of mental functioning in patients with mild symptoms, a major setback for the company and millions of people at risk of developing the memory-robbing disease.Many investors and families had been counting on solanezumab to become the first approved medicine to slow progression of the disease, which the Alzheimer's Association estimates will strike as many as 28 million Americans by midcentury.Lilly shares were down 11.7 percent on Wednesday after the U.S. drugmaker announced the long-awaited results of its large Expedition 3 study, which showed patients treated with solanezumab did not experience a significantly greater slowing in cognitive decline than those given placebos.The news also caused a 4.3 percent drop in shares of Biogen Inc, which is testing a drug that, like solanezumab, targets the beta amyloid protein believed to cause toxic brain plaques that are considered a hallmark of Alzheimer's.Given the trial's results, Lilly said it would not seek U.S. approval of its drug for mild dementia.Incoming Chief Executive Officer David Ricks called the news ""heart-breaking.""Lilly spent more than $3 billion on Alzheimer's research over the past 27 years and will keep pushing for effective treatments, he said. He noted solanezumab was being studied in a separate trial called ""A4"" among people with no Alzheimer's symptoms but who have the brain plaques. The company said it would take a $150 million charge in the fourth quarter for the failed trial and provide an updated 2016 financial outlook, as well as 2017 forecasts, on Dec. 15.Ricks affirmed Lilly's forecast for annual revenue growth of at least 5 percent between 2015 and 2020. The company has strong growth prospects without solanezumab because of recently approved treatments for diabetes, cancer and other conditions, he said.Some analysts had said solanezumab, if approved, could generate up to $10 billion in annual sales and boost Lilly's earnings for years to come.The infused drug works by binding in the bloodstream to beta amyloid.Biogen is racing to complete Phase III trials of aducanumab, which is designed to clear beta amyloid that has already formed plaques. However, the solanezumab data raises questions about whether beta amyloid is a valid target for Alzheimer's drugs. Biogen officials did not respond to requests for comment.STILL HOPE FOR TREATMENTS As with cancer, many experts believe combinations of medicines, each having different mechanisms, will be needed to greatly slow Alzheimer's progress or stop it in its tracks. One of the biggest hopes is a class of experimental drugs called BACE inhibitors, which work by blocking production of beta amyloid. Lilly and others, including Biogen and Merck & Co , are conducting late-stage trials of such drugs.Dr. Sam Gandy, director of Mount Sinai School of Medicine's Center for Cognitive Health, was not ready to abandon drugs that reduce amyloid.""My guess is that they would be part of a cocktail with something else, that they won't in and of themselves be enough,"" he said.Amyloid drugs may work best in patients who have yet to develop plaques readable on scans, Gandy added.In two original 18-month studies completed in 2012, solanezumab failed to slow cognitive decline or loss of physical functioning for the 1,000 patients with mild to moderate disease in each trial.But the combined data for just mildly affected patients suggested solanezumab caused significant slowdowns of 34 percent in mental decline and 18 percent in loss of functional abilities, compared with those taking a placebo, researchers said.For Expedition 3, Lilly extended the pair of large trials by another two years and enrolled only mildly impaired patients. Researchers continued to provide solanezumab to patients who had taken it during the initial studies and also allowed the placebo groups to switch to solanezumab.(Reporting by Ransdell Pierson; Additional reporting by Bill Berkrot; Editing by Lisa Von Ahn)",2016-11-23,BIIB,"Wed Nov 23, 2016 | 1:49pm EST",CORRECTED-UPDATE 4-Lilly's drug for Alzheimer's fails big trial; shares drop,http://www.reuters.com//article/health-alzheimers-lilly-idUSL1N1DO0HR?type=companyNews
